Johnson & Johnson (JNJ) 10-K22 Feb 212020 FY Annual reportFinancial data

Company Profile

Cover Page

Cover Page - USD ($) $ in Billions	12 Months Ended
Cover Page - USD ($) $ in Billions	Jan. 03, 2021	Feb. 16, 2021	Jun. 28, 2020
Document Information [Line Items]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Jan. 3, 2021
Document Transition Report	false
Entity File Number	1-3215
Entity Registrant Name	JOHNSON & JOHNSON
Entity Incorporation, State or Country Code	NJ
Entity Tax Identification Number	22-1024240
Entity Address, Address Line One	One Johnson & Johnson Plaza
Entity Address, City or Town	New Brunswick
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08933
City Area Code	732
Local Phone Number	524-0400
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Public Float			$ 363
Entity Common Stock, Shares Outstanding		2,628,679,824
Entity Central Index Key	0000200406
Current Fiscal Year End Date	--01-03
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Amendment Flag	false
Common Stock, Par Value $1.00
Document Information [Line Items]
Title of 12(b) Security	Common Stock, Par Value $1.00
Trading Symbol	JNJ
Security Exchange Name	NYSE
0.250% Notes Due January 2022
Document Information [Line Items]
Title of 12(b) Security	0.250% Notes Due January 2022
Trading Symbol	JNJ22
Security Exchange Name	NYSE
0.650% Notes Due May 2024
Document Information [Line Items]
Title of 12(b) Security	0.650% Notes Due May 2024
Trading Symbol	JNJ24C
Security Exchange Name	NYSE
5.50% Notes Due November 2024
Document Information [Line Items]
Title of 12(b) Security	5.50% Notes Due November 2024
Trading Symbol	JNJ24BP
Security Exchange Name	NYSE
1.150% Notes Due November 2028
Document Information [Line Items]
Title of 12(b) Security	1.150% Notes Due November 2028
Trading Symbol	JNJ28
Security Exchange Name	NYSE
1.650% Notes Due May 2035
Document Information [Line Items]
Title of 12(b) Security	1.650% Notes Due May 2035
Trading Symbol	JNJ35
Security Exchange Name	NYSE

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Jan. 03, 2021	Dec. 29, 2019
Current assets:
Cash and cash equivalents (Notes 1 and 2)	$ 13,985	$ 17,305
Marketable securities (Notes 1 and 2)	11,200	1,982
Accounts receivable trade, less allowances for doubtful accounts $293 (2019, $226)	13,576	14,481
Inventories (Notes 1 and 3)	9,344	9,020
Prepaid expenses and other receivables	3,132	2,392
Assets held for sale (Note 18)	0	94
Total current assets	51,237	45,274
Property, plant and equipment, net (Notes 1 and 4)	18,766	17,658
Intangible assets, net (Notes 1 and 5)	53,402	47,643
Goodwill (Notes 1 and 5)	36,393	33,639
Deferred taxes on income (Note 8)	8,534	7,819
Other assets	6,562	5,695
Total assets	174,894	157,728
Current liabilities:
Loans and notes payable (Note 7)	2,631	1,202
Accounts payable	9,505	8,544
Accrued liabilities	13,968	9,715
Accrued rebates, returns and promotions	11,513	10,883
Accrued compensation and employee related obligations	3,484	3,354
Accrued taxes on income (Note 8)	1,392	2,266
Total current liabilities	42,493	35,964
Long-term debt (Note 7)	32,635	26,494
Deferred taxes on income (Note 8)	7,214	5,958
Employee related obligations (Notes 9 and 10)	10,771	10,663
Long-term taxes payable (Note 1)	6,559	7,444
Other liabilities	11,944	11,734
Total liabilities	111,616	98,257
Shareholders' equity:
Preferred stock — without par value (authorized and unissued 2,000,000 shares)	0	0
Common stock — par value $1.00 per share (Note 12) (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)	3,120	3,120
Accumulated other comprehensive income (loss) (Note 13)	(15,242)	(15,891)
Retained earnings	113,890	110,659
Stockholders' Equity before Treasury Stock	101,768	97,888
Less: common stock held in treasury, at cost (Note 12) (487,331,000 shares and 487,336,000 shares)	38,490	38,417
Total shareholders’ equity	63,278	59,471
Total liabilities and shareholders’ equity	$ 174,894	$ 157,728
Preferred stock, shares authorized (in shares)	2,000,000	2,000,000
Common Stock, Par or Stated Value Per Share	$ 1	$ 1
Common Stock, Shares Authorized	4,320,000,000	4,320,000,000
Common Stock, Shares, Issued	3,119,843,000	3,119,843,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Jan. 03, 2021	Dec. 29, 2019
Current assets:
Allowances for doubtful accounts	$ 293	$ 226
Shareholders' equity:
Preferred stock, shares authorized (in shares)	2,000,000	2,000,000
Common stock, par value per share (in dollars per share)	$ 1	$ 1
Common stock, shares authorized (in shares)	4,320,000,000	4,320,000,000
Common stock, shares issued (in shares)	3,119,843,000	3,119,843,000
Treasury stock, shares	487,331,000	487,336,000

Consolidated Statements of Earn

Consolidated Statements of Earnings - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Income Statement [Abstract]
Sales to customers	$ 82,584	$ 82,059	$ 81,581
Cost of products sold	28,427	27,556	27,091
Gross profit	54,157	54,503	54,490
Selling, marketing and administrative expenses	22,084	22,178	22,540
Research and development expense	12,159	11,355	10,775
In-process research and development (Note 5)	181	890	1,126
Interest income	(111)	(357)	(611)
Interest expense, net of portion capitalized (Note 4)	201	318	1,005
Other (income) expense, net	2,899	2,525	1,405
Restructuring (Note 20)	247	266	251
Earnings before provision for taxes on income	16,497	17,328	17,999
Provision for taxes on income (Note 8)	1,783	2,209	2,702
Net earnings	$ 14,714	$ 15,119	$ 15,297
Net earnings per share (Notes 1 and 15)
Basic (in dollars per share)	$ 5.59	$ 5.72	$ 5.70
Diluted (in dollars per share)	$ 5.51	$ 5.63	$ 5.61
Average shares outstanding (Notes 1 and 15)
Basic (in shares)	2,632.8	2,645.1	2,681.5
Diluted (in shares)	2,670.7	2,684.3	2,728.7

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Statement of Comprehensive Income [Abstract]
Net earnings	$ 14,714	$ 15,119	$ 15,297
Other Comprehensive Income (Loss), net of tax
Foreign currency translation	(233)	164	(1,518)
Securities
Unrealized holding gain (loss) arising during period	1	0	(1)
Reclassifications to earnings	0	0	1
Net change	1	0	0
Employee benefit plans
Prior service credit (cost), net of amortization	1,298	(18)	(44)
Gain (loss), net of amortization	(1,135)	(714)	(56)
Effect of exchange rates	(229)	(1)	92
Net change	(66)	(733)	(8)
Derivatives & hedges
Unrealized gain (loss) arising during period	1,000	(107)	(73)
Reclassifications to earnings	(53)	7	(192)
Net change	947	(100)	(265)
Other comprehensive income (loss)	649	(669)	(1,791)
Comprehensive income	$ 15,363	$ 14,450	$ 13,506

Consolidated Statements of Co_2

Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Statement of Comprehensive Income [Abstract]
Foreign currency translation	$ 536	$ 19	$ 236
Employee benefits	21	(222)	4
Derivatives & hedges	$ 252	$ (27)	$ (70)

Consolidated Statements of Equi

Consolidated Statements of Equity - USD ($) $ in Millions	Total	Cumulative Effect, Period of Adoption, Adjustment	Retained Earnings	Retained EarningsCumulative Effect, Period of Adoption, Adjustment	Accumulated Other Comprehensive Income (Loss)	Accumulated Other Comprehensive Income (Loss)Cumulative Effect, Period of Adoption, Adjustment	Common Stock Issued Amount	Treasury Stock Amount
Beginning Balance at Dec. 31, 2017	$ 60,160	$ (486)	$ 101,793	$ (254)	$ (13,199)	$ (232)	$ 3,120	$ (31,554)
Net earnings	15,297		15,297
Cash dividends paid	(9,494)		(9,494)
Employee compensation and stock option plans	1,949		(1,111)					3,060
Repurchase of common stock	(5,868)							(5,868)
Other	(15)		(15)
Other comprehensive income (loss), net of tax	(1,791)				(1,791)
Ending Balance at Dec. 30, 2018	59,752		106,216		(15,222)		3,120	(34,362)
Net earnings	15,119		15,119
Cash dividends paid	(9,917)		(9,917)
Employee compensation and stock option plans	1,933		(758)					2,691
Repurchase of common stock	(6,746)							(6,746)
Other	(1)		(1)
Other comprehensive income (loss), net of tax	(669)				(669)
Ending Balance at Dec. 29, 2019	59,471		110,659		(15,891)		3,120	(38,417)
Net earnings	14,714		14,714
Cash dividends paid	(10,481)		(10,481)
Employee compensation and stock option plans	2,217		(931)					3,148
Repurchase of common stock	(3,221)							(3,221)
Other	(71)		(71)
Other comprehensive income (loss), net of tax	649				649
Ending Balance at Jan. 03, 2021	$ 63,278		$ 113,890		$ (15,242)		$ 3,120	$ (38,490)

Consolidated Statements of Eq_2

Consolidated Statements of Equity (Parenthetical) - $ / shares	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Statement of Stockholders' Equity [Abstract]
Cash dividends paid (in dollars per share)	$ 3.98	$ 3.75	$ 3.54

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Cash flows from operating activities
Net earnings	$ 14,714	$ 15,119	$ 15,297
Adjustments to reconcile net earnings to cash flows from operating activities:
Depreciation and amortization of property and intangibles	7,231	7,009	6,929
Stock based compensation	1,005	977	978
Asset write-downs	233	1,096	1,258
Contingent consideration reversal	(1,148)	0	0
Net gain on sale of assets/businesses	(111)	(2,154)	(1,217)
Deferred tax provision	(1,141)	(2,476)	(1,016)
Credit losses and accounts receivable allowances	63	(20)	(31)
Changes in assets and liabilities, net of effects from acquisitions and divestitures:
Decrease/(Increase) in accounts receivable	774	(289)	(1,185)
Increase in inventories	(265)	(277)	(644)
Increase in accounts payable and accrued liabilities	5,141	4,060	3,951
Increase in other current and non-current assets	(3,704)	(1,054)	(275)
Increase/(Decrease) in other current and non-current liabilities	744	1,425	(1,844)
Net cash flows from operating activities	23,536	23,416	22,201
Cash flows from investing activities
Additions to property, plant and equipment	(3,347)	(3,498)	(3,670)
Proceeds from the disposal of assets/businesses, net	305	3,265	3,203
Acquisitions, net of cash acquired (Note 18)	(7,323)	(5,810)	(899)
Purchases of investments	(21,089)	(3,920)	(5,626)
Sales of investments	12,137	3,387	4,289
Credit support agreements activity, net	(987)	338	0
Other (primarily licenses and milestones)	(521)	44	(464)
Net cash used by investing activities	(20,825)	(6,194)	(3,167)
Cash flows from financing activities
Dividends to shareholders	(10,481)	(9,917)	(9,494)
Repurchase of common stock	(3,221)	(6,746)	(5,868)
Proceeds from short-term debt	3,391	39	80
Repayment of short-term debt	(2,663)	(100)	(2,479)
Proceeds from long-term debt, net of issuance costs	7,431	3	5
Repayment of long-term debt	(1,064)	(2,823)	(1,555)
Proceeds from the exercise of stock options/employee withholding tax on stock awards, net	1,114	954	949
Credit support agreements activity, net	(333)	100	25
Other	(294)	475	(173)
Net cash used by financing activities	(6,120)	(18,015)	(18,510)
Effect of exchange rate changes on cash and cash equivalents	89	(9)	(241)
(Decrease)/Increase in cash and cash equivalents	(3,320)	(802)	283
Cash and cash equivalents, beginning of year (Note 1)	17,305	18,107	17,824
Cash and cash equivalents, end of year (Note 1)	13,985	17,305	18,107
Cash paid during the year for:
Interest	904	995	1,049
Interest, net of amount capitalized	841	925	963
Income taxes	4,619	4,191	4,570
Supplemental schedule of non-cash investing and financing activities
Treasury stock issued for employee compensation and stock option plans, net of cash proceeds/ employee withholding tax on stock awards	1,937	1,736	2,095
Conversion of debt	27	1	6
Acquisitions
Fair value of assets acquired	7,755	7,228	1,047
Fair value of liabilities assumed and noncontrolling interests	(432)	(1,418)	(148)
Net cash paid for acquisitions (Note 18)	$ 7,323	$ 5,810	$ 899

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
Summary of Significant Accounting Policies	Jan. 03, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Principles of Consolidation The consolidated financial statements include the accounts of Johnson & Johnson and its subsidiaries (the Company). Intercompany accounts and transactions are eliminated. Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures. Description of the Company and Business Segments The Company has approximately 134,500 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the health care field. The Company conducts business in virtually all countries of the world and its primary focus is on products related to human health and well-being. The Company is organized into three business segments: Consumer Health (previously referred to as Consumer), Pharmaceutical and Medical Devices. The Consumer Health segment includes a broad range of products used in the baby care, oral care, skin health/beauty, over-the-counter pharmaceutical, women’s health and wound care markets. These products are marketed to the general public and sold online (eCommerce) and to retail outlets and distributors throughout the world. The Pharmaceutical segment is focused on six therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, hospitals and health care professionals for prescription use. The Medical Devices segment includes a broad range of products used in the orthopaedic, surgery, interventional solutions (cardiovascular and neurovascular) and eye health fields, which are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. New Accounting Standards Recently Adopted Accounting Standards ASU 2018-18: Collaborative Arrangements The Company adopted this standard as of the beginning of the fiscal year 2020. This update clarifies the interaction between ASC 808, Collaborative Arrangements and ASC 606, Revenue from Contracts with Customers. The update clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer. In addition, the update precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue if the counterparty is not a customer for that transaction. The adoption of this standard did not have a material impact on the Company's consolidated financial statements. ASU 2016-13: Financial Instruments - Credit Losses The Company adopted this standard as of the beginning of the fiscal year 2020. This update introduces the current expected credit loss (CECL) model, which requires an entity to measure credit losses for certain financial instruments and financial assets, including trade receivables. Under this update, on initial recognition and at each reporting period, an entity is required to recognize an allowance that reflects the entity’s current estimate of credit losses expected to be incurred over the life of the financial instrument. The adoption of this standard did not have a material impact on the Company's consolidated financial statements. ASU 2018-14: Compensation - Defined Benefit Plans The Company adopted this standard in the fiscal year ended 2020. This standard revised the financial statement note disclosure requirements of ASC 715-20 for defined benefit plan sponsors. The adoption of this standard had no impact on the Company's consolidated financial statements. See Note 10 to the Consolidated Financial Statements for defined benefit plan disclosures. Accounting Standards adopted in the fiscal 2018 with a cumulative effect to the 2018 opening balance of Retained Earnings The following table summarizes the cumulative effect adjustments made to the 2018 opening balance of retained earnings upon adoption of these accounting standards in 2018: (Dollars in Millions) Cumulative Effect Adjustment Increase (Decrease) to Retained Earnings ASU 2014-09 - Revenue from Contracts with Customers $ (47) ASU 2016-01 - Financial Instruments 232 ASU 2016-16 - Income Taxes: Intra-Entity Transfers (439) Total $ (254) Recently Issued Accounting Standards Not Adopted as of January 3, 2021 The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company’s Annual Report on Form 10-K for the fiscal year ended December 29, 2019. There were no new material accounting standards issued in fiscal 2020 that impacted the Company. Cash Equivalents The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. The Company has a policy of making investments only with commercial institutions that have at least an investment grade credit rating. The Company invests its cash primarily in government securities and obligations, corporate debt securities, money market funds and reverse repurchase agreements (RRAs). RRAs are collateralized by deposits in the form of Government Securities and Obligations for an amount not less than 102% of their value. The Company does not record an asset or liability as the Company is not permitted to sell or repledge the associated collateral. The Company has a policy that the collateral has at least an A (or equivalent) credit rating. The Company utilizes a third party custodian to manage the exchange of funds and ensure that collateral received is maintained at 102% of the value of the RRAs on a daily basis. RRAs with stated maturities of greater than three months from the date of purchase are classified as marketable securities. Investments Investments classified as held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. Investments classified as available-for-sale debt securities are carried at estimated fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income. Available-for-sale securities available for current operations are classified as current assets otherwise, they are classified as long term. Management determines the appropriate classification of its investment in debt and equity securities at the time of purchase and re-evaluates such determination at each balance sheet date. The Company reviews its investments for impairment and adjusts these investments to fair value through earnings, as required. Property, Plant and Equipment and Depreciation Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets: Building and building equipment 20 - 30 years Land and leasehold improvements 10 - 20 years Machinery and equipment 2 - 13 years The Company capitalizes certain computer software and development costs, included in machinery and equipment, when incurred in connection with developing or obtaining computer software for internal use. Capitalized software costs are amortized over the estimated useful lives of the software, which generally range from 3 to 8 years. The Company reviews long-lived assets to assess recoverability using undiscounted cash flows. When certain events or changes in operating or economic conditions occur, an impairment assessment may be performed on the recoverability of the carrying value of these assets. If the asset is determined to be impaired, the loss is measured based on the difference between the asset’s fair value and its carrying value. If quoted market prices are not available, the Company will estimate fair value using a discounted value of estimated future cash flows. Revenue Recognition The Company recognizes revenue from product sales when obligations under the terms of a contract with the customer are satisfied; generally, this occurs with the transfer of control of the goods to customers. The Company's global payment terms are typically between 30 to 90 days. Provisions for certain rebates, sales incentives, trade promotions, coupons, product returns and discounts to customers are accounted for as variable consideration and recorded as a reduction in sales. The liability is recognized within Accrued Rebates, Returns, and Promotions on the consolidated balance sheet. Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including consideration of competitor pricing. Rebates are estimated based on contractual terms, historical experience, patient outcomes, trend analysis and projected market conditions in the various markets served. A significant portion of the liability related to rebates is from the sale of the Company's pharmaceutical products within the U.S., primarily t he Managed Care, Medicare and Medicaid programs, which amounted to $7.2 billion and $7.0 billion as of January 3, 2021 and December 29, 2019, respectively. The Company evaluates market conditions for products or groups of products primarily through the analysis of wholesaler and other third-party sell-through and market research data, as well as internally generated information. Sales returns are estimated and recorded based on historical sales and returns information. Products that exhibit unusual sales or return patterns due to dating, competition or other marketing matters are specifically investigated and analyzed as part of the accounting for sales return accruals. Sales returns allowances represent a reserve for products that may be returned due to expiration, destruction in the field, or in specific areas, product recall. The sales returns reserve is based on historical return trends by product and by market as a percent to gross sales. In accordance with the Company’s accounting policies, the Company generally issues credit to customers for returned goods. The Company’s sales returns reserves are accounted for in accordance with the U.S. GAAP guidance for revenue recognition when right of return exists. Sales returns reserves are recorded at full sales value. Sales returns in the Consumer Health and Pharmaceutical segments are almost exclusively not resalable. Sales returns for certain franchises in the Medical Devices segment are typically resalable but are not material. The Company infrequently exchanges products from inventory for returned products. The sales returns reserve for the total Company has been approximately 1.0% of annual net trade sales during each of the fiscal years 2020, 2019 and 2018. Promotional programs, such as product listing allowances and cooperative advertising arrangements, are recorded in the same period as related sales. Continuing promotional programs include coupons and volume-based sales incentive programs. The redemption cost of consumer coupons is based on historical redemption experience by product and value. Volume-based incentive programs are based on the estimated sales volumes for the incentive period and are recorded as products are sold. These arrangements are evaluated to determine the appropriate amounts to be deferred or recorded as a reduction of revenue. The Company also earns profit-share payments through collaborative arrangements for certain products, which are included in sales to customers. For all years presented, profit-share payments were less than 3.0% of the total revenues and are included in sales to customers. See Note 17 to the Consolidated Financial Statements for further disaggregation of revenue. Shipping and Handling Shipping and handling costs incurred were $1.0 billion, $1.0 billion and $1.1 billion in fiscal years 2020, 2019 and 2018, respectively, and are included in selling, marketing and administrative expense. The amount of revenue received for shipping and handling is less than 0.5% of sales to customers for all periods presented. Inventories Inventories are stated at the lower of cost or net realizable value determined by the first-in, first-out method. Intangible Assets and Goodwill The authoritative literature on U.S. GAAP requires that goodwill and intangible assets with indefinite lives be assessed annually for impairment. The Company completed its annual impairment test for 2020 in the fiscal fourth quarter. Future impairment tests will be performed annually in the fiscal fourth quarter, or sooner if warranted. Purchased in-process research and development is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset, or abandoned, at which point the intangible asset will be written off or partially impaired. Intangible assets that have finite useful lives continue to be amortized over their useful lives, and are reviewed for impairment when warranted by economic conditions. See Note 5 for further details on Intangible Assets and Goodwill. Financial Instruments As required by U.S. GAAP, all derivative instruments are recorded on the balance sheet at fair value. Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value, with Level 1 having the highest priority and Level 3 having the lowest. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction. The Company documents all relationships between hedged items and derivatives. The overall risk management strategy includes reasons for undertaking hedge transactions and entering into derivatives. The objectives of this strategy are: (1) minimize foreign currency exposure’s impact on the Company’s financial performance; (2) protect the Company’s cash flow from adverse movements in foreign exchange rates; (3) ensure the appropriateness of financial instruments; and (4) manage the enterprise risk associated with financial institutions. See Note 6 for additional information on Financial Instruments. Leases The Company determines whether an arrangement is a lease at contract inception by establishing if the contract conveys the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. Right of Use (ROU) Assets and Lease Liabilities for operating leases are included in Other assets Accrued liabilities Other liabilities ROU Assets and Lease Liabilities are recognized at the lease commencement date based on the present value of all minimum lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments, when the implicit rate is not readily determinable. Lease terms may include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected the following policy elections on adoption: use of portfolio approach on leases of assets under master service agreements, exclusion of short term leases on the balance sheet, and not separating lease and non-lease components. The Company primarily has operating lease for space, vehicles, manufacturing equipment and data processing equipment. The ROU asset pertaining to operating leases was $1.0 billion and $1.0 billion in 2020 and 2019, respectively. The lease liability was $1.1 billion and $1.0 billion in 2020 and 2019, respectively. The operating lease costs were $0.3 billion, $0.3 billion and $0.3 billion in 2020, 2019 and 2018, respectively. Cash paid for amounts included in the measurement of lease liabilities were $0.3 billion and $0.3 billion in 2020 and 2019, respectively. Product Liability Accruals for product liability claims are recorded, on an undiscounted basis, when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on existing information and actuarially determined estimates where applicable. The accruals are adjusted periodically as additional information becomes available. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. To the extent adverse verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated. The Company has self insurance through a wholly-owned captive insurance company. In addition to accruals in the self insurance program, claims that exceed the insurance coverage are accrued when losses are probable and amounts can be reasonably estimated. Research and Development Research and development expenses are expensed as incurred in accordance with ASC 730, Research and Development. Upfront and milestone payments made to third parties in connection with research and development collaborations are expensed as incurred up to the point of regulatory approval. Payments made to third parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product. Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization. The Company enters into collaborative arrangements, typically with other pharmaceutical or biotechnology companies, to develop and commercialize drug candidates or intellectual property. These arrangements typically involve two (or more) parties who are active participants in the collaboration and are exposed to significant risks and rewards dependent on the commercial success of the activities. These collaborations usually involve various activities by one or more parties, including research and development, marketing and selling and distribution. Often, these collaborations require upfront, milestone and royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. Amounts due from collaborative partners related to development activities are generally reflected as a reduction of research and development expense because the performance of contract development services is not central to the Company’s operations. In general, the income statement presentation for these collaborations is as follows: Nature/Type of Collaboration Statement of Earnings Presentation Third-party sale of product & profit share payments received Sales to customers Royalties/milestones paid to collaborative partner (post-regulatory approval)* Cost of products sold Royalties received from collaborative partner Other income (expense), net Upfront payments & milestones paid to collaborative partner (pre-regulatory approval) Research and development expense Research and development payments to collaborative partner Research and development expense Research and development payments received from collaborative partner or government entity Reduction of Research and development expense * Milestones are capitalized as intangible assets and amortized to cost of products sold over the useful life. For all years presented, there was no individual project that represented greater than 5% of the total annual consolidated research and development expense. The Company has a number of products and compounds developed in collaboration with strategic partners including XARELTO ® , co-developed with Bayer HealthCare AG and IMBRUVICA ® , developed in collaboration and co-marketed with Pharmacyclics LLC, an AbbVie company. Separately, the Company has a number of licensing arrangements for products and compounds including DARZALEX ® , licensed from Genmab A/S. Advertising Costs associated with advertising are expensed in the year incurred and are included in selling, marketing and administrative expenses. Advertising expenses worldwide, which comprised television, radio, print media and Internet advertising, were $2.1 billion, $2.2 billion and $2.6 billion in fiscal years 2020, 2019 and 2018, respectively. Income Taxes Income taxes are recorded based on amounts refundable or payable for the current year and include the results of any difference between U.S. GAAP accounting and tax reporting, recorded as deferred tax assets or liabilities. The Company estimates deferred tax assets and liabilities based on enacted tax regulations and rates. Future changes in tax laws and rates may affect recorded deferred tax assets and liabilities in the future. The Company has unrecognized tax benefits for uncertain tax positions. The Company follows U.S. GAAP which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management believes that changes in these estimates would not have a material effect on the Company's results of operations, cash flows or financial position. In 2017, the United States enacted into law new U.S. tax legislation, the U.S. Tax Cuts and Jobs Act (TCJA). This law included provisions for a comprehensive overhaul of the corporate income tax code, including a reduction of the statutory corporate tax rate from 35% to 21%, effective on January 1, 2018. The TCJA included a provision for a tax on all previously undistributed earnings of U.S. companies located in foreign jurisdictions. Undistributed earnings in the form of cash and cash equivalents were taxed at a rate of 15.5% and all other earnings were taxed at a rate of 8.0%. This tax is payable over 8 years and will not accrue interest. These payments began in 2018 and will continue through 2025. The remaining balance at the end of the 2020 was approximately $7.7 billion, of which $6.9 billion is classified as noncurrent and reflected as “Long-term taxes payable” on the Company’s balance sheet. The balance of this account is related to receivables from tax authorities not expected to be received in the next 12 months. The TCJA also includes provisions for a tax on global intangible low-taxed income (GILTI). GILTI is described as the excess of a U.S. shareholder’s total net foreign income over a deemed return on tangible assets, as provided by the TCJA. In January 2018, the FASB issued guidance that allows companies to elect as an accounting policy whether to record the tax effects of GILTI in the period the tax liability is generated (i.e., “period cost”) or provide for deferred tax assets and liabilities related to basis differences that exist and are expected to effect the amount of GILTI inclusion in future years upon reversal (i.e., “deferred method”). In 2018, the Company elected to account for GILTI under the deferred method. The deferred tax amounts recorded are based on the evaluation of temporary differences that are expected to reverse as GILTI is incurred in future periods. The Company has recorded deferred tax liabilities on all undistributed earnings prior to December 31, 2017 from its international subsidiaries. The Company has not provided deferred taxes on the undistributed earnings subsequent to January 1, 2018 from certain international subsidiaries where the earnings are considered to be indefinitely reinvested. The Company intends to continue to reinvest these earnings in those international operations. If the Company decides at a later date to repatriate these earnings to the U.S., the Company would be required to provide for the net tax effects on these amounts. The Company estimates that the total tax effect of this repatriation would be approximately $0.7 billion under current enacted tax laws and regulations and at current currency exchange rates. See Note 8 to the Consolidated Financial Statements for further information regarding income taxes. Net Earnings Per Share Basic earnings per share is computed by dividing net earnings available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution that could occur if securities were exercised or converted into common stock using the treasury stock method. Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the amounts reported. Estimates are used when accounting for sales discounts, rebates, allowances and incentives, product liabilities, income taxes, withholding taxes, depreciation, amortization, employee benefits, contingencies and intangible asset and liability valuations. Actual results may or may not differ from those estimates. The Company follows the provisions of U.S. GAAP when recording litigation related contingencies. A liability is recorded when a loss is probable and can be reasonably estimated. The best estimate of a loss within a range is accrued; however, if no estimate in the range is better than any other, the minimum amount is accrued. The extent to which COVID-19 impacts the Company’s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of January 3, 2021 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s allowance for doubtful accounts and credit losses, inventory and related reserves, accrued rebates and associated reserves, and the carrying value of the goodwill and other long-lived assets. While there was not a material impact to the Company’s consolidated financial statements as of and for the fiscal year ended January 3, 2021, the Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company’s consolidated financial statements in future reporting periods. Annual Closing Date The Company follows the concept of a fiscal year, which ends on the Sunday nearest to the end of the month of December. Normally each fiscal year consists of 52 weeks, but every five or six years the fiscal year consists of 53 weeks, and therefore includes additional shipping days, as was the case in fiscal year 2020, and will be the case again in fiscal year 2026. Reclassification Certain prior period amounts have been reclassified to conform to current year presentation.

Cash, Cash Equivalents and Curr

Cash, Cash Equivalents and Current Marketable Securities	12 Months Ended
Cash, Cash Equivalents and Current Marketable Securities	Jan. 03, 2021
Cash and Cash Equivalents [Abstract]
Cash, Cash Equivalents and Current Marketable Securities	Cash, Cash Equivalents and Current Marketable Securities At the end of the fiscal year 2020 and 2019, cash, cash equivalents and current marketable securities were comprised of: (Dollars in Millions) 2020 Carrying Amount Unrecognized Gain Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities Cash $ 2,863 — 2,863 2,863 — Non-U.S. Sovereign Securities (1) 690 — 690 — 690 U.S. Reverse repurchase agreements 1,937 — 1,937 1,937 — Corporate debt securities (1) 2,674 — 2,674 1,451 1,223 Money market funds 2,102 — 2,102 2,102 — Time deposits (1) 877 — 877 877 — Subtotal $ 11,143 — 11,143 9,230 1,913 U.S. Gov't Securities $ 13,777 1 13,778 4,731 9,047 Other Sovereign Securities 14 — 14 — 14 Corporate debt securities 250 — 250 24 226 Subtotal available for sale (2) $ 14,041 1 14,042 4,755 9,287 Total cash, cash equivalents and current marketable securities $ 13,985 11,200 (Dollars in Millions) 2019 Carrying Amount Cash & Cash Equivalents Current Marketable Securities Cash $ 2,637 2,637 — Non-U.S. Sovereign Securities (1) 439 149 290 U.S. Reverse repurchase agreements 6,375 6,375 — Other Reverse repurchase agreements 375 375 — Corporate debt securities (1) 1,323 889 434 Money market funds 2,864 2,864 — Time deposits (1) 906 906 — Subtotal $ 14,919 14,195 724 Gov't Securities $ 4,102 3,095 1,007 Corporate debt securities 266 15 251 Subtotal available for sale (2) $ 4,368 3,110 1,258 Total cash, cash equivalents and current marketable securities $ 17,305 1,982 (1) Held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. (2) Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income. At the end of fiscal year 2019, the carrying amount was the same as the estimated fair value. Fair value of government securities and obligations and corporate debt securities were estimated using quoted broker prices and significant other observable inputs. The contractual maturities of the available for sale debt securities at January 3, 2021 are as follows: (Dollars in Millions) Cost Basis Fair Value Due within one year $ 14,026 14,027 Due after one year through five years 15 15 Due after five years through ten years — — Total debt securities $ 14,041 14,042 The Company invests its excess cash in both deposits with major banks throughout the world and other high-quality money market instruments. The Company has a policy of making investments only with commercial institutions that have at least an investment grade credit rating.

Inventories

Inventories	12 Months Ended
Inventories	Jan. 03, 2021
Inventory Disclosure [Abstract]
Inventories	Inventories At the end of fiscal years 2020 and 2019, inventories were comprised of: (Dollars in Millions) 2020 2019 Raw materials and supplies $ 1,410 1,117 Goods in process 2,040 1,832 Finished goods 5,894 6,071 Total inventories (1) $ 9,344 9,020 (1)

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
Property, Plant and Equipment	Jan. 03, 2021
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property, Plant and Equipment At the end of fiscal years 2020 and 2019, property, plant and equipment at cost and accumulated depreciation were: (Dollars in Millions) 2020 2019 Land and land improvements $ 882 854 Buildings and building equipment 12,502 11,877 Machinery and equipment 29,104 26,964 Construction in progress 4,316 3,637 Total property, plant and equipment, gross $ 46,804 43,332 Less accumulated depreciation 28,038 25,674 Total property, plant and equipment, net (1) $ 18,766 17,658 (1) See Note 18 to the Consolidated Financial Statements for details on assets held for sale and the related divestitures for the fiscal year ended December 29, 2019. There were no assets held for sale at January 3, 2021. The Company capitalizes interest expense as part of the cost of construction of facilities and equipment. Interest expense capitalized in fiscal years 2020, 2019 and 2018 was $63 million, $70 million and $86 million, respectively. Depreciation expense, including the amortization of capitalized interest in fiscal years 2020, 2019 and 2018 was $2.6 billion, $2.5 billion and $2.6 billion, respectively. Upon retirement or other disposal of property, plant and equipment, the costs and related amounts of accumulated depreciation or amortization are eliminated from the asset and accumulated depreciation accounts, respectively. The difference, if any, between the net asset value and the proceeds are recorded in earnings.

Intangible Assets and Goodwill

Intangible Assets and Goodwill	12 Months Ended
Intangible Assets and Goodwill	Jan. 03, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	Intangible Assets and Goodwill At the end of fiscal years 2020 and 2019, the gross and net amounts of intangible assets were: (Dollars in Millions) 2020 2019 Intangible assets with definite lives: Patents and trademarks — gross $ 39,990 36,634 Less accumulated amortization 17,618 13,154 Patents and trademarks — net $ 22,372 23,480 Customer relationships and other intangibles — gross $ 22,898 22,056 Less accumulated amortization 10,912 9,462 Customer relationships and other intangibles — net* $ 11,986 12,594 Intangible assets with indefinite lives: Trademarks $ 7,195 6,922 Purchased in-process research and development (1) 11,849 4,647 Total intangible assets with indefinite lives $ 19,044 11,569 Total intangible assets — net $ 53,402 47,643 *The majority is comprised of customer relationships (1) In fiscal year 2020, the Company completed multiple acquisitions and recorded in-process research and development intangible assets of $6.0 billion from Momenta Pharmaceuticals, Inc., $0.8 billion for bermekimab and certain related assets from XBiotech, Inc., and $0.4 billion from the acquisition of all outstanding shares in Verb Surgical, Inc. Goodwill as of January 3, 2021 and December 29, 2019, as allocated by segment of business, was as follows: (Dollars in Millions) Consumer Health Pharmaceutical Medical Devices Total Goodwill at December 30, 2018 $ 8,670 9,063 12,720 30,453 Goodwill, related to acquisitions 1,188 75 2,018 3,281 Currency translation/other (122) 31 (4) (95) Goodwill at December 29, 2019 $ 9,736 9,169 14,734 33,639 Goodwill, related to acquisitions — 1,222 238 1,460 Currency translation/other 600 618 76 1,294 Goodwill at January 3, 2021 $ 10,336 11,009 15,048 36,393 The weighted average amortization period for patents and trademarks is 12 years. The weighted average amortization period for customer relationships and other intangible assets is 21 years. The amortization expense of amortizable assets included in cost of products sold was $4.7 billion, $4.5 billion and $4.4 billion before tax, for the fiscal years ended January 3, 2021, December 29, 2019 and December 30, 2018, respectively. Intangible asset write-downs are included in Other (income) expense, net. The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately: (Dollars in Millions) 2021 2022 2023 2024 2025 $4,600 4,200 4,100 3,900 3,200 See Note 18 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
Fair Value Measurements	Jan. 03, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany products and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges. Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings. These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of January 3, 2021, the total amount of cash collateral paid by the Company under the CSA amounted to $1.1 billion net, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of January 3, 2021, the Company had notional amounts outstanding for forward foreign exchange contracts, and cross currency interest rate swaps of $37.8 billion and $30.6 billion, respectively. As of December 29, 2019, the Company had notional amounts outstanding for forward foreign exchange contracts and cross currency interest rate swaps of $45.3 billion and $20.1 billion, respectively. All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction. The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings. Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings, and are then reclassified to earnings in the same account as the hedged transaction. Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur. The effect of which are immaterial for the fiscal years ended January 3, 2021 and December 29, 2019. Gains and losses on net investment hedge are accounted through the currency translation account within accumulated other comprehensive income. The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued. The Company designated its Euro denominated notes issued in May 2016 with due dates ranging from 2022 to 2035 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates. As of January 3, 2021, the balance of deferred net gain on derivatives included in accumulated other comprehensive income was $652 million after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 13. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts, net investment hedges. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative. The following table is a summary of the activity related to derivatives and hedges for the fiscal years ended January 3, 2021 and December 29, 2019, net of tax: January 3, 2021 December 29, 2019 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing $ — — — 153 — — — — 159 — Amount of gain or (loss) recognized in AOCI — — — 153 — — — — 159 — Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income 12 (329) (137) — (16) (54) (321) (105) — 22 Amount of gain or (loss) recognized in AOCI 44 298 (191) — (52) (20) (606) (94) — 39 Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income — — — 370 — — — — 292 — Amount of gain or (loss) recognized in AOCI $ — — — 748 — — — — 417 — The following table is the effect of derivatives not designated as hedging instrument for the fiscal years ended January 3, 2021 and December 29, 2019: (Dollars in Millions) Location of Gain /(Loss) Recognized in Income on Derivative Gain/(Loss) Derivatives Not Designated as Hedging Instruments January 3, 2021 December 29, 2019 Foreign Exchange Contracts Other (income) expense $ 24 (144) The following table is the effect of net investment hedges for the fiscal years ended January 3, 2021 and December 29, 2019: Gain/(Loss) Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income Gain/(Loss) Reclassified From (Dollars in Millions) January 3, 2021 December 29, 2019 January 3, 2021 December 29, 2019 Debt $ (473) 121 Interest (income) expense — — Cross Currency interest rate swaps $ 65 488 Interest (income) expense — — The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values. The Company measures equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. The following table is a summary of the activity related to equity investments for the fiscal years ended January 3, 2021 and December 29, 2019: December 29, 2019 January 3, 2021 (Dollars in Millions) Carrying Value Changes in Fair Value Reflected in Net Income (1) Sales/ Purchases/Other (2) Carrying Value Non Current Other Assets Equity Investments with readily determinable value $ 1,148 527 (194) 1,481 1,481 Equity Investments without readily determinable value $ 712 (55) 81 738 738 December 30, 2018 December 29, 2019 (Dollars in Millions) Carrying Value Changes in Fair Value Reflected in Net Income (1) Sales/ Purchases/Other (2) Carrying Value Non Current Other Assets Equity Investments with readily determinable value $ 511 533 104 1,148 1,148 Equity Investments without readily determinable value $ 681 (38) 69 712 712 (1) Recorded in Other Income/Expense (2) Other includes impact of currency For the fiscal years ended January 3, 2021 and December 29, 2019 for equity investments without readily determinable market values, $76 million and $57 million, respectively, of the changes in fair value reflected in net income were the result of impairments. There were $21 million and $19 million, respectively, of changes in fair value reflected in net income due to changes in observable prices. Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. In accordance with ASC 820, a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 having the highest priority and Level 3 having the lowest. The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company’s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations. The following three levels of inputs are used to measure fair value: Level 1 — Quoted prices in active markets for identical assets and liabilities. Level 2 — Significant other observable inputs. Level 3 — Significant unobservable inputs. The Company’s significant financial assets and liabilities measured at fair value as of the fiscal year ended January 3, 2021 and December 29, 2019 were as follows: 2020 2019 (Dollars in Millions) Level 1 Level 2 Level 3 Total Total (1) Derivatives designated as hedging instruments: Assets: Forward foreign exchange contracts $ — 849 — 849 209 Interest rate contracts (2)(3) — 240 — 240 693 Total $ — 1,089 — 1,089 902 Liabilities: Forward foreign exchange contracts — 702 — 702 426 Interest rate contracts (3) — 1,569 — 1,569 193 Total $ — 2,271 — 2,271 619 Derivatives not designated as hedging instruments: Assets: Forward foreign exchange contracts $ — 49 — 49 23 Liabilities: Forward foreign exchange contracts — 38 — 38 33 Available For Sale Other Investments: Equity investments (4) 1,481 — — 1,481 1,148 Debt securities (5) — 14,042 — 14,042 4,368 Other Liabilities Contingent Consideration (6) $ 633 633 1,715 Gross to Net Derivative Reconciliation 2020 2019 (Dollars in Millions) Total Gross Assets $ 1,138 925 Credit Support Agreement (CSA) (1,107) (841) Total Net Asset 31 84 Total Gross Liabilities 2,309 652 Credit Support Agreement (CSA) (2,172) (586) Total Net Liabilities $ 137 66 Summarized information about changes in liabilities for contingent consideration is as follows: 2020 2019 2018 (Dollars in Millions) Beginning Balance $ 1,715 397 600 Changes in estimated fair value (7) (1,089) 151 (156) Additions 106 1,246 125 Payments (99) (79) (172) Ending Balance $ 633 1,715 397 (1) 2019 assets and liabilities are all classified as Level 2 with the exception of equity investments of $1,148 million, which are classified as Level 1 and contingent consideration of $1,715 million, classified as Level 3. (2) Includes $1 million of non-current assets as of December 29, 2019. (3) Includes cross currency interest rate swaps and interest rate swaps. (4) Classified as non-current other assets. (5) Classified as cash equivalents and current marketable securities. (6) Includes $594 million, $1,631 million (primarily related to Auris Health) and $397 million, classified as non-current other liabilities as of January 3, 2021, December 29, 2019 and December 30, 2018, respectively. Includes $39 million and $84 million classified as current liabilities as of January 3, 2021 and December 29, 2019, respectively. (7) Ongoing fair value adjustment amounts are recorded primarily in Research and Development expense. The Company recorded a contingent consideration reversal of $1,148 million in 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. The reversal of the contingent consideration was recorded in Other income and expense See Notes 2 and 7 for financial assets and liabilities held at carrying amount on the Consolidated Balance Sheet.

Borrowings

Borrowings	12 Months Ended
Borrowings	Jan. 03, 2021
Debt Disclosure [Abstract]
Borrowings	Borrowings The components of long-term debt are as follows: (Dollars in Millions) 2020 Effective Rate % 2019 Effective Rate % 3% Zero Coupon Convertible Subordinated Debentures due 2020 $ — — 51 3.00 2.95% Debentures due 2020 — — 549 3.15 1.950% Notes due 2020 — — 500 1.99 3.55% Notes due 2021 450 3.67 449 3.67 2.45% Notes due 2021 350 2.48 349 2.48 1.65% Notes due 2021 999 1.65 999 1.65 0.250% Notes due 2022 (1B Euro 1.2281) (2) /(1B Euro 1.1096) (3) 1,227 (2) 0.26 1,108 (3) 0.26 2.25% Notes due 2022 999 2.31 998 2.31 6.73% Debentures due 2023 250 6.73 250 6.73 3.375% Notes due 2023 803 3.17 804 3.17 2.05% Notes due 2023 499 2.09 498 2.09 0.650% Notes due 2024 (750MM Euro 1.2281) (2) /(750MM Euro 1.1096) (3) 919 (2) 0.68 829 (3) 0.68 5.50% Notes due 2024 (500MM 1.3654 GBP ) (2) /(500MM GBP 1.2987) (3) 679 (2) 6.75 645 (3) 6.75 2.625% Notes due 2025 748 2.63 748 2.63 0.55% Notes due 2025 (5) 996 0.57 — — 2.45% Notes due 2026 1,994 2.47 1,993 2.47 2.95% Notes due 2027 997 2.96 996 2.96 0.95% Notes due 2027 (5) 1,494 0.96 — — 1.150% Notes due 2028 (750MM Euro 1.2281) (2) /(750MM Euro 1.1096) (3) 915 (2) 1.21 825 (3) 1.21 2.90% Notes due 2028 1,495 2.91 1,494 2.91 6.95% Notes due 2029 297 7.14 297 7.14 1.30% Notes due 2030 (5) 1,743 1.30 — — 4.95% Debentures due 2033 498 4.95 498 4.95 4.375% Notes due 2033 855 4.24 855 4.24 1.650% Notes due 2035 (1.5B Euro 1.2281) (2) /(1.5B Euro 1.1096) (3) 1,827 (2) 1.68 1,649 (3) 1.68 3.55% Notes due 2036 989 3.59 989 3.59 5.95% Notes due 2037 992 5.99 992 5.99 3.625% Notes due 2037 1,488 3.64 1,487 3.64 5.85% Debentures due 2038 696 5.85 696 5.85 3.400% Notes due 2038 991 3.42 991 3.42 4.50% Debentures due 2040 539 4.63 539 4.63 2.10% Notes due 2040 (5) 986 2.14 — — 4.85% Notes due 2041 297 4.89 297 4.89 4.50% Notes due 2043 496 4.52 495 4.52 3.70% Notes due 2046 1,974 3.74 1,973 3.74 3.75% Notes due 2047 991 3.76 991 3.76 3.500% Notes due 2048 742 3.52 742 3.52 2.250% Notes due 2050 (5) 984 2.29 — — 2.450% Notes due 2060 (5) 1,228 2.49 — — Other 7 — 18 — Subtotal 34,434 (4) 2.85 % (1) 27,594 (4) 3.19 (1) Less current portion 1,799 1,100 Total long-term debt $ 32,635 26,494 (1) Weighted average effective rate. (2) Translation rate at January 3, 2021. (3) Translation rate at December 29, 2019. (4) The excess of the fair value over the carrying value of debt was $5.4 billion at the end of fiscal year 2020 and $3.0 billion at the end of fiscal year 2019. (5) In the fiscal third quarter of 2020, the Company issued senior unsecured notes for a total of $7.5 billion. Fair value of the long-term debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs. The Company has access to substantial sources of funds at numerous banks worldwide. In September 2020, the Company secured a new 364-day Credit Facility. Total credit available to the Company approximates $10 billion, which expires on September 9, 2021. Interest charged on borrowings under the credit line agreement is based on either bids provided by banks, London Interbank Offered Rates (LIBOR), Secured Overnight Financing Rate (SOFR) Swap Curve or other applicable market rate as allowed plus applicable margins. Commitment fees under the agreements are not material. Throughout fiscal year 2020, the Company continued to have access to liquidity through the commercial paper market. Short-term borrowings and the current portion of long-term debt amounted to approximately $2.6 billion at the end of fiscal year 2020, of which $1.8 billion is the current portion of the long-term debt, and the remainder is commercial paper and local borrowings by international subsidiaries. Throughout fiscal year 2019, the Company continued to have access to liquidity through the commercial paper market. Short-term borrowings and the current portion of long-term debt amounted to approximately $1.2 billion at the end of fiscal year 2019, of which $1.1 billion is the current portion of the long term debt, and the remainder principally represents local borrowing by international subsidiaries. Aggregate maturities of long-term debt obligations commencing in 2021 are: (Dollars in Millions) 2021 2022 2023 2024 2025 After 2025 $1,799 2,226 1,552 1,598 1,744 25,515

Income Taxes

Income Taxes	12 Months Ended
Income Taxes	Jan. 03, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The provision for taxes on income consists of: (Dollars in Millions) 2020 2019 2018 Currently payable: U.S. taxes $ 1,026 1,941 1,284 International taxes 1,898 2,744 2,434 Total currently payable 2,924 4,685 3,718 Deferred: U.S. taxes (76) (814) 1,210 (1) International taxes (1,065) (1,662) (2,226) Total deferred (1,141) (2,476) (1,016) Provision for taxes on income $ 1,783 2,209 2,702 (1) Includes $1.4 billion of deferred tax expense for the adoption of the deferred method to account for GILTI. A comparison of income tax expense at the U.S. statutory rate of 21% in fiscal years 2020, 2019 and 2018, to the Company’s effective tax rate is as follows: (Dollars in Millions) 2020 2019 2018 U.S. $ 4,312 3,543 5,575 International 12,185 13,785 12,424 Earnings before taxes on income: $ 16,497 17,328 17,999 Tax rates: U.S. statutory rate 21.0 % 21.0 21.0 International operations (1) (9.9) (5.9) (3.7) U.S. taxes on international income (2) 2.7 1.8 1.4 Tax benefits on Capital Loss (1.2) (0.3) (4) — Tax benefits on share-based compensation (1.5) (0.5) (1.5) TCJA and related impacts 0.7 (3.9) (3) (1.9) (3) All other (1.0) 0.5 (4) (0.3) Effective Rate 10.8 % 12.7 15.0 (1) For all periods presented the Company has subsidiaries operating in Puerto Rico under various tax incentives. International operations reflects the impacts of operations in jurisdictions with statutory tax rates different than the U.S., particularly Ireland, Switzerland and Puerto Rico, which is a favorable impact on the effective tax rate as compared with the U.S. statutory rate. The 2020 and 2019 amounts include the impact of the new tax legislation enactment in Switzerland, which is further described below. (2) Includes the impact of the GILTI tax, the Foreign-Derived Intangible Income deduction and other foreign income that is taxable under the U.S. tax code. (3) Represents impact of adjustments to balances originally recorded as part of the 2017 TCJA provisional tax charge. Further information provided below. (4) Certain prior year amounts have been reclassified to conform to current year presentation. The fiscal year 2020 tax rate decreased by 1.9% compared to the fiscal year 2019 tax rate, which was primarily driven by the following items. In fiscal year 2019, Switzerland enacted the Federal Act on Tax Reform and AHV Financing (TRAF) which became effective on January 1, 2020. The Federal transitional provisions of TRAF allow companies, under certain conditions, to adjust the tax basis in certain assets to fair value (i.e., “step-up”) to be depreciated and amortized resulting in an incremental Swiss tax deduction over the transitional period. TRAF also provides for parameters which enable the Swiss cantons to establish localized tax rates and regulations for companies. The new cantonal tax parameters include favorable tax benefits for patents and additional research and development tax deductions. The cantonal transitional provisions of TRAF allowed companies to elect either 1) tax basis step-up similar to the Federal transition benefit or 2) alternative statutory tax rate for a period not to exceed 5 years. The Company currently has operations located in various Swiss cantons. During the fiscal year 2019, as described in further detail below, the Company recorded the impacts of the TRAF that were enacted in that period. During the fiscal year 2020, the final canton where the Company maintains significant operations enacted TRAF legislation. Additionally, the Company received rulings from the Swiss Federal and cantonal tax authorities in the remaining jurisdictions where it has significant operations. These rulings resulted in the Company revising its estimate on the tax basis adjustment (i.e., “step-up”) for its assets and as a result, the Company recorded additional deferred tax benefits in 2020. The Company recognized a net benefit in the fiscal year 2020 for Swiss Tax Reform of approximately $0.4 billion or 2.6% benefit to the Company’s annual effective tax rate, comprised of the following items: • approximately $0.3 billion tax benefit relating to the remeasurement of Swiss deferred tax assets and liabilities for the change in the Federal and cantonal tax rates, where enactment occurred in the fiscal year 2020; this benefit has been reflected as “International Operations” on the Company’s effective tax rate reconciliation. • a $450 million deferred tax asset related to the estimated value of a Federal tax basis step-up of the Company’s Swiss subsidiaries’ assets as described above; this benefit has been reflected as “International Operations” on the Company’s effective tax rate reconciliation. • approximately $0.3 billion of U.S. deferred tax expense relating to the GILTI deferred tax liability resulting from the remeasurement of the Swiss deferred tax assets and liabilities in the fiscal year 2020. This benefit has been reflected as “U.S. tax on international income” on the Company’s effective tax rate reconciliation. The Company does not expect to receive future rulings regarding the transitional provisions of TRAF. Also, in the fiscal fourth quarter of 2020, the Company recognized a capital loss on certain U.S. affiliates related to the previously impaired book value of certain intangibles, which reduced the 2020 tax rate by approximately 1.2% which is reflected as a “Tax Benefits on Capital Loss” on the effective tax rate reconciliation. In addition in the fiscal year 2020, the Company had lower income in higher tax jurisdictions, primarily driven by: • the impact of the accrual of litigation costs related to Talc for $4.0 billion which reduced the U.S. earnings before taxes at an effective tax rate of 23.5%; • the accrual of additional legal costs, including an additional $1.0 billion associated with a revised agreement in principle to settle opioid litigation at an effective tax rate of 21.4% The Company also generated additional tax benefits from stock-based compensation that were either exercised or vested; reduced the contingent consideration liability related to the Auris Health acquisition (see Note 18); and reversal of some of its unrecognized tax benefits due to the completion of several years of tax examinations in certain jurisdictions during the fiscal year 2020. The fiscal year 2019 tax rate decreased by 2.3% compared to the fiscal year 2018 tax rate. In addition to the impact of TRAF discussed in more detail below, the primary drivers of the net decrease were as follows: • The Company reorganized the ownership structure of certain wholly-owned international subsidiaries in the fiscal fourth quarter of 2019, which resulted in a reduction of certain withholding and local taxes that it had previously recognized as part of the provisional Tax Cuts and Jobs Act (TCJA) tax charge in the fiscal year 2017 and finalized in the fiscal year 2018. Following the completion of this restructuring and approval by the applicable local authorities, the Company reversed a deferred tax liability of $0.6 billion and a related deferred tax asset of $0.2 billion for U.S. foreign tax credits, for a net deferred tax benefit of $0.4 billion decreasing the annual effective tax rate by 2.2%. This benefit has been reflected as “TCJA and related impacts” on the Company’s effective tax rate reconciliation. • The impact of the agreement in principle to settle opioid litigation for $4 billion (see Note 19 to the Consolidated Financial Statements) which reduced the U.S. earnings before taxes at an effective tax rate of 23.5% and decreased the Company’s annual effective tax rate by approximately 2.1%. • In December of fiscal year 2019, the U.S. Treasury issued final foreign tax credit regulations, which resulted in the Company revising the amount of foreign tax credits that were initially recorded in the fiscal year 2017 as part of the provisional TCJA tax charge. As a result, the Company recorded an increased deferred tax asset related to these foreign tax credits of approximately $0.3 billion or 1.7% to the annual effective tax rate. This benefit has been reflected as “TCJA and related impacts” on the Company’s effective tax rate reconciliation. • The Company reassessed its uncertain tax positions related to the current IRS audit and increased its unrecognized tax benefit by $0.3 billion liability which increased the annual effective tax rate by approximately 1.5% (see section on Unrecognized Tax Benefits for additional information). As these positions were related to uncertain tax regarding international transfer pricing, this expense has been classified as “International Operations” on the Company’s effective tax rate reconciliation. Subsequent to December 29, 2019, the Company received and agreed to Notices of Proposed Adjustments (NOPAs) from the IRS. The Company believes it is adequately reserved for potential exposures. • There were several one-time tax impacts that resulted in a cumulative net tax benefit to the 2018 annual effective tax rate of 1.2%. These items included the LifeScan divestiture, the adjustment to the 2017 provisional TCJA tax charge and the acceleration of certain tax deductions as part of the 2017 tax return. • More income in higher tax jurisdictions relative to lower tax jurisdictions as compared to 2018. As described above for the Swiss tax legislation, in the fiscal year 2019, the Company recorded a net tax expense of $0.1 billion which increased the effective tax rate for the fiscal year 2019 by approximately 0.6%. This net tax expense related to federal and certain cantonal enactments in the fiscal year 2019 consisting of the following provisions: • approximately $0.6 billion tax expense relating to the remeasurement of Swiss deferred tax assets and liabilities for the change in the Federal and cantonal tax rates, where enactment occurred by December 29, 2019; this expense has been reflected as “International Operations” on the Company’s effective tax rate reconciliation. • a $0.9 billion deferred tax asset related to the estimated value of a Federal tax basis step-up of the Company’s Swiss subsidiaries’ assets; this benefit has been reflected as “International Operations” on the Company’s effective tax rate reconciliation. • approximately $450 million of U.S. deferred tax expense relating to the GILTI deferred tax liability resulting from the remeasurement of the Swiss deferred tax assets and liabilities and the new deferred tax asset for the Federal step-up. This benefit has been reflected as “U.S. tax on international income” on the Company’s effective tax rate reconciliation. In the fiscal year 2018, the Company completed its full assessment and finalized the accounting for the impact of the TCJA. The Company recorded net adjustments to the above components of the provisional charge of approximately $0.2 billion. These revisions were based on updated estimates and additional analysis by management as well as applying interpretative guidance issued by the U.S. Department of Treasury to the facts and circumstances that existed as of the TCJA enactment date. This charge was primarily related to additional deferred tax liabilities for foreign local and withholding taxes for the remaining balance of undistributed foreign earnings as of December 31, 2017 that were not provided for in the 2017 provisional charge. As described in Note 1, in the fiscal year 2018, the Company elected to treat GILTI as a period expense under the deferred method and recorded a deferred tax cost of approximately $1.4 billion in the fiscal year 2018 related to facts and circumstances that existed on the date of TCJA enactment. During 2018, the Company reorganized the ownership structure of certain foreign subsidiaries which resulted in a reduction of certain foreign withholding taxes that it had recognized as part of the provisional TCJA tax charge in the fourth quarter of 2017. Following the completion of this restructuring and as a result of clarification by Swiss tax authorities regarding the applicability of withholding tax to repatriation of certain earnings, the Company reversed a deferred tax liability of $2.8 billion and a related deferred tax asset of $0.9 billion for U.S. foreign tax credits, for a net deferred tax benefit of $1.9 billion. This benefit has been reflected as “TCJA and related impacts” on the Company’s effective tax rate reconciliation. Temporary differences and carryforwards at the end of fiscal years 2020 and 2019 were as follows: 2020 Deferred Tax 2019 Deferred Tax* (Dollars in Millions) Asset Liability Asset Liability Employee related obligations $ 2,434 2,473 Stock based compensation 627 595 Depreciation & amortization 721 1,122 Non-deductible intangibles (6,567) (5,835) International R&D capitalized for tax 1,517 1,189 Reserves & liabilities 3,466 2,337 Income reported for tax purposes 1,705 1,605 Net operating loss carryforward international 990 838 Undistributed foreign earnings 812 (1,435) 765 (1,289) Global intangible low-taxed income (3,606) (2,965) Miscellaneous international 854 (211) 696 (81) Miscellaneous U.S. 12 411 Total deferred income taxes $ 13,138 (11,819) 12,031 (10,170) * Certain prior year amounts have been reclassified to conform to current year presentation The Company has wholly-owned international subsidiaries that have cumulative net losses. The Company believes that it is more likely than not that these subsidiaries will generate future taxable income sufficient to utilize these deferred tax assets. The following table summarizes the activity related to unrecognized tax benefits: (Dollars in Millions) 2020 2019 2018 Beginning of year $ 3,853 3,326 3,151 Increases related to current year tax positions 265 249 242 Increases related to prior period tax positions 668 408 145 Decreases related to prior period tax positions (551) (105) (137) Settlements (839) (9) (40) Lapse of statute of limitations (23) (16) (35) End of year $ 3,373 3,853 3,326 The unrecognized tax benefits of $3.4 billion at January 3, 2021, if recognized, would affect the Company’s annual effective tax rate. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress with a number of tax authorities. With respect to the United States, the Internal Revenue Service (IRS) has completed its audit for the tax years through 2012. As of December 29, 2019, the Company classified unrecognized tax benefits and related interest of approximately $0.9 billion as a current liability on the “Accrued taxes on Income” line of the Consolidated Balance Sheet. In the fiscal year 2020, the Company made its final payments for approximately $0.7 billion to the U.S. Treasury related to the final settlement of 2010-2012 tax audit liability. In other major jurisdictions where the Company conducts business, the years that remain open to tax audit go back to the year 2006. The Company believes it is possible that tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions outside of the United States. However, the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments relating to uncertain tax positions. The Company classifies liabilities for unrecognized tax benefits and related interest and penalties as long-term liabilities, except as previously noted on amounts related to the current United States IRS audit. Interest expense and penalties related to unrecognized tax benefits are classified as income tax expense. The Company recognized after tax interest expense of $32 million, $50 million and $53 million in fiscal years 2020, 2019 and 2018, respectively. The total amount of accrued interest was $468 million and $559 million in fiscal years 2020 and 2019, respectively.

Employee Related Obligations

Employee Related Obligations	12 Months Ended
Employee Related Obligations	Jan. 03, 2021
Compensation Related Costs [Abstract]
Employee Related Obligations	Employee Related Obligations At the end of fiscal 2020 and fiscal 2019, employee related obligations recorded on the Consolidated Balance Sheets were: (Dollars in Millions) 2020 2019 Pension benefits $ 5,761 5,538 Postretirement benefits 2,229 2,297 Postemployment benefits 3,078 3,004 Deferred compensation 250 338 Total employee obligations 11,318 11,177 Less current benefits payable 547 514 Employee related obligations — non-current $ 10,771 10,663 Prepaid employee related obligations of $656 million and $551 million for 2020 and 2019, respectively, are included in Other assets on the Consolidated Balance Sheets.

Pensions and Other Benefit Plan

Pensions and Other Benefit Plans	12 Months Ended
Pensions and Other Benefit Plans	Jan. 03, 2021
Retirement Benefits [Abstract]
Pensions and Other Benefit Plans	Pensions and Other Benefit Plans The Company sponsors various retirement and pension plans, including defined benefit, defined contribution and termination indemnity plans, which cover most employees worldwide. The Company also provides post-retirement benefits, primarily health care, to all eligible U.S. retired employees and their dependents. Many international employees are covered by government-sponsored programs and the cost to the Company is not significant. In the U.S, non-union pension benefits for employees hired before January 1, 2015 are primarily based on the employee’s compensation during the last five years before retirement and the number of years of service (the Final Average Pay formula). U.S. pension benefits for employees hired after 2014, are calculated using a different formula based on employee compensation over total years of service (the Retirement Value formula). In January 2021, the Company announced that, effective on January 1, 2026, all eligible U.S. non-union employees, regardless of hire date, will earn benefits under the Retirement Value formula. This amendment does not affect the benefits accrued under the Final Average Pay formula for service before January 1, 2026. The impact of this change decreases the PBO as of January 3, 2021 by approximately $1.8 billion and is included in the “Amendments” line in the Change in Benefit Obligation. International subsidiaries have plans under which funds are deposited with trustees, annuities are purchased under group contracts, or reserves are provided. The Company does not fund retiree health care benefits in advance and has the right to modify these plans in the future. In 2020 and 2019 the Company used December 31, 2020 and December 31, 2019, respectively, as the measurement date for all U.S. and international retirement and other benefit plans. Net periodic benefit costs for the Company’s defined benefit retirement plans and other benefit plans for 2020, 2019 and 2018 include the following components: Retirement Plans Other Benefit Plans (Dollars in Millions) 2020 2019 2018 2020 2019 2018 Service cost $ 1,380 1,163 1,283 287 274 269 Interest cost 955 1,096 996 133 185 148 Expected return on plan assets (2,461) (2,322) (2,212) (7) (6) (7) Amortization of prior service cost 2 4 3 (31) (31) (31) Recognized actuarial losses (gains) 891 579 852 142 129 123 Curtailments and settlements 23 73 1 — — — Net periodic benefit cost $ 790 593 923 524 551 502 Unrecognized gains and losses for the U.S. pension plans are amortized over the average remaining future service for each plan. For plans with no active employees, they are amortized over the average life expectancy. The amortization of gains and losses for the other U.S. benefit plans is determined by using a 10% corridor of the greater of the market value of assets or the accumulated postretirement benefit obligation. Total unamortized gains and losses in excess of the corridor are amortized over the average remaining future service. Prior service costs/benefits for the U.S. pension plans are amortized over the average remaining future service of plan participants at the time of the plan amendment. Prior service cost/benefit for the other U.S. benefit plans is amortized over the average remaining service to full eligibility age of plan participants at the time of the plan amendment. The following table represents the weighted-average actuarial assumptions: Retirement Plans Other Benefit Plans Worldwide Benefit Plans 2020 2019 2018 2020 2019 2018 Net Periodic Benefit Cost Service cost discount rate 2.82 % 3.63 3.20 3.04 4.45 3.85 Interest cost discount rate 3.13 % 4.13 3.60 3.08 4.25 3.62 Rate of increase in compensation levels 4.00 % 3.99 3.98 4.25 4.29 4.29 Expected long-term rate of return on plan assets 8.12 % 8.31 8.46 Benefit Obligation Discount rate 2.14 % 2.91 3.76 2.23 3.39 4.40 Rate of increase in compensation levels 4.00 % 4.01 3.97 4.27 4.29 4.29 The Company’s discount rates are determined by considering current yield curves representing high quality, long-term fixed income instruments. The resulting discount rates are consistent with the duration of plan liabilities. The Company's methodology in determining service and interest cost uses duration specific spot rates along that yield curve to the plans' liability cash flows. The expected rates of return on plan asset assumptions represent the Company's assessment of long-term returns on diversified investment portfolios globally. The assessment is determined using projections from external financial sources, long-term historical averages, actual returns by asset class and the various asset class allocations by market. The following table displays the assumed health care cost trend rates, for all individuals: Health Care Plans 2020 2019 Health care cost trend rate assumed for next year 5.68 % 5.87 % Rate to which the cost trend rate is assumed to decline (ultimate trend) 4.49 % 4.50 % Year the rate reaches the ultimate trend rate 2040 2040 The following table sets forth information related to the benefit obligation and the fair value of plan assets at fiscal year-end 2020 and 2019 for the Company’s defined benefit retirement plans and other post-retirement plans: Retirement Plans Other Benefit Plans (Dollars in Millions) 2020 2019 2020 2019 Change in Benefit Obligation Projected benefit obligation — beginning of year $ 37,188 31,670 5,076 4,480 Service cost 1,380 1,163 287 274 Interest cost 955 1,096 133 185 Plan participant contributions 61 63 — — Amendments (1) (1,780) — — — Actuarial (gains) losses (2) 5,716 5,178 (75) 562 Divestitures & acquisitions (88) (278) — — Curtailments, settlements & restructuring (24) (172) — — Benefits paid from plan (1,111) (1,555) (3) (396) (431) Effect of exchange rates 1,003 23 3 6 Projected benefit obligation — end of year $ 43,300 37,188 5,028 5,076 Change in Plan Assets Plan assets at fair value — beginning of year $ 32,201 26,818 115 180 Actual return on plan assets 5,524 6,185 14 19 Company contributions 870 908 357 347 Plan participant contributions 61 63 — — Settlements (13) (16) — — Divestitures & acquisitions (84) (274) — — Benefits paid from plan assets (1,111) (1,555) (3) (396) (431) Effect of exchange rates 747 72 — — Plan assets at fair value — end of year $ 38,195 32,201 90 115 Funded status — end of year $ (5,105) (4,987) (4,938) (4,961) Amounts Recognized in the Company’s Balance Sheet consist of the following: Non-current assets $ 656 551 — — Current liabilities (125) (113) (418) (397) Non-current liabilities (5,636) (5,425) (4,520) (4,564) Total recognized in the consolidated balance sheet — end of year $ (5,105) (4,987) (4,938) (4,961) Amounts Recognized in Accumulated Other Comprehensive Income consist of the following: Net actuarial loss $ 10,860 8,835 1,463 1,685 Prior service cost (credit) (1) (1,797) (8) (44) (75) Unrecognized net transition obligation — — — — Total before tax effects $ 9,063 8,827 1,419 1,610 Accumulated Benefit Obligations — end of year $ 40,356 33,416 (1) In January 2021, the Company announced that, effective on January 1, 2026, all eligible U.S. non-union employees, regardless of hire date, will earn benefits under the Retirement Value formula. This amendment does not affect the benefits accrued under the Final Average Pay formula for service before January 1, 2026. (2) The actuarial losses for retirement plans in 2020 and 2019 was primarily related to decreases in discount rates. (3) In 2019, the Company offered a voluntary lump-sum payment option for certain eligible former employees who are vested participants of the U.S. Qualified Defined Benefit Pension Plan. The distribution of the lump-sums was completed by the end of fiscal 2019. The amount distributed in 2019 was approximately $514 million. Retirement Plans Other Benefit Plans (Dollars in Millions) 2020 2019 2020 2019 Amounts Recognized in Net Periodic Benefit Cost and Other Comprehensive Income Net periodic benefit cost $ 790 593 524 551 Net actuarial (gain) loss 2,616 1,084 (81) 550 Amortization of net actuarial loss (891) (579) (142) (129) Prior service cost (credit) (1,780) — — — Amortization of prior service (cost) credit (2) (4) 31 31 Effect of exchange rates 293 1 1 1 Total loss/(income) recognized in other comprehensive income, before tax $ 236 502 (191) 453 Total recognized in net periodic benefit cost and other comprehensive income $ 1,026 1,095 333 1,004 The Company plans to continue to fund its U.S. Qualified Plans to comply with the Pension Protection Act of 2006. International Plans are funded in accordance with local regulations. Additional discretionary contributions are made when deemed appropriate to meet the long-term obligations of the plans. For certain plans, funding is not a common practice, as funding provides no economic benefit. Consequently, the Company has several pension plans that are not funded. In 2020, the Company contributed $441 million and $429 million to its U.S. and international pension plans, respectively. The following table displays the funded status of the Company's U.S. Qualified & Non-Qualified pension plans and international funded and unfunded pension plans at December 31, 2020 and December 31, 2019, respectively: U.S. Plans International Plans Qualified Plans Non-Qualified Plans Funded Plans Unfunded Plans (Dollars in Millions) 2020 2019 2020 2019 2020 2019 2020 2019 Plan Assets $ 25,554 21,398 — — 12,641 10,803 — — Projected Benefit Obligation 25,466 22,034 2,748 2,544 14,541 12,132 545 478 Accumulated Benefit Obligation 24,158 19,831 2,495 2,115 13,210 11,040 493 430 Over (Under) Funded Status Projected Benefit Obligation $ 88 (636) (2,748) (2,544) (1,900) (1,329) (545) (478) Accumulated Benefit Obligation 1,396 1,567 (2,495) (2,115) (569) (237) (493) (430) Plans with accumulated benefit obligations in excess of plan assets have an accumulated benefit obligation, projected benefit obligation and plan assets of $8.8 billion, $9.8 billion and $4.4 billion, respectively, at the end of 2020, and $4.3 billion, $5.2 billion and $0.9 billion, respectively, at the end of 2019. The following table displays the projected future benefit payments from the Company’s retirement and other benefit plans: (Dollars in Millions) 2021 2022 2023 2024 2025 2026-2030 Projected future benefit payments Retirement plans $ 1,257 1,292 1,388 1,424 1,494 8,795 Other benefit plans $ 427 440 453 465 417 2,273 The following table displays the projected future minimum contributions to the unfunded retirement plans. These amounts do not include any discretionary contributions that the Company may elect to make in the future. (Dollars in Millions) 2021 2022 2023 2024 2025 2026-2030 Projected future contributions $ 110 116 121 130 136 787 Each pension plan is overseen by a local committee or board that is responsible for the overall administration and investment of the pension plans. In determining investment policies, strategies and goals, each committee or board considers factors including, local pension rules and regulations; local tax regulations; availability of investment vehicles (separate accounts, commingled accounts, insurance funds, etc.); funded status of the plans; ratio of actives to retirees; duration of liabilities; and other relevant factors including: diversification, liquidity of local markets and liquidity of base currency. A majority of the Company’s pension funds are open to new entrants and are expected to be on-going plans. Permitted investments are primarily liquid and/or listed, with little reliance on illiquid and non-traditional investments such as hedge funds. The Company’s retirement plan asset allocation at the end of 2020 and 2019 and target allocations for 2021 are as follows: Percent of Target 2020 2019 2021 Worldwide Retirement Plans Equity securities 66 % 74 % 67 % Debt securities 34 26 33 Total plan assets 100 % 100 % 100 % Determination of Fair Value of Plan Assets The Plan has an established and well-documented process for determining fair values. Fair value is based upon quoted market prices, where available. If listed prices or quotes are not available, fair value is based upon models that primarily use, as inputs, market-based or independently sourced market parameters, including yield curves, interest rates, volatilities, equity or debt prices, foreign exchange rates and credit curves. While the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. Valuation Hierarchy The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described in the table below with Level 1 having the highest priority and Level 3 having the lowest. The Net Asset Value (NAV) is based on the value of the underlying assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding. A financial instrument’s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Following is a description of the valuation methodologies used for the investments measured at fair value. • Short-term investment funds — Cash and quoted short-term instruments are valued at the closing price or the amount held on deposit by the custodian bank. Other investments are through investment vehicles valued using the NAV provided by the administrator of the fund. The NAV is a quoted price in a market that is not active and classified as Level 2. • Government and agency securities — A limited number of these investments are valued at the closing price reported on the major market on which the individual securities are traded. Where quoted prices are available in an active market, the investments are classified within Level 1 of the valuation hierarchy. If quoted market prices are not available for the specific security, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows. When quoted market prices for a security are not available in an active market, they are classified as Level 2. • Debt instruments — A limited number of these investments are valued at the closing price reported on the major market on which the individual securities are traded. Where quoted prices are available in an active market, the investments are classified as Level 1. If quoted market prices are not available for the specific security, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows and are classified as Level 2. Level 3 debt instruments are priced based on unobservable inputs. • Equity securities — Equity securities are valued at the closing price reported on the major market on which the individual securities are traded. Substantially all equity securities are classified within Level 1 of the valuation hierarchy. • Commingled funds — These investment vehicles are valued using the NAV provided by the fund administrator. Assets in the Level 2 category have a quoted market price. • Other assets — Other assets are represented primarily by limited partnerships. These investment vehicles are valued using the NAV provided by the fund administrator. Other assets that are exchange listed and actively traded are classified as Level 1, while inactively traded assets are classified as Level 2. The following table sets forth the Retirement Plans' investments measured at fair value as of December 31, 2020 and December 31, 2019: Quoted Prices Significant Significant Unobservable Inputs (1) Investments Measured at Net Asset Value (Level 1) (Level 2) (Level 3) Total Assets (Dollars in Millions) 2020 2019 2020 2019 2020 2019 2020 2019 2020 2019 Short-term investment funds $ 127 119 763 405 — — — — 890 524 Government and agency securities — — 5,023 4,140 — — — — 5,023 4,140 Debt instruments — — 3,931 3,452 — — — — 3,931 3,452 Equity securities 14,375 12,483 2 2 — — — — 14,377 12,485 Commingled funds — — 4,690 3,338 160 181 8,236 7,580 13,086 11,099 Other assets — — 11 9 21 19 856 473 888 501 Investments at fair value $ 14,502 12,602 14,420 11,346 181 200 9,092 8,053 38,195 32,201 (1) The activity for the Level 3 assets is not significant for all years presented. The Company's Other Benefit Plans are unfunded except for U.S. commingled funds (Level 2) of $90 million and $84 million at December 31, 2020 and December 31, 2019, respectively and U.S. short-term investment funds (Level 2) of $31 million at December 31, 2019.

Savings Plan

Savings Plan	12 Months Ended
Savings Plan	Jan. 03, 2021
Savings Plan [Abstract]
Savings Plan	Savings PlanThe Company has voluntary 401(k) savings plans designed to enhance the existing retirement programs covering eligible employees. The Company matches a percentage of each employee’s contributions consistent with the provisions of the plan for which he/she is eligible. Total Company matching contributions to the plans were $243 million, $235 million and $242 million in fiscal years 2020, 2019 and 2018, respectively.

Capital and Treasury Stock

Capital and Treasury Stock	12 Months Ended
Capital and Treasury Stock	Jan. 03, 2021
Equity [Abstract]
Capital and Treasury Stock	Capital and Treasury Stock Changes in treasury stock were: Treasury Stock (Amounts in Millions Except Treasury Stock Shares in Thousands) Shares Amount Balance at December 31, 2017 437,318 $ 31,554 Employee compensation and stock option plans (22,082) (3,060) Repurchase of common stock 42,283 5,868 Balance at December 30, 2018 457,519 34,362 Employee compensation and stock option plans (20,053) (2,691) Repurchase of common stock 49,870 6,746 Balance at December 29, 2019 487,336 38,417 Employee compensation and stock option plans (21,765) (3,148) Repurchase of common stock 21,760 3,221 Balance at January 3, 2021 487,331 $ 38,490 Aggregate shares of common stock issued were approximately 3,119,843,000 shares at the end of fiscal years 2020, 2019 and 2018. Cash dividends paid were $3.98 per share in fiscal year 2020, compared with dividends of $3.75 per share in fiscal year 2019, and $3.54 per share in fiscal year 2018. On January 4, 2021, the Board of Directors declared a regular cash dividend of $1.01 per share, payable on March 9, 2021 to shareholders of record as of February 23, 2021. On December 17, 2018, the Company announced that its Board of Directors approved a share repurchase program, authorizing the Company to purchase up to $5.0 billion of the Company's shares of common stock. This share repurchase program was completed as of September 29, 2019.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income (Loss)	12 Months Ended
Accumulated Other Comprehensive Income (Loss)	Jan. 03, 2021
Equity [Abstract]
Accumulated Other Comprehensive Income (Loss)	Accumulated Other Comprehensive Income (Loss) Components of other comprehensive income (loss) consist of the following: (Dollars in Millions) Foreign Gain/(Loss) On Securities Employee Benefit Plans Gain/ Total December 31, 2017 $ (7,351) 232 (6,150) 70 (13,199) Cumulative adjustment to retained earnings (232) (1) (232) Net 2018 changes (1,518) — (8) (265) (1,791) December 30, 2018 (8,869) — (6,158) (195) (15,222) Net 2019 changes 164 — (733) (100) (669) December 29, 2019 (8,705) — (6,891) (295) (15,891) Net 2020 changes (233) 1 (66) 947 649 January 3, 2021 $ (8,938) 1 (6,957) 652 (15,242) (1) Per the adoption of ASU 2016-01- Financial Instruments Amounts in accumulated other comprehensive income are presented net of the related tax impact. Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries. For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income. Details on reclassifications out of Accumulated Other Comprehensive Income: Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net. Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 10 for additional details. Gain/(Loss) On Derivatives & Hedges - reclassifications to earnings are recorded in the same account as the hedged transaction. See Note 6 for additional details.

International Currency Translat

International Currency Translation	12 Months Ended
International Currency Translation	Jan. 03, 2021
Foreign Currency Translation [Abstract]
International Currency Transalation	International Currency Translation For translation of its subsidiaries operating in non-U.S. Dollar currencies, the Company has determined that the local currencies of its international subsidiaries are the functional currencies except those in highly inflationary economies, which are defined as those which have had compound cumulative rates of inflation of 100% or more during the past three years, or where a substantial portion of its cash flows are not in the local currency. For the majority of the Company's subsidiaries the local currency is the functional currency. In consolidating international subsidiaries, balance sheet currency effects are recorded as a component of accumulated other comprehensive income. The other current and non current assets line within the Statement of Cash flows includes the impact of foreign currency translation. This equity account includes the results of translating certain balance sheet assets and liabilities at current exchange rates and some accounts at historical rates, except for those located in highly inflationary economies, (Argentina and Venezuela). The translation of balance sheet accounts for highly inflationary economies are reflected in the operating results. A rollforward of the changes during fiscal years 2020, 2019 and 2018 for foreign currency translation adjustments is included in Note 13. Net currency transaction gains and losses included in Other (income) expense were losses of $209 million, $267 million and $265 million in fiscal years 2020, 2019 and 2018, respectively.

Earnings Per Share

Earnings Per Share	12 Months Ended
Earnings Per Share	Jan. 03, 2021
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal years ended January 3, 2021, December 29, 2019 and December 30, 2018: (In Millions Except Per Share Amounts) 2020 2019 2018 Basic net earnings per share $ 5.59 5.72 5.70 Average shares outstanding — basic 2,632.8 2,645.1 2,681.5 Potential shares exercisable under stock option plans 118.3 136.3 139.0 Less: shares repurchased under treasury stock method (80.4) (97.8) (92.5) Convertible debt shares — 0.7 0.7 Adjusted average shares outstanding — diluted 2,670.7 2,684.3 2,728.7 Diluted net earnings per share $ 5.51 5.63 5.61 The diluted net earnings per share calculation for fiscal year 2020 excluded 18 million shares related to stock options, as the exercise price of these options was greater than their average market value. As of January 3, 2021, the Company did not have convertible debt. The diluted net earnings per share calculation for fiscal year 2019 excluded an insignificant number of shares related to stock options, as the exercise price of these options was greater than the average market value of the Company’s stock. The diluted net earnings per share calculation for fiscal year 2019 included the dilutive effect of convertible debt that was offset by the related reduction in interest expense of $1 million after-tax. The diluted net earnings per share calculation for fiscal year 2018 included all shares related to stock options, as the exercise price of all options was less than the average market value of the Company's stock. The diluted net earnings per share calculation for fiscal year 2018 included the dilutive effect of convertible debt that was offset by the related reduction in interest expense of $1 million after-tax.

Common Stock, Stock Option Plan

Common Stock, Stock Option Plans and Stock Compensation Agreements	12 Months Ended
	Jan. 03, 2021
Share-based Payment Arrangement [Abstract]
Common Stock, Stock Option Plans and Stock Compensation Agreements	Common Stock, Stock Option Plans and Stock Compensation Agreements At January 3, 2021, the Company had 2 stock-based compensation plans. The shares outstanding are for contracts under the Company's 2005 Long-Term Incentive Plan and the 2012 Long-Term Incentive Plan. The 2005 Long-Term Incentive Plan expired April 26, 2012. All options and restricted shares granted subsequent to that date were under the 2012 Long-Term Incentive Plan. Under the 2012 Long-Term Incentive Plan, the Company may issue up to 650 million shares of common stock, plus any shares canceled, expired, forfeited, or not issued from the 2005 Long-Term Incentive Plan subsequent to April 26, 2012. Shares available for future grants under the 2012 Long-Term Incentive Plan were 277 million at the end of fiscal year 2020. The compensation cost that has been charged against income for these plans was $1,005 million, $977 million and $978 million for fiscal years 2020, 2019 and 2018, respectively. The total income tax benefit recognized in the income statement for share-based compensation costs was $210 million, $227 million and $192 million for fiscal years 2020, 2019 and 2018, respectively. The Company also recognized additional income tax benefits of $248 million, $209 million and $264 million for fiscal years 2020, 2019 and 2018, respectively, for which options were exercised or restricted shares were vested. The total unrecognized compensation cost was $804 million, $823 million and $827 million for fiscal years 2020, 2019 and 2018, respectively. The weighted average period for this cost to be recognized was 1.76 years, 1.71 years and 1.73 years for fiscal years 2020, 2019, and 2018, respectively. Share-based compensation costs capitalized as part of inventory were insignificant in all periods. The Company settles employee benefit equity issuances with treasury shares. Treasury shares are replenished through market purchases throughout the year for the number of shares used to settle employee benefit equity issuances. Stock Options Stock options expire 10 years from the date of grant and vest over service periods that range from 6 months to 4 years. All options are granted at the average of the high and low prices of the Company’s Common Stock on the New York Stock Exchange on the date of grant. The fair value of each option award was estimated on the date of grant using the Black-Scholes option valuation model that uses the assumptions noted in the following table. For 2020, 2019 and 2018 grants, expected volatility represents a blended rate of 10-year weekly historical overall volatility rate, and a 5-week average implied volatility rate based on at-the-money traded Johnson & Johnson options with a life of 2 years. For all grants, historical data is used to determine the expected life of the option. The risk-free rate was based on the U.S. Treasury yield curve in effect at the time of grant. The average fair value of options granted was $16.42, $17.80 and $17.98, in fiscal years 2020, 2019 and 2018, respectively. The fair value was estimated based on the weighted average assumptions of: 2020 2019 2018 Risk-free rate 1.47 % 2.56 % 2.77 % Expected volatility 15.33 % 16.27 % 15.77 % Expected life (in years) 7.0 7.0 7.0 Expected dividend yield 2.60 % 2.80 % 2.70 % A summary of option activity under the Plan as of January 3, 2021, December 29, 2019 and December 30, 2018, and changes during the years ending on those dates is presented below: (Shares in Thousands) Outstanding Shares Weighted Aggregate Shares at December 31, 2017 111,306 $ 90.48 $ 5,480 Options granted 17,115 129.51 Options exercised (16,228) 75.44 Options canceled/forfeited (2,541) 112.90 Shares at December 30, 2018 109,652 98.29 3,214 Options granted 19,745 131.94 Options exercised (14,785) 82.43 Options canceled/forfeited (2,975) 125.11 Shares at December 29, 2019 111,637 105.63 4,478 Options granted 20,723 151.41 Options exercised (16,275) 86.05 Options canceled/forfeited (1,835) 137.62 Shares at January 3, 2021 114,250 $ 116.22 $ 4,703 The total intrinsic value of options exercised was $1,021 million, $807 million and $1,028 million in fiscal years 2020, 2019 and 2018, respectively. The following table summarizes stock options outstanding and exercisable at January 3, 2021: (Shares in Thousands) Outstanding Exercisable Exercise Price Range Options Average Life (1) Weighted Average Exercise Price Options Weighted Average Exercise Price $62.20-$72.54 11,111 1.8 $70.79 11,111 $70.79 $90.44-$100.06 22,304 3.6 $95.36 22,304 $95.36 $100.48-$115.67 28,180 5.6 $108.64 27,695 $108.51 $129.51-$131.94 32,553 7.6 $130.85 145 $130.53 $141.06-$151.41 20,102 9.1 $151.41 34 $151.41 114,250 6.0 $116.22 61,289 $96.97 (1) Average contractual life remaining in years. Stock options outstanding at December 29, 2019 and December 30, 2018 were 111,637 and an average life of 6.0 years and 109,652 and an average life of 6.2 years, respectively. Stock options exercisable at December 29, 2019 and December 30, 2018 were 60,761 at an average price of $88.88 and 54,862 at an average price of $82.03, respectively. Restricted Share Units and Performance Share Units The Company grants restricted share units which vest over service periods that range from 6 months to 3 years. The Company also grants performance share units, which are paid in shares of Johnson & Johnson Common Stock after the end of a three-year performance period. Whether any performance share units vest, and the amount that does vest, is tied to the completion of service periods that range from 6 months to 3 years and the achievement, over a three-year period, of three equally-weighted goals that directly align with or help drive long-term total shareholder return: operational sales, adjusted operational earnings per share, and relative total shareholder return. Beginning in fiscal 2020, performance shares were granted with two equally-weighted goals that directly align with or help drive long-term total shareholder return: adjusted operational earnings per share and relative total shareholder return. The number of shares actually earned at the end of the three-year period will vary, based only on actual performance, from 0% to 200% of the target number of performance share units granted . A summary of the restricted share units and performance share units activity under the Plans as of January 3, 2021 is presented below: (Shares in Thousands) Outstanding Restricted Share Units Outstanding Performance Share Units Shares at December 29, 2019 16,769 2,174 Granted 5,051 816 Issued (6,042) (702) Canceled/forfeited/adjusted (780) (52) Shares at January 3, 2021 14,998 2,236 The average fair value of the restricted share units granted was $139.58, $121.31 and $119.67 in fiscal years 2020, 2019 and 2018, respectively, using the fair market value at the date of grant. The fair value of restricted share units was discounted for dividends, which are not paid on the restricted share units during the vesting period. The fair value of restricted share units issued was $650 million, $586 million and $614 million in 2020, 2019 and 2018, respectively. The weighted average fair value of the performance share units granted was $160.54, $124.67 and $120.64 in fiscal years 2020, 2019 and 2018, calculated using the weighted average fair market value for each of the component goals at the date of grant.

Segments of Business and Geogra

Segments of Business and Geographic Areas	12 Months Ended
Segments of Business and Geographic Areas	Jan. 03, 2021
Segment Reporting [Abstract]
Segments of Business and Geographic Areas	Segments of Business* and Geographic Areas Sales to Customers % Change (Dollars in Millions) 2020 2019 2018 ’20 vs. ’19 ’19 vs. ’18 Consumer Health) (1) OTC U.S. $ 2,460 2,010 1,850 22.4 % 8.6 International 2,364 2,434 2,484 (2.9) (2.0) Worldwide 4,824 4,444 4,334 8.5 2.5 Skin Health/Beauty (2) U.S. 2,350 2,392 2,403 (1.7) (0.4) International 2,100 2,201 1,979 (4.6) 11.2 Worldwide 4,450 4,593 4,382 (3.1) 4.8 Oral Care U.S. 683 621 637 9.9 (2.5) International 958 906 918 5.7 (1.2) Worldwide 1,641 1,528 1,555 7.4 (1.7) Baby Care U.S. 376 362 422 3.7 (14.2) International 1,141 1,313 1,436 (13.1) (8.6) Worldwide 1,517 1,675 1,858 (9.4) (9.9) Women's Health U.S. 13 12 13 8.2 (5.5) International 888 974 1,036 (8.8) (6.0) Worldwide 901 986 1,049 (8.6) (6.0) Wound Care/Other U.S. 480 441 436 8.9 1.2 International 240 230 239 4.1 (3.9) Worldwide 720 671 675 7.2 (0.6) TOTAL CONSUMER HEALTH U.S. 6,362 5,839 5,761 9.0 1.4 International 7,691 8,059 8,092 (4.6) (0.4) Worldwide 14,053 13,898 13,853 1.1 0.3 (1) Previously referred to as Consumer (2) Previously referred to as Beauty PHARMACEUTICAL Immunology U.S. 10,175 9,641 9,073 5.5 6.3 International 4,880 4,309 4,047 13.2 6.5 Worldwide 15,055 13,950 13,120 7.9 6.3 REMICADE ® U.S. 2,508 3,079 3,664 (18.5) (16.0) U.S. Exports 346 294 436 18.0 (32.7) International 893 1,007 1,226 (11.4) (17.8) Worldwide 3,747 4,380 5,326 (14.4) (17.8) SIMPONI / SIMPONI ARIA ® U.S. 1,155 1,159 1,051 (0.3) 10.2 International 1,088 1,029 1,033 5.8 (0.4) Worldwide 2,243 2,188 2,084 2.6 5.0 STELARA ® U.S. 5,240 4,346 3,469 20.6 25.3 International 2,467 2,015 1,687 22.4 19.4 Worldwide 7,707 6,361 5,156 21.1 23.4 TREMFYA ® U.S. 926 764 453 21.3 68.5 International 421 248 91 69.9 Worldwide 1,347 1,012 544 33.2 85.9 OTHER IMMUNOLOGY U.S. — — — — — International 11 10 10 6.4 4.5 Worldwide 11 10 10 6.4 4.5 Infectious Diseases U.S. 1,735 1,597 1,378 8.6 15.9 International 1,839 1,815 1,926 1.3 (5.7) Worldwide 3,574 3,413 3,304 4.7 3.3 EDURANT ® / rilpivirine U.S. 44 50 58 (11.2) (13.7) International 920 812 758 13.3 7.1 Worldwide 964 861 816 11.9 5.6 PREZISTA ® / PREZCOBIX ® / REZOLSTA ® / SYMTUZA ® U.S. 1,587 1,422 1,169 11.6 21.6 International 597 689 786 (13.4) (12.3) Worldwide 2,184 2,110 1,955 3.5 8.0 OTHER INFECTIOUS DISEASES U.S. 104 126 151 (17.6) (16.5) International 323 315 382 2.6 (17.6) Worldwide 427 441 533 (3.2) (17.3) Neuroscience U.S. 3,091 2,919 2,574 5.9 13.4 International 3,457 3,409 3,503 1.4 (2.7) Worldwide 6,548 6,328 6,077 3.5 4.1 CONCERTA ® / methylphenidate U.S. 183 233 229 (21.4) 1.7 International 439 463 434 (5.1) 6.6 Worldwide 622 696 663 (10.6) 4.9 INVEGA SUSTENNA ® / XEPLION ® / INVEGA TRINZA ® / TREVICTA ® U.S. 2,314 2,107 1,791 9.8 17.6 International 1,339 1,224 1,137 9.4 7.7 Worldwide 3,653 3,330 2,928 9.7 13.7 RISPERDAL CONSTA ® U.S. 296 314 315 (5.9) (0.3) International 346 374 422 (7.5) (11.4) Worldwide 642 688 737 (6.8) (6.7) OTHER NEUROSCIENCE U.S. 298 266 239 12.4 11.4 International 1,334 1,349 1,510 (1.1) (10.7) Worldwide 1,632 1,614 1,749 1.1 (7.7) Oncology U.S. 5,092 4,299 4,331 18.5 (0.7) International 7,275 6,393 5,513 13.8 16.0 Worldwide 12,367 10,692 9,844 15.7 8.6 DARZALEX ® U.S. 2,232 1,567 1,203 42.4 30.3 International 1,958 1,430 822 36.9 73.9 Worldwide 4,190 2,998 2,025 39.8 48.0 ERLEADA ® U.S. 583 297 124 96.1 International 176 35 — * * ** Worldwide 760 332 124 * * IMBRUVICA ® U.S. 1,821 1,555 1,129 17.1 37.7 International 2,307 1,856 1,486 24.3 24.9 Worldwide 4,128 3,411 2,615 21.0 30.4 VELCADE ® U.S. — — — — — International 408 751 1,116 (45.7) (32.7) Worldwide 408 751 1,116 (45.7) (32.7) ZYTIGA ® / abiraterone acetate U.S. 373 810 1,771 (54.0) (54.3) International 2,097 1,985 1,727 5.6 15.0 Worldwide 2,470 2,795 3,498 (11.6) (20.1) OTHER ONCOLOGY U.S. 83 70 104 19.2 (32.7) International 330 336 362 (1.9) (7.2) Worldwide 413 407 466 1.7 (12.7) Pulmonary Hypertension U.S. 2,133 1,684 1,651 26.6 2.0 International 1,015 939 922 8.2 1.9 Worldwide 3,148 2,623 2,573 20.0 1.9 OPSUMIT ® U.S. 1,008 766 700 31.7 9.4 International 631 562 515 12.3 9.0 Worldwide 1,639 1,327 1,215 23.5 9.2 UPTRAVI ® U.S. 955 714 598 33.8 19.3 International 138 105 65 30.9 62.4 Worldwide 1,093 819 663 33.5 23.5 OTHER U.S. 169 205 353 (17.6) (41.9) International 247 272 342 (9.2) (20.5) Worldwide 416 476 695 (12.8) (31.5) Cardiovascular / Metabolism / Other U.S. 3,509 3,734 4,279 (6.0) (12.7) International 1,369 1,458 1,537 (6.1) (5.2) Worldwide 4,878 5,192 5,816 (6.0) (10.7) XARELTO ® U.S. 2,345 2,313 2,477 1.4 (6.6) International — — — — — Worldwide 2,345 2,313 2,477 1.4 (6.6) INVOKANA ® / INVOKAMET ® U.S. 564 536 711 5.2 (24.6) International 231 199 170 16.3 17.3 Worldwide 795 735 881 8.2 (16.5) PROCRIT ® / EPREX ® U.S. 277 505 674 (45.1) (25.1) International 274 285 314 (3.8) (9.2) Worldwide 552 790 988 (30.2) (20.0) OTHER U.S. 323 380 417 (15.1) (9.1) International 864 974 1,053 (11.3) (7.6) Worldwide 1,186 1,353 1,470 (12.4) (8.0) TOTAL PHARMACEUTICAL U.S. 25,735 23,874 23,286 7.8 2.5 International 19,837 18,324 17,448 8.3 5.0 Worldwide 45,572 42,198 40,734 8.0 3.6 MEDICAL DEVICES Diabetes Care U.S. — — 371 — International — — 638 — Worldwide — — 1,009 — Interventional Solutions U.S. 1,452 1,443 1,283 0.6 12.5 International 1,594 1,554 1,363 2.6 14.0 Worldwide 3,046 2,997 2,646 1.6 13.3 Orthopaedics U.S. 4,779 5,319 5,281 (10.2) 0.7 International 2,984 3,520 3,604 (15.2) (2.3) Worldwide 7,763 8,839 8,885 (12.2) (0.5) HIPS U.S. 793 863 841 (8.2) 2.6 International 487 575 577 (15.3) (0.3) Worldwide 1,280 1,438 1,418 (11.0) 1.4 KNEES U.S. 743 889 911 (16.4) (2.4) International 427 591 591 (27.8) 0.0 Worldwide 1,170 1,480 1,502 (21.0) (1.4) TRAUMA U.S. 1,648 1,652 1,599 (0.2) 3.3 International 966 1,068 1,100 (9.6) (2.9) Worldwide 2,614 2,720 2,699 (3.9) 0.8 SPINE, SPORTS & OTHER (3) U.S. 1,595 1,915 1,930 (16.7) (0.8) International 1,104 1,286 1,336 (14.1) (3.8) Worldwide 2,699 3,201 3,266 (15.7) (2.0) Surgery U.S. 3,249 3,828 4,125 (15.1) (7.2) International 4,983 5,673 5,776 (12.2) (1.8) Worldwide 8,232 9,501 9,901 (13.4) (4.0) ADVANCED U.S. 1,535 1,637 1,657 (6.2) (1.2) International 2,304 2,458 2,345 (6.2) 4.8 Worldwide 3,839 4,095 4,002 (6.2) 2.3 GENERAL U.S. 1,714 2,192 2,468 (21.8) (11.2) International 2,679 3,215 3,431 (16.7) (6.3) Worldwide 4,392 5,406 5,899 (18.8) (8.4) Vision U.S. 1,557 1,794 1,777 (13.2) 0.9 International 2,362 2,830 2,776 (16.5) 2.0 Worldwide 3,919 4,624 4,553 (15.2) 1.6 CONTACT LENSES / OTHER U.S. 1,213 1,304 1,237 (7.0) 5.4 International 1,781 2,088 2,065 (14.7) 1.1 Worldwide 2,994 3,392 3,302 (11.7) 2.7 SURGICAL U.S. 344 490 540 (29.7) (9.4) International 581 742 711 (21.7) 4.4 Worldwide 925 1,232 1,251 (24.9) (1.6) TOTAL MEDICAL DEVICES U.S. 11,036 12,384 12,837 (10.9) (3.5) International 11,923 13,579 14,157 (12.2) (4.1) Worldwide 22,959 25,963 26,994 (11.6) (3.8) WORLDWIDE U.S. 43,133 42,097 41,884 2.5 0.5 International 39,451 39,962 39,697 (1.3) 0.7 Worldwide $ 82,584 82,059 81,581 0.6 % 0.6 (3) Previously referred to as Spine & Other Certain prior year amounts have been reclassified to conform to current year presentation *Percentage greater than 100% or not meaningful Income (Loss) Before Tax Identifiable Assets (Dollars in Millions) 2020 (3) 2019 (4) 2018 (5) 2020 2019 Consumer Health $ (1,064) 2,061 2,320 $ 27,355 26,618 Pharmaceutical 15,462 8,816 12,568 66,158 56,292 Medical Devices 3,044 7,286 4,397 49,578 49,462 Total 17,442 18,163 19,285 143,091 132,372 Less: Expense not allocated to segments (1) 945 835 1,286 General corporate (2) 31,803 25,356 Worldwide total $ 16,497 17,328 17,999 $ 174,894 157,728 Additions to Property, Depreciation and (Dollars in Millions) 2020 2019 2018 2020 2019 2018 Consumer Health $ 248 328 438 $ 785 765 688 Pharmaceutical 863 950 1,012 4,006 3,910 3,802 Medical Devices 1,980 1,912 1,843 2,140 2,014 2,103 Segments total 3,091 3,190 3,293 6,931 6,689 6,593 General corporate 256 308 377 300 320 336 Worldwide total $ 3,347 3,498 3,670 $ 7,231 7,009 6,929 Sales to Customers Long-Lived Assets (6) (Dollars in Millions) 2020 2019 2018 2020 2019 United States $ 43,133 42,097 41,884 $ 49,951 41,528 Europe 18,980 18,466 18,753 49,363 48,015 Western Hemisphere excluding U.S. 5,335 5,941 6,113 2,734 2,862 Asia-Pacific, Africa 15,136 15,555 14,831 5,484 5,486 Segments total 82,584 82,059 81,581 107,532 97,891 General corporate 1,029 1,049 Other non long-lived assets 66,333 58,788 Worldwide total $ 82,584 82,059 81,581 $ 174,894 157,728 See Note 1 for a description of the segments in which the Company operates. Export sales are not significant. In fiscal year 2020, the Company utilized three wholesalers distributing products for all three segments that represented approximately 16.0%, 12.0% and 12.0% of the total consolidated revenues. In fiscal year 2019, the Company had three wholesalers distributing products for all three segments that represented approximately 15.0%, 12.0% and 11.0% of the total consolidated revenues. In fiscal year 2018, the Company had three wholesalers distributing products for all three segments that represented approximately 14.0%, 11.0%, and 11.0% of the total consolidated revenues. (1) Amounts not allocated to segments include interest (income) expense and general corporate (income) expense. (2) General corporate includes cash, cash equivalents and marketable securities. (3) Consumer Health includes: • Litigation expense of $3.9 billion, primarily talc related reserves and certain settlements. Pharmaceutical includes: • Litigation expense of $0.8 billion, primarily related to the agreement in principle to settle opioid litigation • An unrealized gain on securities of $0.5 billion • A restructuring related charge of $0.1 billion Medical Devices includes: • A contingent consideration reversal of $1.1 billion related to the timing of certain developmental milestones associated with the Auris Health acquisition. • Litigation expense of $0.3 billion • A restructuring related charge of $0.3 billion • An in-process research and development expense of $0.2 billion • A Medical Device Regulation charge of $0.1 billion (4) Consumer Health includes: • A gain of $0.3 billion related to the Company's previously held equity investment in DR. CI:LABO • Litigation expense of $0.4 billion • A restructuring related charge of $0.1 billion Pharmaceutical includes: • Litigation expense of $4.3 billion of which $4.0 billion is related to the agreement in principle to settle opioid litigation • An in-process research and development expense of $0.9 billion related to the Alios asset • A research and development expense of $0.3 billion for an upfront payment related to argenx • An unrealized gain on securities of $0.6 billion • Actelion acquisition and integration related costs of $0.2 billion • A restructuring charge of $0.1 billion Medical Devices includes: • A gain of $2.0 billion from the divestiture of the ASP business • A restructuring related charge of $0.4 billion • Litigation expense of $0.4 billion • Auris Health acquisition and integration related costs of $0.1 billion (5) Consumer Health includes: • A gain of $0.3 billion from the divestiture of NIZORAL ® • Litigation expense of $0.3 billion Pharmaceutical includes: • An in-process research and development charge of $1.1 billion related to the Alios and XO1 assets and the corresponding XO1 contingent liability reversal of $0.2 billion • Actelion acquisition and integration related costs of $0.2 billion • An unrealized loss on securities of $0.2 billion • A gain of $0.2 billion from the divestiture of certain non-strategic Pharmaceutical products Medical Devices includes: • Litigation expense of $1.7 billion • A restructuring related charge of $0.6 billion • AMO acquisition and integration related costs of $0.1 billion • A gain of $0.5 billion from the divestiture of the LifeScan business (6) Long-lived assets include property, plant and equipment, net for fiscal years 2020, and 2019 of $18,766 and $17,658, respectively, and intangible assets and goodwill, net for fiscal years 2020 and 2019 of $89,795 and $81,282, respectively.

Acquisitions and Divestitures

Acquisitions and Divestitures	12 Months Ended
Acquisitions and Divestitures	Jan. 03, 2021
Business Combinations [Abstract]
Acquisitions and Divestitures	Acquisitions and Divestitures Certain businesses were acquired for $7.3 billion in cash and $0.4 billion of liabilities assumed during fiscal year 2020. These acquisitions were accounted for using the acquisition method and, accordingly, results of operations have been included in the financial statements from their respective dates of acquisition. The excess of purchase price over the estimated fair value of tangible assets acquired amounted to $7.5 billion and has been assigned to identifiable intangible assets, with any residual recorded to goodwill. The fiscal year 2020 acquisitions primarily included: all rights to the investigational compound bermekimab, which has multiple dermatological indications, along with certain employees from XBiotech Inc. (XBiotech), Momenta Pharmaceuticals, Inc. (Momenta), a company that discovers and develops novel therapies for immune-mediated diseases and the outstanding shares in Verb Surgical Inc., a company with significant robotics and data science capabilities. During the fiscal first quarter of 2020, the Company completed the acquisition of all rights to the investigational compound bermekimab, which has multiple dermatological indications, along with certain employees from XBiotech Inc., for a purchase price of $0.8 billion. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets, primarily IPR&D, for $0.8 billion applying a probability of success factor that ranged from 20% to 60% to reflect inherent development, regulatory and commercial risk for the different indications. The discount rate applied was approximately 16%. XBiotech may be eligible to receive additional payments upon the receipt of certain commercialization authorizations. The transaction was accounted for as a business combination and included in the Pharmaceutical segment. Additionally, in the fiscal first quarter of 2020, the Company completed the acquisition of all outstanding shares in Verb Surgical Inc., a company with significant robotics and data science capabilities, including those shares previously held by Verily. The transaction was accounted for as a business combination and included in the Medical Devices segment. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets, primarily IPR&D, for $0.4 billion, goodwill for $0.2 billion, other assets of $0.2 billion and liabilities assumed of $0.3 billion. The fair value of the Company's previously held equity investment in Verb Surgical Inc. was $0.4 billion. On October 1, 2020, the Company completed the acquisition of Momenta for a purchase price of approximately $6.1 billion, net of cash acquired. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets (IPR&D) of $6.0 billion, goodwill of $1.2 billion, other assets of $0.5 billion and liabilities of $1.6 billion. The assets acquired are intended to address substantial unmet medical need in maternal-fetal disorders, neuro-inflammatory disorders, rheumatology, dermatology and autoimmune hematology. Depending on the asset, probability of success factors ranging from 20% to 77% were used in the fair value calculation to reflect inherent development and regulatory risk of the IPR&D. The discount rate applied was approximately 13%. The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes. The transaction was accounted for as a business combination and included in the Pharmaceutical segment. During fiscal year 2019 certain businesses were acquired for $5.8 billion in cash and $1.4 billion of liabilities assumed. These acquisitions were accounted for using the acquisition method and, accordingly, results of operations have been included in the financial statements from their respective dates of acquisition. The excess of purchase price over the estimated fair value of tangible assets acquired amounted to $6.8 billion and has been assigned to identifiable intangible assets, with any residual recorded to goodwill. The fiscal year 2019 acquisitions primarily included DR. CI:LABO, a Japanese company focused on the marketing, development and distribution of a broad range of dermocosmetic, cosmetic and skincare products and Auris Health, Inc. a privately held developer of robotic technologies, initially focused in lung cancer, with an FDA-cleared platform currently used in bronchoscopic diagnostic and therapeutic procedures. On January 17, 2019, the Company acquired DR. CI:LABO, a Japanese company focused on the marketing, development and distribution of a broad range of dermocosmetic, cosmetic and skincare products for a total purchase price of approximately ¥230 billion, which equates to approximately $2.1 billion, using the exchange rate of 109.06 Japanese Yen to each U.S. Dollar on January 16, 2019. Additionally, in the fiscal first quarter of 2019, the Company recognized a pre-tax gain recorded in Other (income) expense, net, of approximately $0.3 billion related to the Company's previously held equity investment in DR. CI:LABO. The Company treated this transaction as a business combination and included it in the Consumer Health segment. During the fiscal first quarter of 2020, the Company finalized the purchase price allocation. The final fair value of the acquisition was allocated primarily to amortizable intangible assets for $1.5 billion, goodwill for $1.2 billion and liabilities of $0.4 billion. The amortizable intangible assets were comprised of brand/trademarks and customer relationships with a weighted average life of 15.3 years The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes. On April 1, 2019 the Company completed the acquisition of Auris Health, Inc. for approximately $3.4 billion, net of cash acquired. Additional contingent payments of up to $2.35 billion, in the aggregate, may be payable upon reaching certain predetermined milestones. Auris Health was a privately held developer of robotic technologies, initially focused in lung cancer, with an FDA-cleared platform currently used in bronchoscopic diagnostic and therapeutic procedures. The Company treated this transaction as a business combination and included it in the Medical Devices segment. The fair value of the acquisition was allocated primarily to amortizable and non-amortizable intangible assets, primarily IPR&D for $3.0 billion, goodwill for $2.0 billion, marketable securities of $0.2 billion and liabilities assumed of $1.8 billion, which includes the fair value of the contingent payments mentioned above. During the fiscal second quarter of 2020, the Company finalized the purchase price allocation. During fiscal 2020, the Company recorded Other income of approximately $1.1 billion for the reversal of all of the contingent consideration related to the timing of certain developmental and commercial milestones, which are not expected to be met based on the Company’s current timelines. During the fiscal third quarter of 2020, the Company recorded a partial IPR&D impairment charge of $0.1 billion related to timing and progression of the digital surgery platforms. A probability of success factor ranging from 55% to 95% was used in the fair value calculation to reflect inherent regulatory and commercial risk of the contingent payments and IPR&D. The discount rate applied was approximately 10%. The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes. During fiscal year 2018 certain businesses were acquired for $0.9 billion in cash and $0.1 billion of liabilities assumed. These acquisitions were accounted for using the acquisition method and, accordingly, results of operations have been included in the financial statements from their respective dates of acquisition. The excess of purchase price over the estimated fair value of tangible assets acquired amounted to $1.0 billion and has been assigned to identifiable intangible assets, with any residual recorded to goodwill. In accordance with U.S. GAAP standards related to business combinations, and goodwill and other intangible assets, supplemental pro forma information for fiscal years 2020, 2019 and 2018 is not provided, as the impact of the aforementioned acquisitions did not have a material effect on the Company’s results of operations, cash flows or financial position. Divestitures Subsequent to fiscal 2020, in separate transactions, the Company divested two brands outside the U.S. within the Pharmaceutical segment and received combined proceeds of approximately $0.6 billion. The Company will reflect these brand divestitures in its 2021 financial results. During fiscal year 2020, the Company sold 11.8 million shares of Idorsia LTD (Idorsia), or its 8.3% ownership in the company. The transaction resulted in gross proceeds of approximately CHF 337 million ($357 million) based on a sales price of CHF 28.55/share and an immaterial net loss. The Company currently has rights to at least an additional 38.7 million shares (or approximately 20% of Idorsia equity) through a convertible loan with a principal amount of CHF 445 million (due June 2027). Idorsia also has access to an approximate CHF 243 million credit facility with the Company. As of January 3, 2021, Idorsia has not made any draw-downs under the credit facility. During fiscal year 2019, the Company divested its ASP business to Fortive Corporation for an aggregate value of approximately $2.8 billion, consisting of $2.7 billion of cash proceeds and $0.1 billion of retained net receivables. The Company recognized a pre-tax gain recorded in Other ( income) expense, net, of approximately $2.0 billion. During fiscal year 2018, the Company divested the LifeScan Inc business for approximately $2.1 billion and retained certain net liabilities. Other divestitures in fiscal year 2018 included: NIZORAL ® , RoC ® and certain non-strategic Pharmaceutical products. In 2018, the pre-tax gains on the divestitures were approximately $1.2 billion. In fiscal year 2018, the Company accepted a binding offer to form a strategic collaboration with Jabil Inc., one of the world’s leading manufacturing services providers for health care products and technology products. The Company is expanding a 12-year relationship with Jabil to produce a range of products within the Ethicon Endo-Surgery and DePuy Synthes businesses. This transaction includes the transfer of employees and manufacturing sites. The transfers were completed in fiscal year 2020. As of January 3, 2021, there were no assets held for sale on the Consolidated Balance Sheet. As of December 29, 2019, the assets held for sale on the Consolidated Balance Sheet were $0.1 billion of inventory and property, plant and equipment, net. For additional details on the global supply chain restructuring see Note 20 to the Consolidated Financial Statements.

Legal Proceedings

Legal Proceedings	12 Months Ended
Legal Proceedings	Jan. 03, 2021
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings	Legal Proceedings Johnson & Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; supplier indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business. Due to the ongoing impacts of the COVID-19 pandemic, certain trials have been rescheduled or delayed. The Company continues to monitor its legal proceedings as the situation evolves. The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred and the amount of the loss can be reasonably estimated. As of January 3, 2021, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated. In the Company's opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company's balance sheet, is not expected to have a material adverse effect on the Company's financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company's results of operations and cash flows for that period. PRODUCT LIABILITY Johnson & Johnson and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has established accruals for product liability claims and lawsuits in compliance with ASC 450-20 based on currently available information, which in some cases may be limited. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available. The most significant of these cases include: the DePuy ASR™ XL Acetabular System and DePuy ASR™ Hip Resurfacing System; the PINNACLE ® Acetabular Cup System; pelvic meshes; RISPERDAL ® ; XARELTO ® ; body powders containing talc, primarily JOHNSONS ® Baby Powder; INVOKANA ® ; and ETHICON PHYSIOMESH ® Flexible Composite Mesh. As of January 3, 2021, in the United States there were approximately 560 plaintiffs with direct claims in pending lawsuits regarding injuries allegedly due to the DePuy ASR™ XL Acetabular System and DePuy ASR™ Hip Resurfacing System; 7,800 with respect to the PINNACLE ® Acetabular Cup System; 14,900 with respect to pelvic meshes; 9,300 with respect to RISPERDAL ® ; 12,600 with respect to XARELTO ® ; 25,000 with respect to body powders containing talc; 300 with respect to INVOKANA ® ; and 4,200 with respect to ETHICON PHYSIOMESH ® Flexible Composite Mesh. In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR ™ XL Acetabular System and DePuy ASR ™ Hip Resurfacing System used in hip replacement surgery. Claims for personal injury have been made against DePuy and Johnson & Johnson. The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip System plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 31, 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 31, 2013 and prior to February 15, 2017. This settlement program has resolved more than 10,000 claims, therefore bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle the class actions filed in that country . The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and DePuy ASR ™ Hip-related product liability litigation. Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and Johnson & Johnson (collectively, DePuy) relating to the PINNACLE ® Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas. Litigation has also been filed in some state courts and in countries outside of the United States. Several adverse verdicts have been rendered against DePuy, one of which was reversed on appeal and remanded for retrial. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE ® Acetabular Cup System and the related settlement program. Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson & Johnson arising out of Ethicon's pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. The MDL Court is remanding cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved a majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Company's accruals. In addition, class actions and individual personal injury cases or claims have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands, and class actions in Israel, Australia and Canada, seeking damages for alleged injury resulting from Ethicon's pelvic mesh devices. In November 2019, the Federal Court of Australia issued a judgment regarding its findings with respect to liability in relation to the three Lead Applicants and generally in relation to the design, manufacture, pre and post-market assessments and testing, and supply and promotion of the devices in Australia used to treat stress urinary incontinence and pelvic organ prolapse. In March 2020, the Court entered damages awards to the three Lead Applicants. The Company is appealing the decision. With respect to other group members, there will be an individual case assessment process which will require proof of use and causally related loss. The form of the individual case assessment process has not yet been determined by the Court. The class actions in Canada were discontinued in 2020 as a result of a settlement of a group of cases. The Company has established accruals with respect to product liability litigation associated with Ethicon's pelvic mesh product s. Following a June 2016 worldwide market withdrawal of ETHICON PHYSIOMESH ® Flexible Composite Mesh, claims for personal injury have been made against Ethicon, Inc. and Johnson & Johnson alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) has also been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending outside the United States. Discovery is proceeding in these cases and certain of the cases are in preparation for trials. Claims have also been filed against Ethicon and Johnson & Johnson alleging personal injuries arising from the PROCEED ® Mesh and PROCEED ® Ventral Patch hernia mesh products. In March 2019, the New Jersey Supreme Court entered an order consolidating these cases pending in New Jersey as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the US, and in jurisdictions outside the US. Discovery is underway in these cases. In September 2019, plaintiffs’ attorney filed an application with the New Jersey Supreme Court seeking centralized management of 107 PROLENE™ Polypropylene Hernia System (“PHS”) cases. The New Jersey Supreme Court granted plaintiffs application in January 2020 and those cases have also been transferred to an MCL in Atlantic County Superior Court. Discovery is underway in these cases. The Company has established accruals with respect to product liability litigation associated with ETHICON PHYSIOMESH ® Flexible Composite Mesh, PROCEED ® Mesh and PROCEED ® Ventral Patch, and PROLENE™ Polypropylene Hernia System products. Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and Johnson & Johnson arising out of the use of RISPERDAL ® , and related compounds, indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism. Lawsuits have been primarily filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a verdict in October 2019 of $8.0 billion of punitive damages related to one single plaintiff which was subsequently reduced in January 2020 to $6.8 million by the trial judge. The Company and plaintiff are each appealing this judgment. The Company has settled or otherwise resolved many of the United States cases and the costs associated with these settlements are reflected in the Company's accruals. Claims for personal injury arising out of the use of XARELTO ® , an oral anticoagulant, have been made against Janssen Pharmaceuticals, Inc. (JPI); Johnson & Johnson (J&J); and JPI’s collaboration partner for XARELTO ® , Bayer AG and certain of its affiliates. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Eastern District of Louisiana. In addition, cases have been filed in state courts across the United States. Many of these cases were consolidated into a state mass tort litigation in Philadelphia, Pennsylvania and in a coordinated proceeding in Los Angeles, California. Class action lawsuits also have been filed in Canada. In March 2019, JPI and J&J announced an agreement in principle to the settle the XARELTO ® cases in the United States; the settlement agreement was executed in May 2019, the settlement became final in December 2019, and the settlement was funded in January 2020. This resolved the majority of cases pending in the United States. The Company has established accruals for its costs associated with the United States settlement program and XARELTO ® related product liability litigation. Personal injury claims alleging that talc causes cancer have been made against Johnson & Johnson Consumer Inc. and Johnson & Johnson arising out of the use of body powders containing talc, primarily JOHNSON’S ® Baby Powder. The number of pending personal injury lawsuits continues to increase, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Lawsuits have been primarily filed in state courts in Missouri, New Jersey and California, and suits have also been filed outside the United States. The majority of cases are pending in federal court, organized into a multi-district litigation (MDL) in the United States District Court for the District of New Jersey. In the MDL, the parties sought to exclude experts through Daubert motions. In April 2020, the Court issued rulings that limit the scope of testimony, including some theories and testing methods, for certain plaintiff expert witnesses and denied plaintiffs’ attempt to limit the scope of testimony of certain of the Company’s witnesses. With this ruling made, case-specific discovery has begun per the Court’s directive. In talc cases that have previously gone to trial, the Company has obtained defense verdicts in a number of them, but there have also been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $4.7 billion in Ingham v. Johnson & Johnson, et al., No. ED 207476 (Mo. App.), reducing the overall award to $2.1 billion and, with additional interest as of January 3, 2021, as the Company pursues further appeal, is currently $2.5 billion (the Ingham decision). An application for transfer of the case to the Missouri Supreme Court was subsequently denied, and the Company is currently seeking review by the United States Supreme Court. The Company continues to believe that it has strong legal grounds for the appeal of this verdict, as well as other verdicts that it has appealed. Notwithstanding the Company’s confidence in the safety of its talc products, in certain circumstances the Company has and may settle cases. The Company has established an accrual for defense costs and reserves for the resolution of certain cases and claims, including the Ingham decision currently on appeal , in connection with product liability litigation associated with body powders containing talc. In February 2019, the Company’s talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary chapter 11 petition commencing a reorganization under the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imerys’ potential liability for personal injury from exposure to talcum powder sold by Imerys (Talc Claims). In its bankruptcy filing, Imerys noted certain claims it alleges it has against the Company for indemnification and rights to joint insurance proceeds. The Company previously proposed to resolve Imerys' (and the Company’s) obligations arising out of the Talc Claims by agreeing to assume the defense of litigation of all Talc Claims involving the Company's products, waiving the Company’s indemnification claims against Imerys, and lifting the automatic stay to enable the Talc Claims to proceed outside the bankruptcy forum with the Company agreeing to settle or pay any judgment against Imerys. In May 2020, Imerys and the asbestos claimants’ committee (Plan Proponents) filed their Plan of Reorganization (the Plan) and the Disclosure Statement related thereto agreeing to put its North American operations up for auction which was subsequently amended. The Company has objected to the Disclosure Statement and intends to object to the Plan of Reorganization as currently structured. Additionally, in June 2020, Cyprus Mines Corporation and its parent (Cyprus) filed an adversary proceeding against the Company as well as Imerys seeking a declaration of indemnity under certain contractual agreements. The Company denies such indemnification is owed and filed a motion to dismiss the adversary complaint arguing, among other things, that the Court does not have subject matter jurisdiction over Cyprus’s claims against the Company. The Plan Proponents filed numerous amendments to the Plan and Disclosure Statement to which the Company objected. A hearing on the Plan Proponent’s Disclosure Statement was held in January 2021, and the Court entered an order approving the Disclosure Statement for the Ninth Amended Joint Chapter 11 Plan of Reorganization of Imerys Talc America, Inc. and its Debtor Affiliates allowing Debtors to proceed with soliciting votes on the Plan. The Company intends to continue to object to the Plan. A hearing to consider confirmation of the Plan has been scheduled for June 2021. In February 2018, a securities class action lawsuit was filed against Johnson & Johnson and certain named officers in the United States District Court for the District of New Jersey, alleging that Johnson & Johnson violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON'S® Baby Powder, and that purchasers of Johnson & Johnson’s shares suffered losses as a result. Plaintiff is seeking damages. In April 2019, the Company moved to dismiss the complaint and briefing on the motion was complete as of August 2019. In December 2019, the Court denied, in part, the motion to dismiss. In March 2020, Defendants answered the complaint. Discovery is underway. In June 2019, a shareholder filed a complaint initiating a summary proceeding in New Jersey state court for a books and records inspection. In August 2019, Johnson & Johnson responded to the books and records complaint and filed a cross motion to dismiss. In September 2019, Plaintiff replied and the Court heard oral argument. The Court has not yet ruled in the books and records action. In October 2019, December 2019, and January 2020, four shareholders filed four separate derivative lawsuits against Johnson & Johnson as the nominal defendant and its current directors and certain officers as defendants in the United States District Court for the District of New Jersey, alleging a breach of fiduciary duties related to the alleged asbestos contamination in body powders containing talc, primarily JOHNSON’S ® Baby Powder, and that Johnson & Johnson has suffered damages as a result of those alleged breaches. In February 2020, the four cases were consolidated into a single action under the caption In re Johnson & Johnson Talc Stockholder Derivative Litigation . In July 2020, a report was delivered to the Company’s Board of Directors by independent counsel retained by the Board to investigate the allegations in the derivative lawsuits and in a series of shareholder letters that the Board received raising similar issues. Four of the shareholders who sent demands are plaintiffs in th e In re Johnson & Johnson Talc Stockholder Derivative Litigation . The independent counsel recommended that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of the derivative lawsuits. The Board unanimously adopted the recommendations of the independent counsel’s report. In October 2020, the shareholders filed a consolidated complaint, and in January 2021, Johnson & Johnson moved to dismiss the consolidated complaint. In January 2019, two ERISA class action lawsuits were filed by participants in the Johnson & Johnson Savings Plan against Johnson & Johnson, its Pension and Benefits Committee, and certain named officers in the United States District Court for the District of New Jersey, alleging that the defendants breached their fiduciary duties by offering Johnson & Johnson stock as a Johnson & Johnson Savings Plan investment option when it was imprudent to do so because of failures to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON’S ® Baby Powder. Plaintiffs are seeking damages and injunctive relief. In September 2019, Defendants filed a motion to dismiss. In April 2020, the Court granted Defendants’ motion but granted leave to amend. In June 2020, Plaintiffs filed an amended complaint, and in July 2020, Defendants moved to dismiss the amended complaint. As of October 2020, briefing on Defendants’ motion was complete . A lawsuit pending in the Superior Court of California for the County of San Diego alleging violations of California’s Consumer Legal Remedies Act relating to JOHNSON’S ® Baby Powder has been resolved in the Company’s favor. In that lawsuit, the plaintiffs allege that Johnson & Johnson violated the CLRA by failing to provide required Proposition 65 warnings. In July 2019, the Company filed a notice of removal to the United States District Court for the Southern District of California and plaintiffs filed a second amended complaint shortly thereafter. In October 2019, the Company moved to dismiss the second amended complaint for failure to state a claim upon which relief may be granted. In response to those motions, plaintiffs filed a third amended complaint. In December 2019, the Company moved to dismiss the third amended complaint for failure to state a claim upon which relief may be granted. In April 2020, the Court granted the motion to dismiss but granted leave to amend. In May 2020, plaintiffs filed a Fourth Amended Complaint but indicated that they would be filing a motion for leave to file a fifth amended complaint. Plaintiffs filed a Fifth Amended Complaint in August 2020. The Company moved to dismiss the Fifth Amended Complaint for failure to state a claim upon which relief may be granted. In January 2021, the Court issued an Order and opinion ruling in the Company’s favor and granting the motion to dismiss with prejudice. In January 2020, the Abtahi Law Group filed an action under Proposition 65 against Johnson & Johnson and Johnson & Johnson Consumer Inc. as well as a number of other alleged talcum powder manufacturers and distributors, including one California company. In that action, the plaintiff alleges contamination of talcum powder products with unsafe levels of arsenic, hexavalent chromium and lead. The plaintiff seeks civil penalties and injunctive relief. Defendants filed a motion for summary judgment in January 2021, and a hearing has been scheduled for April 2021. Limited informal discovery is continuing. In addition, the Company has received preliminary inquiries and subpoenas to produce documents regarding these matters from Senator Murray, a member of the Senate Committee on Health, Education, Labor and Pensions, the Department of Justice, the Securities and Exchange Commission (SEC) and the U.S. Congressional Subcommittee on Economic and Consumer Policy. The Company produced documents as required in response and will continue to cooperate with government inquiries. In November 2020, the SEC terminated its investigation. Claims for personal injury have been made against a number of Johnson & Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson & Johnson, arising out of the use of INVOKANA ® , a prescription medication indicated to improve glycemic control in adults with Type 2 diabetes. In December 2016, lawsuits filed in federal courts in the United States were organized as a multi-district litigation in the United States District Court for the District of New Jersey. Cases have also been filed in state courts. Class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has settled or otherwise resolved many of the cases and claims in the United States and the costs associated with these settlements are reflected in the Company's accruals. Claims for personal injury have been made against a number of Johnson & Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson & Johnson, arising out of the use of ELMIRON ® , a prescription medication indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON ® contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, the federal cases, including two putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New Jersey. In addition, three class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established accruals for defense costs associated with ELMIRON ® related product liability litigation. INTELLECTUAL PROPERTY Certain subsidiaries of Johnson & Johnson are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the coverage and/or validity of the patents on various products and allegations that certain of the Company’s products infringe the patents of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset. Significant matters are described below. Medical Devices In November 2016, MedIdea, L.L.C. (MedIdea) filed a patent infringement lawsuit against DePuy Orthopaedics, Inc. in the United States District Court for the Northern District of Illinois alleging infringement by the ATTUNE ® Knee System. In April 2017, MedIdea filed an amended complaint adding DePuy Synthes Products, Inc. and DePuy Synthes Sales, Inc. as named defendants (collectively, DePuy). MedIdea alleged infringement of United States Patent Nos. 6,558,426 (’426); 8,273,132 (’132); 8,721,730 (’730) and 9,492,280 (’280) relating to posterior stabilized knee systems. Specifically, MedIdea alleges that the SOFCAM TM Contact feature of the ATTUNE ® posterior stabilized knee products infringes the patents-in-suit. MedIdea is seeking monetary damages and injunctive relief. In June 2017, the case was transferred to the United States District Court for the District of Massachusetts. In November 2019, judgment was entered in favor of DePuy. In January 2021, the U.S. Court of Appeals for the Federal Circuit affirmed. In December 2016, Dr. Ford Albritton sued Acclarent, Inc. (Acclarent) in United States District Court for the Northern District of Texas alleging that Acclarent’s RELIEVA ® Spin and RELIEVEA SpinPlus ® products infringe U.S. Patent No. 9,011,412. Dr. Albritton also alleges breach of contract, fraud and that he is the true owner of Acclarent’s U.S. Patent No. 8,414,473. Trial is scheduled to begin in October 2021. In November 2017, Board of Regents, The University of Texas System and TissueGen, Inc. (collectively, UT) filed a lawsuit in the United States District Court for the Western District of Texas against Ethicon, Inc. and Ethicon US, LLC (collectively, Ethicon) alleging the manufacture and sale of VICRYL ® Plus Antibacterial Sutures, MONOCRYL ® Plus Antibacterial Sutures, PDS ® Plus Antibacterial Sutures, STRATAFIX ® PDS ® Antibacterial Sutures and STRATAFIX ® MONOCRYL ® Plus Antibacterial Sutures infringe plaintiffs’ United States Patent Nos. 6,596,296 (’296) and 7,033,603 (’603) directed to implantable polymer drug releasing biodegradable fibers containing a therapeutic agent. UT is seeking damages and an injunction. In December 2018, Ethicon filed petitions with the United States Patent and Trademark Office (USPTO), seeking Inter Partes Review (IPR) of both asserted patents. In June 2020, the USPTO denied institution of the ’296 patent IPR and granted institution of the ’603 patent IPR. UT dismissed the ’603 patent from the suit and no longer accuses PDS ® Plus Antibacterial Sutures or STRATAFIX ® PDS ® Plus Antibacterial Sutures of infringement. The previously scheduled district court trial has been postponed. In August 2018, Intuitive Surgical, Inc. and Intuitive Surgical Operations, Inc. (collectively, Intuitive) filed a patent infringement suit against Auris Health, Inc. (Auris) in United States District Court for the District of Delaware. In the suit, Intuitive alleges willful infringement of U.S. Patent Nos. 6,246,200 (’200); 6,491,701 (’701); 6,522,906 (’906); 6,800,056 (’056); 8,142,447 (’447); 8,620,473 (’473); 8,801,601 (’601); and 9,452,276 (’276) based on Auris’ Monarch™ Platform. Auris filed IPR Petitions with the USPTO regarding the ’200, ’056, ’601 ’701, ’447, ’276 and ’906 patents. Intuitive subsequently dropped the ’200, ’473 and ’701 patents from the suit. In December 2019, the USPTO instituted review of the ’601 patent and denied review of the ’056 patent. In February and March 2020, the USPTO instituted review of the ’200, ’447, ’701 and ’906 patents and denied review of the ’276 patent. In December 2020, the USPTO declared all of

Restructuring

Restructuring	12 Months Ended
Restructuring	Jan. 03, 2021
Restructuring and Related Activities [Abstract]
Restructuring	Restructuring In the fiscal second quarter of 2018, the Company announced plans to implement a series of actions across its Global Supply Chain that are intended to focus resources and increase investments in the critical capabilities, technologies and solutions necessary to manufacture and supply its product portfolio, enhance agility and drive growth. The Global Supply Chain actions include expanding the use of strategic collaborations and bolstering initiatives to reduce complexity, improve cost-competitiveness, enhance capabilities and optimize the Supply Chain network. For additional details on the Global Supply Chain restructuring strategic collaborations see Note 18 to the Consolidated Financial Statements. In fiscal year 2020, the Company recorded a pre-tax charge of $0.4 billion, which is included on the following lines of the Consolidated Statement of Earnings, $0.2 billion in restructuring, $0.1 billion in other (income) expense and $0.1 billion in cost of products sold. Total project costs of approximately $1.3 billion have been recorded since the restructuring was announced. See the following table for additional details on the restructuring program. In total, the Company expects the Global Supply Chain actions to generate approximately $0.6 billion to $0.8 billion in annual pre-tax cost savings that will be substantially delivered by 2022. The Company expects to record pre-tax restructuring charges of approximately $1.9 billion to $2.3 billion, over the 4 to 5 year period of this activity. These costs are associated with network optimizations, exit costs and accelerated depreciation and amortization. The following table summarizes the severance charges and the associated spending under these initiatives through the fiscal year ended 2020: (Dollars in Millions) Severance Asset Write-offs/Sales Other (2) Total Reserve balance, December 30, 2018 $ 194 — 48 242 2019 activity (30) — (32) (62) Reserve balance, December 29, 2019 164 — 16 180 Current year activity: Charges — 43 405 448 Cash settlements (29) 24 (4) (399) (404) Settled non cash — (67) (13) (3) (80) Reserve balance, January 3, 2021 (1) $ 135 — 9 144 (1) Cash outlays for severance are expected to be substantially paid out over the next 2 years in accordance with the Company's plans and local laws. (2) Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses. (3) Relates to pension related net actuarial losses associated with the transfer of employees to Jabil Inc. as part of the strategic collaboration. (4) Represents gain on sale of an asset

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
Summary of Significant Accounting Policies (Policies)	Jan. 03, 2021
Accounting Policies [Abstract]
Principles of Consolidation	Principles of ConsolidationThe consolidated financial statements include the accounts of Johnson & Johnson and its subsidiaries (the Company). Intercompany accounts and transactions are eliminated.
Description of the Company And Business Segments	Description of the Company and Business Segments The Company has approximately 134,500 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the health care field. The Company conducts business in virtually all countries of the world and its primary focus is on products related to human health and well-being.
New Accounting Standards	New Accounting Standards Recently Adopted Accounting Standards ASU 2018-18: Collaborative Arrangements The Company adopted this standard as of the beginning of the fiscal year 2020. This update clarifies the interaction between ASC 808, Collaborative Arrangements and ASC 606, Revenue from Contracts with Customers. The update clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer. In addition, the update precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue if the counterparty is not a customer for that transaction. The adoption of this standard did not have a material impact on the Company's consolidated financial statements. ASU 2016-13: Financial Instruments - Credit Losses The Company adopted this standard as of the beginning of the fiscal year 2020. This update introduces the current expected credit loss (CECL) model, which requires an entity to measure credit losses for certain financial instruments and financial assets, including trade receivables. Under this update, on initial recognition and at each reporting period, an entity is required to recognize an allowance that reflects the entity’s current estimate of credit losses expected to be incurred over the life of the financial instrument. The adoption of this standard did not have a material impact on the Company's consolidated financial statements. ASU 2018-14: Compensation - Defined Benefit Plans The Company adopted this standard in the fiscal year ended 2020. This standard revised the financial statement note disclosure requirements of ASC 715-20 for defined benefit plan sponsors. The adoption of this standard had no impact on the Company's consolidated financial statements. See Note 10 to the Consolidated Financial Statements for defined benefit plan disclosures. Accounting Standards adopted in the fiscal 2018 with a cumulative effect to the 2018 opening balance of Retained Earnings The following table summarizes the cumulative effect adjustments made to the 2018 opening balance of retained earnings upon adoption of these accounting standards in 2018: (Dollars in Millions) Cumulative Effect Adjustment Increase (Decrease) to Retained Earnings ASU 2014-09 - Revenue from Contracts with Customers $ (47) ASU 2016-01 - Financial Instruments 232 ASU 2016-16 - Income Taxes: Intra-Entity Transfers (439) Total $ (254) Recently Issued Accounting Standards Not Adopted as of January 3, 2021 The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company’s Annual Report on Form 10-K for the fiscal year ended December 29, 2019. There were no new material accounting standards issued in fiscal 2020 that impacted the Company.
Cash Equivalents	Cash Equivalents The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. The Company has a policy of making investments only with commercial institutions that have at least an investment grade credit rating. The Company invests its cash primarily in government securities and obligations, corporate debt securities, money market funds and reverse repurchase agreements (RRAs). RRAs are collateralized by deposits in the form of Government Securities and Obligations for an amount not less than 102% of their value. The Company does not record an asset or liability as the Company is not permitted to sell or repledge the associated collateral. The Company has a policy that the collateral has at least an A (or equivalent) credit rating. The Company utilizes a third party custodian to manage the exchange of funds and ensure that collateral received is maintained at 102% of the value of the RRAs on a daily basis. RRAs with stated maturities of greater than three months from the date of purchase are classified as marketable securities.
Investments	InvestmentsInvestments classified as held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. Investments classified as available-for-sale debt securities are carried at estimated fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income. Available-for-sale securities available for current operations are classified as current assets otherwise, they are classified as long term. Management determines the appropriate classification of its investment in debt and equity securities at the time of purchase and re-evaluates such determination at each balance sheet date. The Company reviews its investments for impairment and adjusts these investments to fair value through earnings, as required.
Property, Plant and Equipment and Depreciation	Property, Plant and Equipment and Depreciation Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets: Building and building equipment 20 - 30 years Land and leasehold improvements 10 - 20 years Machinery and equipment 2 - 13 years The Company capitalizes certain computer software and development costs, included in machinery and equipment, when incurred in connection with developing or obtaining computer software for internal use. Capitalized software costs are amortized over the estimated useful lives of the software, which generally range from 3 to 8 years. The Company reviews long-lived assets to assess recoverability using undiscounted cash flows. When certain events or changes in operating or economic conditions occur, an impairment assessment may be performed on the recoverability of the carrying value of these assets. If the asset is determined to be impaired, the loss is measured based on the difference between
Revenue Recognition	Revenue Recognition The Company recognizes revenue from product sales when obligations under the terms of a contract with the customer are satisfied; generally, this occurs with the transfer of control of the goods to customers. The Company's global payment terms are typically between 30 to 90 days. Provisions for certain rebates, sales incentives, trade promotions, coupons, product returns and discounts to customers are accounted for as variable consideration and recorded as a reduction in sales. The liability is recognized within Accrued Rebates, Returns, and Promotions on the consolidated balance sheet. Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including consideration of competitor pricing. Rebates are estimated based on contractual terms, historical experience, patient outcomes, trend analysis and projected market conditions in the various markets served. A significant portion of the liability related to rebates is from the sale of the Company's pharmaceutical products within the U.S., primarily t he Managed Care, Medicare and Medicaid programs, which amounted to $7.2 billion and $7.0 billion as of January 3, 2021 and December 29, 2019, respectively. The Company evaluates market conditions for products or groups of products primarily through the analysis of wholesaler and other third-party sell-through and market research data, as well as internally generated information. Sales returns are estimated and recorded based on historical sales and returns information. Products that exhibit unusual sales or return patterns due to dating, competition or other marketing matters are specifically investigated and analyzed as part of the accounting for sales return accruals. Sales returns allowances represent a reserve for products that may be returned due to expiration, destruction in the field, or in specific areas, product recall. The sales returns reserve is based on historical return trends by product and by market as a percent to gross sales. In accordance with the Company’s accounting policies, the Company generally issues credit to customers for returned goods. The Company’s sales returns reserves are accounted for in accordance with the U.S. GAAP guidance for revenue recognition when right of return exists. Sales returns reserves are recorded at full sales value. Sales returns in the Consumer Health and Pharmaceutical segments are almost exclusively not resalable. Sales returns for certain franchises in the Medical Devices segment are typically resalable but are not material. The Company infrequently exchanges products from inventory for returned products. The sales returns reserve for the total Company has been approximately 1.0% of annual net trade sales during each of the fiscal years 2020, 2019 and 2018. Promotional programs, such as product listing allowances and cooperative advertising arrangements, are recorded in the same period as related sales. Continuing promotional programs include coupons and volume-based sales incentive programs. The redemption cost of consumer coupons is based on historical redemption experience by product and value. Volume-based incentive programs are based on the estimated sales volumes for the incentive period and are recorded as products are sold. These arrangements are evaluated to determine the appropriate amounts to be deferred or recorded as a reduction of revenue. The Company also earns profit-share payments through collaborative arrangements for certain products, which are included in sales to customers. For all years presented, profit-share payments were less than 3.0% of the total revenues and are included in sales to customers. See Note 17 to the Consolidated Financial Statements for further disaggregation of revenue.
Shipping and Handling	Shipping and Handling Shipping and handling costs incurred were $1.0 billion, $1.0 billion and $1.1 billion in fiscal years 2020, 2019 and 2018, respectively, and are included in selling, marketing and administrative expense. The amount of revenue received for shipping and handling is less than 0.5% of sales to customers for all periods presented.
Inventories	Inventories Inventories are stated at the lower of cost or net realizable value determined by the first-in, first-out method.
Intangible Assets and Goodwill	Intangible Assets and Goodwill The authoritative literature on U.S. GAAP requires that goodwill and intangible assets with indefinite lives be assessed annually for impairment. The Company completed its annual impairment test for 2020 in the fiscal fourth quarter. Future impairment tests will be performed annually in the fiscal fourth quarter, or sooner if warranted. Purchased in-process research and development is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset, or abandoned, at which point the intangible asset will be written off or partially impaired. Intangible assets that have finite useful lives continue to be amortized over their useful lives, and are reviewed for impairment when warranted by economic conditions. See Note 5 for further details on Intangible Assets and Goodwill.
Financial Instruments	Financial Instruments As required by U.S. GAAP, all derivative instruments are recorded on the balance sheet at fair value. Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value, with Level 1 having the highest priority and Level 3 having the lowest. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction. The Company documents all relationships between hedged items and derivatives. The overall risk management strategy includes reasons for undertaking hedge transactions and entering into derivatives. The objectives of this strategy are: (1) minimize foreign currency exposure’s impact on the Company’s financial performance; (2) protect the Company’s cash flow from adverse movements in foreign exchange rates; (3) ensure the appropriateness of financial instruments; and (4) manage the enterprise risk associated with financial institutions. See Note 6 for additional information on Financial Instruments.
Leases	Leases The Company determines whether an arrangement is a lease at contract inception by establishing if the contract conveys the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. Right of Use (ROU) Assets and Lease Liabilities for operating leases are included in Other assets Accrued liabilities Other liabilities ROU Assets and Lease Liabilities are recognized at the lease commencement date based on the present value of all minimum lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments, when the implicit rate is not readily determinable. Lease terms may include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected the following policy elections on adoption: use of portfolio approach on leases of assets under master service agreements, exclusion of short term leases on the balance sheet, and not separating lease and non-lease components. The Company primarily has operating lease for space, vehicles, manufacturing equipment and data processing equipment. The ROU asset pertaining to operating leases was $1.0 billion and $1.0 billion in 2020 and 2019, respectively. The lease liability was $1.1 billion and $1.0 billion in 2020 and 2019, respectively. The operating lease costs were $0.3 billion, $0.3 billion and $0.3 billion in 2020, 2019 and 2018, respectively. Cash paid for amounts included in the measurement of lease liabilities were $0.3 billion and $0.3 billion in 2020 and 2019, respectively.
Product Liability	Product Liability Accruals for product liability claims are recorded, on an undiscounted basis, when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on existing information and actuarially determined estimates where applicable. The accruals are adjusted periodically as additional information becomes available. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. To the extent adverse verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.
Research and Development	Research and Development Research and development expenses are expensed as incurred in accordance with ASC 730, Research and Development. Upfront and milestone payments made to third parties in connection with research and development collaborations are expensed as incurred up to the point of regulatory approval. Payments made to third parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product. Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization. The Company enters into collaborative arrangements, typically with other pharmaceutical or biotechnology companies, to develop and commercialize drug candidates or intellectual property. These arrangements typically involve two (or more) parties who are active participants in the collaboration and are exposed to significant risks and rewards dependent on the commercial success of the activities. These collaborations usually involve various activities by one or more parties, including research and development, marketing and selling and distribution. Often, these collaborations require upfront, milestone and royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. Amounts due from collaborative partners related to development activities are generally reflected as a reduction of research and development expense because the performance of contract development services is not central to the Company’s operations. In general, the income statement presentation for these collaborations is as follows: Nature/Type of Collaboration Statement of Earnings Presentation Third-party sale of product & profit share payments received Sales to customers Royalties/milestones paid to collaborative partner (post-regulatory approval)* Cost of products sold Royalties received from collaborative partner Other income (expense), net Upfront payments & milestones paid to collaborative partner (pre-regulatory approval) Research and development expense Research and development payments to collaborative partner Research and development expense Research and development payments received from collaborative partner or government entity Reduction of Research and development expense * Milestones are capitalized as intangible assets and amortized to cost of products sold over the useful life. For all years presented, there was no individual project that represented greater than 5% of the total annual consolidated research and development expense. The Company has a number of products and compounds developed in collaboration with strategic partners including XARELTO ® , co-developed with Bayer HealthCare AG and IMBRUVICA ® , developed in collaboration and co-marketed with Pharmacyclics LLC, an AbbVie company. Separately, the Company has a number of licensing arrangements for products and compounds including DARZALEX ® , licensed from Genmab A/S.
Advertising	AdvertisingCosts associated with advertising are expensed in the year incurred and are included in selling, marketing and administrative expenses.
Income Taxes	Income Taxes Income taxes are recorded based on amounts refundable or payable for the current year and include the results of any difference between U.S. GAAP accounting and tax reporting, recorded as deferred tax assets or liabilities. The Company estimates deferred tax assets and liabilities based on enacted tax regulations and rates. Future changes in tax laws and rates may affect recorded deferred tax assets and liabilities in the future. The Company has unrecognized tax benefits for uncertain tax positions. The Company follows U.S. GAAP which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management believes that changes in these estimates would not have a material effect on the Company's results of operations, cash flows or financial position. In 2017, the United States enacted into law new U.S. tax legislation, the U.S. Tax Cuts and Jobs Act (TCJA). This law included provisions for a comprehensive overhaul of the corporate income tax code, including a reduction of the statutory corporate tax rate from 35% to 21%, effective on January 1, 2018. The TCJA included a provision for a tax on all previously undistributed earnings of U.S. companies located in foreign jurisdictions. Undistributed earnings in the form of cash and cash equivalents were taxed at a rate of 15.5% and all other earnings were taxed at a rate of 8.0%. This tax is payable over 8 years and will not accrue interest. These payments began in 2018 and will continue through 2025. The remaining balance at the end of the 2020 was approximately $7.7 billion, of which $6.9 billion is classified as noncurrent and reflected as “Long-term taxes payable” on the Company’s balance sheet. The balance of this account is related to receivables from tax authorities not expected to be received in the next 12 months. The TCJA also includes provisions for a tax on global intangible low-taxed income (GILTI). GILTI is described as the excess of a U.S. shareholder’s total net foreign income over a deemed return on tangible assets, as provided by the TCJA. In January 2018, the FASB issued guidance that allows companies to elect as an accounting policy whether to record the tax effects of GILTI in the period the tax liability is generated (i.e., “period cost”) or provide for deferred tax assets and liabilities related to basis differences that exist and are expected to effect the amount of GILTI inclusion in future years upon reversal (i.e., “deferred method”). In 2018, the Company elected to account for GILTI under the deferred method. The deferred tax amounts recorded are based on the evaluation of temporary differences that are expected to reverse as GILTI is incurred in future periods. The Company has recorded deferred tax liabilities on all undistributed earnings prior to December 31, 2017 from its international subsidiaries. The Company has not provided deferred taxes on the undistributed earnings subsequent to January 1, 2018 from certain international subsidiaries where the earnings are considered to be indefinitely reinvested. The Company
Net Earnings Per Share	Net Earnings Per Share Basic earnings per share is computed by dividing net earnings available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution that could occur if securities were exercised or converted into common stock using the treasury stock method.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the amounts reported. Estimates are used when accounting for sales discounts, rebates, allowances and incentives, product liabilities, income taxes, withholding taxes, depreciation, amortization, employee benefits, contingencies and intangible asset and liability valuations. Actual results may or may not differ from those estimates. The Company follows the provisions of U.S. GAAP when recording litigation related contingencies. A liability is recorded when a loss is probable and can be reasonably estimated. The best estimate of a loss within a range is accrued; however, if no estimate in the range is better than any other, the minimum amount is accrued. The extent to which COVID-19 impacts the Company’s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of January 3, 2021 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s allowance for doubtful accounts and credit losses, inventory and related reserves, accrued rebates and associated reserves, and the carrying value of the goodwill and other long-lived assets. While there was not a material impact to the Company’s consolidated financial statements as of and for the fiscal year ended January 3, 2021, the Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company’s consolidated financial statements in future reporting periods.
Annual Closing Date	Annual Closing Date The Company follows the concept of a fiscal year, which ends on the Sunday nearest to the end of the month of December. Normally each fiscal year consists of 52 weeks, but every five or six years the fiscal year consists of 53 weeks, and therefore includes additional shipping days, as was the case in fiscal year 2020, and will be the case again in fiscal year 2026.
Reclassification	Reclassification Certain prior period amounts have been reclassified to conform to current year presentation.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
Summary of Significant Accounting Policies (Tables)	Jan. 03, 2021
Accounting Policies [Abstract]
Schedule of New Accounting Pronouncements	The following table summarizes the cumulative effect adjustments made to the 2018 opening balance of retained earnings upon adoption of these accounting standards in 2018: (Dollars in Millions) Cumulative Effect Adjustment Increase (Decrease) to Retained Earnings ASU 2014-09 - Revenue from Contracts with Customers $ (47) ASU 2016-01 - Financial Instruments 232 ASU 2016-16 - Income Taxes: Intra-Entity Transfers (439) Total $ (254)
Estimated Useful Lives of Assets	Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets: Building and building equipment 20 - 30 years Land and leasehold improvements 10 - 20 years Machinery and equipment 2 - 13 years

Cash, Cash Equivalents and Cu_2

Cash, Cash Equivalents and Current Marketable Securities (Tables)	12 Months Ended
	Jan. 03, 2021
Cash and Cash Equivalents [Abstract]
Cash and Cash Equivalent Composition	At the end of the fiscal year 2020 and 2019, cash, cash equivalents and current marketable securities were comprised of: (Dollars in Millions) 2020 Carrying Amount Unrecognized Gain Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities Cash $ 2,863 — 2,863 2,863 — Non-U.S. Sovereign Securities (1) 690 — 690 — 690 U.S. Reverse repurchase agreements 1,937 — 1,937 1,937 — Corporate debt securities (1) 2,674 — 2,674 1,451 1,223 Money market funds 2,102 — 2,102 2,102 — Time deposits (1) 877 — 877 877 — Subtotal $ 11,143 — 11,143 9,230 1,913 U.S. Gov't Securities $ 13,777 1 13,778 4,731 9,047 Other Sovereign Securities 14 — 14 — 14 Corporate debt securities 250 — 250 24 226 Subtotal available for sale (2) $ 14,041 1 14,042 4,755 9,287 Total cash, cash equivalents and current marketable securities $ 13,985 11,200 (Dollars in Millions) 2019 Carrying Amount Cash & Cash Equivalents Current Marketable Securities Cash $ 2,637 2,637 — Non-U.S. Sovereign Securities (1) 439 149 290 U.S. Reverse repurchase agreements 6,375 6,375 — Other Reverse repurchase agreements 375 375 — Corporate debt securities (1) 1,323 889 434 Money market funds 2,864 2,864 — Time deposits (1) 906 906 — Subtotal $ 14,919 14,195 724 Gov't Securities $ 4,102 3,095 1,007 Corporate debt securities 266 15 251 Subtotal available for sale (2) $ 4,368 3,110 1,258 Total cash, cash equivalents and current marketable securities $ 17,305 1,982 (1) Held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. (2) Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.
Contractual Maturities of Available for Sale Securities	The contractual maturities of the available for sale debt securities at January 3, 2021 are as follows: (Dollars in Millions) Cost Basis Fair Value Due within one year $ 14,026 14,027 Due after one year through five years 15 15 Due after five years through ten years — — Total debt securities $ 14,041 14,042

Inventories (Tables)

Inventories (Tables)	12 Months Ended
Inventories (Tables)	Jan. 03, 2021
Inventory Disclosure [Abstract]
Summary of Inventories	At the end of fiscal years 2020 and 2019, inventories were comprised of: (Dollars in Millions) 2020 2019 Raw materials and supplies $ 1,410 1,117 Goods in process 2,040 1,832 Finished goods 5,894 6,071 Total inventories (1) $ 9,344 9,020 (1)

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
Property, Plant and Equipment (Tables)	Jan. 03, 2021
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment at Cost and Accumulated Depreciation	At the end of fiscal years 2020 and 2019, property, plant and equipment at cost and accumulated depreciation were: (Dollars in Millions) 2020 2019 Land and land improvements $ 882 854 Buildings and building equipment 12,502 11,877 Machinery and equipment 29,104 26,964 Construction in progress 4,316 3,637 Total property, plant and equipment, gross $ 46,804 43,332 Less accumulated depreciation 28,038 25,674 Total property, plant and equipment, net (1) $ 18,766 17,658 (1) See Note 18 to the Consolidated Financial Statements for details on assets held for sale and the related divestitures for the fiscal year ended December 29, 2019. There were no assets held for sale at January 3, 2021.

Intangible Assets and Goodwill

Intangible Assets and Goodwill (Tables)	12 Months Ended
Intangible Assets and Goodwill (Tables)	Jan. 03, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets and Goodwill	At the end of fiscal years 2020 and 2019, the gross and net amounts of intangible assets were: (Dollars in Millions) 2020 2019 Intangible assets with definite lives: Patents and trademarks — gross $ 39,990 36,634 Less accumulated amortization 17,618 13,154 Patents and trademarks — net $ 22,372 23,480 Customer relationships and other intangibles — gross $ 22,898 22,056 Less accumulated amortization 10,912 9,462 Customer relationships and other intangibles — net* $ 11,986 12,594 Intangible assets with indefinite lives: Trademarks $ 7,195 6,922 Purchased in-process research and development (1) 11,849 4,647 Total intangible assets with indefinite lives $ 19,044 11,569 Total intangible assets — net $ 53,402 47,643 *The majority is comprised of customer relationships (1) In fiscal year 2020, the Company completed multiple acquisitions and recorded in-process research and development intangible assets of $6.0 billion from Momenta Pharmaceuticals, Inc., $0.8 billion for bermekimab and certain related assets from XBiotech, Inc., and $0.4 billion from the acquisition of all outstanding shares in Verb Surgical, Inc.
Goodwill	Goodwill as of January 3, 2021 and December 29, 2019, as allocated by segment of business, was as follows: (Dollars in Millions) Consumer Health Pharmaceutical Medical Devices Total Goodwill at December 30, 2018 $ 8,670 9,063 12,720 30,453 Goodwill, related to acquisitions 1,188 75 2,018 3,281 Currency translation/other (122) 31 (4) (95) Goodwill at December 29, 2019 $ 9,736 9,169 14,734 33,639 Goodwill, related to acquisitions — 1,222 238 1,460 Currency translation/other 600 618 76 1,294 Goodwill at January 3, 2021 $ 10,336 11,009 15,048 36,393
Intangible Asset Amortization Expense	The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately: (Dollars in Millions) 2021 2022 2023 2024 2025 $4,600 4,200 4,100 3,900 3,200

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
Fair Value Measurements (Tables)	Jan. 03, 2021
Fair Value Disclosures [Abstract]
Summary of Derivative Activity	The following table is a summary of the activity related to derivatives and hedges for the fiscal years ended January 3, 2021 and December 29, 2019, net of tax: January 3, 2021 December 29, 2019 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing $ — — — 153 — — — — 159 — Amount of gain or (loss) recognized in AOCI — — — 153 — — — — 159 — Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income 12 (329) (137) — (16) (54) (321) (105) — 22 Amount of gain or (loss) recognized in AOCI 44 298 (191) — (52) (20) (606) (94) — 39 Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income — — — 370 — — — — 292 — Amount of gain or (loss) recognized in AOCI $ — — — 748 — — — — 417 —
Schedule of Effect of Derivatives not Designated as Hedging Instruments	The following table is the effect of derivatives not designated as hedging instrument for the fiscal years ended January 3, 2021 and December 29, 2019: (Dollars in Millions) Location of Gain /(Loss) Recognized in Income on Derivative Gain/(Loss) Derivatives Not Designated as Hedging Instruments January 3, 2021 December 29, 2019 Foreign Exchange Contracts Other (income) expense $ 24 (144)
Schedule of Effect of Net Investment Hedges	The following table is the effect of net investment hedges for the fiscal years ended January 3, 2021 and December 29, 2019: Gain/(Loss) Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income Gain/(Loss) Reclassified From (Dollars in Millions) January 3, 2021 December 29, 2019 January 3, 2021 December 29, 2019 Debt $ (473) 121 Interest (income) expense — — Cross Currency interest rate swaps $ 65 488 Interest (income) expense — —
Summary of Activity Related to Equity Investments	The following table is a summary of the activity related to equity investments for the fiscal years ended January 3, 2021 and December 29, 2019: December 29, 2019 January 3, 2021 (Dollars in Millions) Carrying Value Changes in Fair Value Reflected in Net Income (1) Sales/ Purchases/Other (2) Carrying Value Non Current Other Assets Equity Investments with readily determinable value $ 1,148 527 (194) 1,481 1,481 Equity Investments without readily determinable value $ 712 (55) 81 738 738 December 30, 2018 December 29, 2019 (Dollars in Millions) Carrying Value Changes in Fair Value Reflected in Net Income (1) Sales/ Purchases/Other (2) Carrying Value Non Current Other Assets Equity Investments with readily determinable value $ 511 533 104 1,148 1,148 Equity Investments without readily determinable value $ 681 (38) 69 712 712 (1) Recorded in Other Income/Expense (2) Other includes impact of currency
Financial Assets and Liabilities at Fair Value	The Company’s significant financial assets and liabilities measured at fair value as of the fiscal year ended January 3, 2021 and December 29, 2019 were as follows: 2020 2019 (Dollars in Millions) Level 1 Level 2 Level 3 Total Total (1) Derivatives designated as hedging instruments: Assets: Forward foreign exchange contracts $ — 849 — 849 209 Interest rate contracts (2)(3) — 240 — 240 693 Total $ — 1,089 — 1,089 902 Liabilities: Forward foreign exchange contracts — 702 — 702 426 Interest rate contracts (3) — 1,569 — 1,569 193 Total $ — 2,271 — 2,271 619 Derivatives not designated as hedging instruments: Assets: Forward foreign exchange contracts $ — 49 — 49 23 Liabilities: Forward foreign exchange contracts — 38 — 38 33 Available For Sale Other Investments: Equity investments (4) 1,481 — — 1,481 1,148 Debt securities (5) — 14,042 — 14,042 4,368 Other Liabilities Contingent Consideration (6) $ 633 633 1,715 Gross to Net Derivative Reconciliation 2020 2019 (Dollars in Millions) Total Gross Assets $ 1,138 925 Credit Support Agreement (CSA) (1,107) (841) Total Net Asset 31 84 Total Gross Liabilities 2,309 652 Credit Support Agreement (CSA) (2,172) (586) Total Net Liabilities $ 137 66 Summarized information about changes in liabilities for contingent consideration is as follows: 2020 2019 2018 (Dollars in Millions) Beginning Balance $ 1,715 397 600 Changes in estimated fair value (7) (1,089) 151 (156) Additions 106 1,246 125 Payments (99) (79) (172) Ending Balance $ 633 1,715 397 (1) 2019 assets and liabilities are all classified as Level 2 with the exception of equity investments of $1,148 million, which are classified as Level 1 and contingent consideration of $1,715 million, classified as Level 3. (2) Includes $1 million of non-current assets as of December 29, 2019. (3) Includes cross currency interest rate swaps and interest rate swaps. (4) Classified as non-current other assets. (5) Classified as cash equivalents and current marketable securities. (6) Includes $594 million, $1,631 million (primarily related to Auris Health) and $397 million, classified as non-current other liabilities as of January 3, 2021, December 29, 2019 and December 30, 2018, respectively. Includes $39 million and $84 million classified as current liabilities as of January 3, 2021 and December 29, 2019, respectively. (7) Ongoing fair value adjustment amounts are recorded primarily in Research and Development expense. The Company recorded a contingent consideration reversal of $1,148 million in 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. The reversal of the contingent consideration was recorded in Other income and expense

Borrowings (Tables)

Borrowings (Tables)	12 Months Ended
Borrowings (Tables)	Jan. 03, 2021
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments	The components of long-term debt are as follows: (Dollars in Millions) 2020 Effective Rate % 2019 Effective Rate % 3% Zero Coupon Convertible Subordinated Debentures due 2020 $ — — 51 3.00 2.95% Debentures due 2020 — — 549 3.15 1.950% Notes due 2020 — — 500 1.99 3.55% Notes due 2021 450 3.67 449 3.67 2.45% Notes due 2021 350 2.48 349 2.48 1.65% Notes due 2021 999 1.65 999 1.65 0.250% Notes due 2022 (1B Euro 1.2281) (2) /(1B Euro 1.1096) (3) 1,227 (2) 0.26 1,108 (3) 0.26 2.25% Notes due 2022 999 2.31 998 2.31 6.73% Debentures due 2023 250 6.73 250 6.73 3.375% Notes due 2023 803 3.17 804 3.17 2.05% Notes due 2023 499 2.09 498 2.09 0.650% Notes due 2024 (750MM Euro 1.2281) (2) /(750MM Euro 1.1096) (3) 919 (2) 0.68 829 (3) 0.68 5.50% Notes due 2024 (500MM 1.3654 GBP ) (2) /(500MM GBP 1.2987) (3) 679 (2) 6.75 645 (3) 6.75 2.625% Notes due 2025 748 2.63 748 2.63 0.55% Notes due 2025 (5) 996 0.57 — — 2.45% Notes due 2026 1,994 2.47 1,993 2.47 2.95% Notes due 2027 997 2.96 996 2.96 0.95% Notes due 2027 (5) 1,494 0.96 — — 1.150% Notes due 2028 (750MM Euro 1.2281) (2) /(750MM Euro 1.1096) (3) 915 (2) 1.21 825 (3) 1.21 2.90% Notes due 2028 1,495 2.91 1,494 2.91 6.95% Notes due 2029 297 7.14 297 7.14 1.30% Notes due 2030 (5) 1,743 1.30 — — 4.95% Debentures due 2033 498 4.95 498 4.95 4.375% Notes due 2033 855 4.24 855 4.24 1.650% Notes due 2035 (1.5B Euro 1.2281) (2) /(1.5B Euro 1.1096) (3) 1,827 (2) 1.68 1,649 (3) 1.68 3.55% Notes due 2036 989 3.59 989 3.59 5.95% Notes due 2037 992 5.99 992 5.99 3.625% Notes due 2037 1,488 3.64 1,487 3.64 5.85% Debentures due 2038 696 5.85 696 5.85 3.400% Notes due 2038 991 3.42 991 3.42 4.50% Debentures due 2040 539 4.63 539 4.63 2.10% Notes due 2040 (5) 986 2.14 — — 4.85% Notes due 2041 297 4.89 297 4.89 4.50% Notes due 2043 496 4.52 495 4.52 3.70% Notes due 2046 1,974 3.74 1,973 3.74 3.75% Notes due 2047 991 3.76 991 3.76 3.500% Notes due 2048 742 3.52 742 3.52 2.250% Notes due 2050 (5) 984 2.29 — — 2.450% Notes due 2060 (5) 1,228 2.49 — — Other 7 — 18 — Subtotal 34,434 (4) 2.85 % (1) 27,594 (4) 3.19 (1) Less current portion 1,799 1,100 Total long-term debt $ 32,635 26,494 (1) Weighted average effective rate. (2) Translation rate at January 3, 2021. (3) Translation rate at December 29, 2019. (4) The excess of the fair value over the carrying value of debt was $5.4 billion at the end of fiscal year 2020 and $3.0 billion at the end of fiscal year 2019. (5) In the fiscal third quarter of 2020, the Company issued senior unsecured notes for a total of $7.5 billion.
Aggregate Maturities of Long Term Obligations	Aggregate maturities of long-term debt obligations commencing in 2021 are: (Dollars in Millions) 2021 2022 2023 2024 2025 After 2025 $1,799 2,226 1,552 1,598 1,744 25,515

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Jan. 03, 2021
Income Tax Disclosure [Abstract]
Provision for Income Taxes	The provision for taxes on income consists of: (Dollars in Millions) 2020 2019 2018 Currently payable: U.S. taxes $ 1,026 1,941 1,284 International taxes 1,898 2,744 2,434 Total currently payable 2,924 4,685 3,718 Deferred: U.S. taxes (76) (814) 1,210 (1) International taxes (1,065) (1,662) (2,226) Total deferred (1,141) (2,476) (1,016) Provision for taxes on income $ 1,783 2,209 2,702 (1)
Comparison of Income Taxes at Statutory Rate and Company's Effective Tax Rate	A comparison of income tax expense at the U.S. statutory rate of 21% in fiscal years 2020, 2019 and 2018, to the Company’s effective tax rate is as follows: (Dollars in Millions) 2020 2019 2018 U.S. $ 4,312 3,543 5,575 International 12,185 13,785 12,424 Earnings before taxes on income: $ 16,497 17,328 17,999 Tax rates: U.S. statutory rate 21.0 % 21.0 21.0 International operations (1) (9.9) (5.9) (3.7) U.S. taxes on international income (2) 2.7 1.8 1.4 Tax benefits on Capital Loss (1.2) (0.3) (4) — Tax benefits on share-based compensation (1.5) (0.5) (1.5) TCJA and related impacts 0.7 (3.9) (3) (1.9) (3) All other (1.0) 0.5 (4) (0.3) Effective Rate 10.8 % 12.7 15.0 (1) For all periods presented the Company has subsidiaries operating in Puerto Rico under various tax incentives. International operations reflects the impacts of operations in jurisdictions with statutory tax rates different than the U.S., particularly Ireland, Switzerland and Puerto Rico, which is a favorable impact on the effective tax rate as compared with the U.S. statutory rate. The 2020 and 2019 amounts include the impact of the new tax legislation enactment in Switzerland, which is further described below. (2) Includes the impact of the GILTI tax, the Foreign-Derived Intangible Income deduction and other foreign income that is taxable under the U.S. tax code. (3) Represents impact of adjustments to balances originally recorded as part of the 2017 TCJA provisional tax charge. Further information provided below. (4) Certain prior year amounts have been reclassified to conform to current year presentation.
Temporary Differences and Carryforwards	Temporary differences and carryforwards at the end of fiscal years 2020 and 2019 were as follows: 2020 Deferred Tax 2019 Deferred Tax* (Dollars in Millions) Asset Liability Asset Liability Employee related obligations $ 2,434 2,473 Stock based compensation 627 595 Depreciation & amortization 721 1,122 Non-deductible intangibles (6,567) (5,835) International R&D capitalized for tax 1,517 1,189 Reserves & liabilities 3,466 2,337 Income reported for tax purposes 1,705 1,605 Net operating loss carryforward international 990 838 Undistributed foreign earnings 812 (1,435) 765 (1,289) Global intangible low-taxed income (3,606) (2,965) Miscellaneous international 854 (211) 696 (81) Miscellaneous U.S. 12 411 Total deferred income taxes $ 13,138 (11,819) 12,031 (10,170) * Certain prior year amounts have been reclassified to conform to current year presentation
Summary of Activity Related to Unrecognized Tax Benefits	The following table summarizes the activity related to unrecognized tax benefits: (Dollars in Millions) 2020 2019 2018 Beginning of year $ 3,853 3,326 3,151 Increases related to current year tax positions 265 249 242 Increases related to prior period tax positions 668 408 145 Decreases related to prior period tax positions (551) (105) (137) Settlements (839) (9) (40) Lapse of statute of limitations (23) (16) (35) End of year $ 3,373 3,853 3,326

Employee Related Obligations (T

Employee Related Obligations (Tables)	12 Months Ended
Employee Related Obligations (Tables)	Jan. 03, 2021
Compensation Related Costs [Abstract]
Employee Related Obligations	At the end of fiscal 2020 and fiscal 2019, employee related obligations recorded on the Consolidated Balance Sheets were: (Dollars in Millions) 2020 2019 Pension benefits $ 5,761 5,538 Postretirement benefits 2,229 2,297 Postemployment benefits 3,078 3,004 Deferred compensation 250 338 Total employee obligations 11,318 11,177 Less current benefits payable 547 514 Employee related obligations — non-current $ 10,771 10,663

Pensions and Other Benefit Pl_2

Pensions and Other Benefit Plans (Tables)	12 Months Ended
Pensions and Other Benefit Plans (Tables)	Jan. 03, 2021
Retirement Benefits [Abstract]
Components of Net Periodic Benefit Cost	Net periodic benefit costs for the Company’s defined benefit retirement plans and other benefit plans for 2020, 2019 and 2018 include the following components: Retirement Plans Other Benefit Plans (Dollars in Millions) 2020 2019 2018 2020 2019 2018 Service cost $ 1,380 1,163 1,283 287 274 269 Interest cost 955 1,096 996 133 185 148 Expected return on plan assets (2,461) (2,322) (2,212) (7) (6) (7) Amortization of prior service cost 2 4 3 (31) (31) (31) Recognized actuarial losses (gains) 891 579 852 142 129 123 Curtailments and settlements 23 73 1 — — — Net periodic benefit cost $ 790 593 923 524 551 502
Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation	The following table represents the weighted-average actuarial assumptions: Retirement Plans Other Benefit Plans Worldwide Benefit Plans 2020 2019 2018 2020 2019 2018 Net Periodic Benefit Cost Service cost discount rate 2.82 % 3.63 3.20 3.04 4.45 3.85 Interest cost discount rate 3.13 % 4.13 3.60 3.08 4.25 3.62 Rate of increase in compensation levels 4.00 % 3.99 3.98 4.25 4.29 4.29 Expected long-term rate of return on plan assets 8.12 % 8.31 8.46 Benefit Obligation Discount rate 2.14 % 2.91 3.76 2.23 3.39 4.40 Rate of increase in compensation levels 4.00 % 4.01 3.97 4.27 4.29 4.29
Assumed Health Care Cost Trend Rates	The following table displays the assumed health care cost trend rates, for all individuals: Health Care Plans 2020 2019 Health care cost trend rate assumed for next year 5.68 % 5.87 % Rate to which the cost trend rate is assumed to decline (ultimate trend) 4.49 % 4.50 % Year the rate reaches the ultimate trend rate 2040 2040
Schedule of Net Funded Status	The following table sets forth information related to the benefit obligation and the fair value of plan assets at fiscal year-end 2020 and 2019 for the Company’s defined benefit retirement plans and other post-retirement plans: Retirement Plans Other Benefit Plans (Dollars in Millions) 2020 2019 2020 2019 Change in Benefit Obligation Projected benefit obligation — beginning of year $ 37,188 31,670 5,076 4,480 Service cost 1,380 1,163 287 274 Interest cost 955 1,096 133 185 Plan participant contributions 61 63 — — Amendments (1) (1,780) — — — Actuarial (gains) losses (2) 5,716 5,178 (75) 562 Divestitures & acquisitions (88) (278) — — Curtailments, settlements & restructuring (24) (172) — — Benefits paid from plan (1,111) (1,555) (3) (396) (431) Effect of exchange rates 1,003 23 3 6 Projected benefit obligation — end of year $ 43,300 37,188 5,028 5,076 Change in Plan Assets Plan assets at fair value — beginning of year $ 32,201 26,818 115 180 Actual return on plan assets 5,524 6,185 14 19 Company contributions 870 908 357 347 Plan participant contributions 61 63 — — Settlements (13) (16) — — Divestitures & acquisitions (84) (274) — — Benefits paid from plan assets (1,111) (1,555) (3) (396) (431) Effect of exchange rates 747 72 — — Plan assets at fair value — end of year $ 38,195 32,201 90 115 Funded status — end of year $ (5,105) (4,987) (4,938) (4,961) Amounts Recognized in the Company’s Balance Sheet consist of the following: Non-current assets $ 656 551 — — Current liabilities (125) (113) (418) (397) Non-current liabilities (5,636) (5,425) (4,520) (4,564) Total recognized in the consolidated balance sheet — end of year $ (5,105) (4,987) (4,938) (4,961) Amounts Recognized in Accumulated Other Comprehensive Income consist of the following: Net actuarial loss $ 10,860 8,835 1,463 1,685 Prior service cost (credit) (1) (1,797) (8) (44) (75) Unrecognized net transition obligation — — — — Total before tax effects $ 9,063 8,827 1,419 1,610 Accumulated Benefit Obligations — end of year $ 40,356 33,416 (1) In January 2021, the Company announced that, effective on January 1, 2026, all eligible U.S. non-union employees, regardless of hire date, will earn benefits under the Retirement Value formula. This amendment does not affect the benefits accrued under the Final Average Pay formula for service before January 1, 2026. (2) The actuarial losses for retirement plans in 2020 and 2019 was primarily related to decreases in discount rates. (3) In 2019, the Company offered a voluntary lump-sum payment option for certain eligible former employees who are vested participants of the U.S. Qualified Defined Benefit Pension Plan. The distribution of the lump-sums was completed by the end of fiscal 2019. The amount distributed in 2019 was approximately $514 million. Retirement Plans Other Benefit Plans (Dollars in Millions) 2020 2019 2020 2019 Amounts Recognized in Net Periodic Benefit Cost and Other Comprehensive Income Net periodic benefit cost $ 790 593 524 551 Net actuarial (gain) loss 2,616 1,084 (81) 550 Amortization of net actuarial loss (891) (579) (142) (129) Prior service cost (credit) (1,780) — — — Amortization of prior service (cost) credit (2) (4) 31 31 Effect of exchange rates 293 1 1 1 Total loss/(income) recognized in other comprehensive income, before tax $ 236 502 (191) 453 Total recognized in net periodic benefit cost and other comprehensive income $ 1,026 1,095 333 1,004
Information Related to the Benefit Obligation and the Fair Value of Plan Assets	The following table displays the funded status of the Company's U.S. Qualified & Non-Qualified pension plans and international funded and unfunded pension plans at December 31, 2020 and December 31, 2019, respectively: U.S. Plans International Plans Qualified Plans Non-Qualified Plans Funded Plans Unfunded Plans (Dollars in Millions) 2020 2019 2020 2019 2020 2019 2020 2019 Plan Assets $ 25,554 21,398 — — 12,641 10,803 — — Projected Benefit Obligation 25,466 22,034 2,748 2,544 14,541 12,132 545 478 Accumulated Benefit Obligation 24,158 19,831 2,495 2,115 13,210 11,040 493 430 Over (Under) Funded Status Projected Benefit Obligation $ 88 (636) (2,748) (2,544) (1,900) (1,329) (545) (478) Accumulated Benefit Obligation 1,396 1,567 (2,495) (2,115) (569) (237) (493) (430)
Projected Future Benefit Payments from Company's Retirement and Other Benefit Plans	The following table displays the projected future benefit payments from the Company’s retirement and other benefit plans: (Dollars in Millions) 2021 2022 2023 2024 2025 2026-2030 Projected future benefit payments Retirement plans $ 1,257 1,292 1,388 1,424 1,494 8,795 Other benefit plans $ 427 440 453 465 417 2,273
Projected Future Minimum Contributions to the Company's U.S. and International Unfunded Retirement Plans	The following table displays the projected future minimum contributions to the unfunded retirement plans. These amounts do not include any discretionary contributions that the Company may elect to make in the future. (Dollars in Millions) 2021 2022 2023 2024 2025 2026-2030 Projected future contributions $ 110 116 121 130 136 787
Company' Retirement Plan Asset Allocation and Target Allocations	The Company’s retirement plan asset allocation at the end of 2020 and 2019 and target allocations for 2021 are as follows: Percent of Target 2020 2019 2021 Worldwide Retirement Plans Equity securities 66 % 74 % 67 % Debt securities 34 26 33 Total plan assets 100 % 100 % 100 %
Schedule of Defined Benefit Plans Disclosures	The following table sets forth the Retirement Plans' investments measured at fair value as of December 31, 2020 and December 31, 2019: Quoted Prices Significant Significant Unobservable Inputs (1) Investments Measured at Net Asset Value (Level 1) (Level 2) (Level 3) Total Assets (Dollars in Millions) 2020 2019 2020 2019 2020 2019 2020 2019 2020 2019 Short-term investment funds $ 127 119 763 405 — — — — 890 524 Government and agency securities — — 5,023 4,140 — — — — 5,023 4,140 Debt instruments — — 3,931 3,452 — — — — 3,931 3,452 Equity securities 14,375 12,483 2 2 — — — — 14,377 12,485 Commingled funds — — 4,690 3,338 160 181 8,236 7,580 13,086 11,099 Other assets — — 11 9 21 19 856 473 888 501 Investments at fair value $ 14,502 12,602 14,420 11,346 181 200 9,092 8,053 38,195 32,201 (1) The activity for the Level 3 assets is not significant for all years presented.

Capital and Treasury Stock (Tab

Capital and Treasury Stock (Tables)	12 Months Ended
Capital and Treasury Stock (Tables)	Jan. 03, 2021
Equity [Abstract]
Changes in Treasury Stock	Changes in treasury stock were: Treasury Stock (Amounts in Millions Except Treasury Stock Shares in Thousands) Shares Amount Balance at December 31, 2017 437,318 $ 31,554 Employee compensation and stock option plans (22,082) (3,060) Repurchase of common stock 42,283 5,868 Balance at December 30, 2018 457,519 34,362 Employee compensation and stock option plans (20,053) (2,691) Repurchase of common stock 49,870 6,746 Balance at December 29, 2019 487,336 38,417 Employee compensation and stock option plans (21,765) (3,148) Repurchase of common stock 21,760 3,221 Balance at January 3, 2021 487,331 $ 38,490

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Loss) (Tables)	12 Months Ended
Accumulated Other Comprehensive Income (Loss) (Tables)	Jan. 03, 2021
Equity [Abstract]
Components of Accumulated Other Comprehensive Income	Components of other comprehensive income (loss) consist of the following: (Dollars in Millions) Foreign Gain/(Loss) On Securities Employee Benefit Plans Gain/ Total December 31, 2017 $ (7,351) 232 (6,150) 70 (13,199) Cumulative adjustment to retained earnings (232) (1) (232) Net 2018 changes (1,518) — (8) (265) (1,791) December 30, 2018 (8,869) — (6,158) (195) (15,222) Net 2019 changes 164 — (733) (100) (669) December 29, 2019 (8,705) — (6,891) (295) (15,891) Net 2020 changes (233) 1 (66) 947 649 January 3, 2021 $ (8,938) 1 (6,957) 652 (15,242) (1) Per the adoption of ASU 2016-01- Financial Instruments

Earnings Per Share (Tables)

Earnings Per Share (Tables)	12 Months Ended
Earnings Per Share (Tables)	Jan. 03, 2021
Earnings Per Share [Abstract]
Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share	The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal years ended January 3, 2021, December 29, 2019 and December 30, 2018: (In Millions Except Per Share Amounts) 2020 2019 2018 Basic net earnings per share $ 5.59 5.72 5.70 Average shares outstanding — basic 2,632.8 2,645.1 2,681.5 Potential shares exercisable under stock option plans 118.3 136.3 139.0 Less: shares repurchased under treasury stock method (80.4) (97.8) (92.5) Convertible debt shares — 0.7 0.7 Adjusted average shares outstanding — diluted 2,670.7 2,684.3 2,728.7 Diluted net earnings per share $ 5.51 5.63 5.61

Common Stock, Stock Option Pl_2

Common Stock, Stock Option Plans and Stock Compensation Agreements (Tables)	12 Months Ended
	Jan. 03, 2021
Share-based Payment Arrangement [Abstract]
Schedule Valuation Assumptions	The average fair value of options granted was $16.42, $17.80 and $17.98, in fiscal years 2020, 2019 and 2018, respectively. The fair value was estimated based on the weighted average assumptions of: 2020 2019 2018 Risk-free rate 1.47 % 2.56 % 2.77 % Expected volatility 15.33 % 16.27 % 15.77 % Expected life (in years) 7.0 7.0 7.0 Expected dividend yield 2.60 % 2.80 % 2.70 %
Summary of Stock Option Activity	A summary of option activity under the Plan as of January 3, 2021, December 29, 2019 and December 30, 2018, and changes during the years ending on those dates is presented below: (Shares in Thousands) Outstanding Shares Weighted Aggregate Shares at December 31, 2017 111,306 $ 90.48 $ 5,480 Options granted 17,115 129.51 Options exercised (16,228) 75.44 Options canceled/forfeited (2,541) 112.90 Shares at December 30, 2018 109,652 98.29 3,214 Options granted 19,745 131.94 Options exercised (14,785) 82.43 Options canceled/forfeited (2,975) 125.11 Shares at December 29, 2019 111,637 105.63 4,478 Options granted 20,723 151.41 Options exercised (16,275) 86.05 Options canceled/forfeited (1,835) 137.62 Shares at January 3, 2021 114,250 $ 116.22 $ 4,703
Summary of Options Outstanding	The following table summarizes stock options outstanding and exercisable at January 3, 2021: (Shares in Thousands) Outstanding Exercisable Exercise Price Range Options Average Life (1) Weighted Average Exercise Price Options Weighted Average Exercise Price $62.20-$72.54 11,111 1.8 $70.79 11,111 $70.79 $90.44-$100.06 22,304 3.6 $95.36 22,304 $95.36 $100.48-$115.67 28,180 5.6 $108.64 27,695 $108.51 $129.51-$131.94 32,553 7.6 $130.85 145 $130.53 $141.06-$151.41 20,102 9.1 $151.41 34 $151.41 114,250 6.0 $116.22 61,289 $96.97 (1) Average contractual life remaining in years.
Summary of Restricted Share Units	A summary of the restricted share units and performance share units activity under the Plans as of January 3, 2021 is presented below: (Shares in Thousands) Outstanding Restricted Share Units Outstanding Performance Share Units Shares at December 29, 2019 16,769 2,174 Granted 5,051 816 Issued (6,042) (702) Canceled/forfeited/adjusted (780) (52) Shares at January 3, 2021 14,998 2,236

Segments of Business and Geog_2

Segments of Business and Geographic Areas (Tables)	12 Months Ended
Segments of Business and Geographic Areas (Tables)	Jan. 03, 2021
Segment Reporting [Abstract]
Schedule of Sales by Segment of Business	Sales to Customers % Change (Dollars in Millions) 2020 2019 2018 ’20 vs. ’19 ’19 vs. ’18 Consumer Health) (1) OTC U.S. $ 2,460 2,010 1,850 22.4 % 8.6 International 2,364 2,434 2,484 (2.9) (2.0) Worldwide 4,824 4,444 4,334 8.5 2.5 Skin Health/Beauty (2) U.S. 2,350 2,392 2,403 (1.7) (0.4) International 2,100 2,201 1,979 (4.6) 11.2 Worldwide 4,450 4,593 4,382 (3.1) 4.8 Oral Care U.S. 683 621 637 9.9 (2.5) International 958 906 918 5.7 (1.2) Worldwide 1,641 1,528 1,555 7.4 (1.7) Baby Care U.S. 376 362 422 3.7 (14.2) International 1,141 1,313 1,436 (13.1) (8.6) Worldwide 1,517 1,675 1,858 (9.4) (9.9) Women's Health U.S. 13 12 13 8.2 (5.5) International 888 974 1,036 (8.8) (6.0) Worldwide 901 986 1,049 (8.6) (6.0) Wound Care/Other U.S. 480 441 436 8.9 1.2 International 240 230 239 4.1 (3.9) Worldwide 720 671 675 7.2 (0.6) TOTAL CONSUMER HEALTH U.S. 6,362 5,839 5,761 9.0 1.4 International 7,691 8,059 8,092 (4.6) (0.4) Worldwide 14,053 13,898 13,853 1.1 0.3 (1) Previously referred to as Consumer (2) Previously referred to as Beauty PHARMACEUTICAL Immunology U.S. 10,175 9,641 9,073 5.5 6.3 International 4,880 4,309 4,047 13.2 6.5 Worldwide 15,055 13,950 13,120 7.9 6.3 REMICADE ® U.S. 2,508 3,079 3,664 (18.5) (16.0) U.S. Exports 346 294 436 18.0 (32.7) International 893 1,007 1,226 (11.4) (17.8) Worldwide 3,747 4,380 5,326 (14.4) (17.8) SIMPONI / SIMPONI ARIA ® U.S. 1,155 1,159 1,051 (0.3) 10.2 International 1,088 1,029 1,033 5.8 (0.4) Worldwide 2,243 2,188 2,084 2.6 5.0 STELARA ® U.S. 5,240 4,346 3,469 20.6 25.3 International 2,467 2,015 1,687 22.4 19.4 Worldwide 7,707 6,361 5,156 21.1 23.4 TREMFYA ® U.S. 926 764 453 21.3 68.5 International 421 248 91 69.9 Worldwide 1,347 1,012 544 33.2 85.9 OTHER IMMUNOLOGY U.S. — — — — — International 11 10 10 6.4 4.5 Worldwide 11 10 10 6.4 4.5 Infectious Diseases U.S. 1,735 1,597 1,378 8.6 15.9 International 1,839 1,815 1,926 1.3 (5.7) Worldwide 3,574 3,413 3,304 4.7 3.3 EDURANT ® / rilpivirine U.S. 44 50 58 (11.2) (13.7) International 920 812 758 13.3 7.1 Worldwide 964 861 816 11.9 5.6 PREZISTA ® / PREZCOBIX ® / REZOLSTA ® / SYMTUZA ® U.S. 1,587 1,422 1,169 11.6 21.6 International 597 689 786 (13.4) (12.3) Worldwide 2,184 2,110 1,955 3.5 8.0 OTHER INFECTIOUS DISEASES U.S. 104 126 151 (17.6) (16.5) International 323 315 382 2.6 (17.6) Worldwide 427 441 533 (3.2) (17.3) Neuroscience U.S. 3,091 2,919 2,574 5.9 13.4 International 3,457 3,409 3,503 1.4 (2.7) Worldwide 6,548 6,328 6,077 3.5 4.1 CONCERTA ® / methylphenidate U.S. 183 233 229 (21.4) 1.7 International 439 463 434 (5.1) 6.6 Worldwide 622 696 663 (10.6) 4.9 INVEGA SUSTENNA ® / XEPLION ® / INVEGA TRINZA ® / TREVICTA ® U.S. 2,314 2,107 1,791 9.8 17.6 International 1,339 1,224 1,137 9.4 7.7 Worldwide 3,653 3,330 2,928 9.7 13.7 RISPERDAL CONSTA ® U.S. 296 314 315 (5.9) (0.3) International 346 374 422 (7.5) (11.4) Worldwide 642 688 737 (6.8) (6.7) OTHER NEUROSCIENCE U.S. 298 266 239 12.4 11.4 International 1,334 1,349 1,510 (1.1) (10.7) Worldwide 1,632 1,614 1,749 1.1 (7.7) Oncology U.S. 5,092 4,299 4,331 18.5 (0.7) International 7,275 6,393 5,513 13.8 16.0 Worldwide 12,367 10,692 9,844 15.7 8.6 DARZALEX ® U.S. 2,232 1,567 1,203 42.4 30.3 International 1,958 1,430 822 36.9 73.9 Worldwide 4,190 2,998 2,025 39.8 48.0 ERLEADA ® U.S. 583 297 124 96.1 International 176 35 — * * ** Worldwide 760 332 124 * * IMBRUVICA ® U.S. 1,821 1,555 1,129 17.1 37.7 International 2,307 1,856 1,486 24.3 24.9 Worldwide 4,128 3,411 2,615 21.0 30.4 VELCADE ® U.S. — — — — — International 408 751 1,116 (45.7) (32.7) Worldwide 408 751 1,116 (45.7) (32.7) ZYTIGA ® / abiraterone acetate U.S. 373 810 1,771 (54.0) (54.3) International 2,097 1,985 1,727 5.6 15.0 Worldwide 2,470 2,795 3,498 (11.6) (20.1) OTHER ONCOLOGY U.S. 83 70 104 19.2 (32.7) International 330 336 362 (1.9) (7.2) Worldwide 413 407 466 1.7 (12.7) Pulmonary Hypertension U.S. 2,133 1,684 1,651 26.6 2.0 International 1,015 939 922 8.2 1.9 Worldwide 3,148 2,623 2,573 20.0 1.9 OPSUMIT ® U.S. 1,008 766 700 31.7 9.4 International 631 562 515 12.3 9.0 Worldwide 1,639 1,327 1,215 23.5 9.2 UPTRAVI ® U.S. 955 714 598 33.8 19.3 International 138 105 65 30.9 62.4 Worldwide 1,093 819 663 33.5 23.5 OTHER U.S. 169 205 353 (17.6) (41.9) International 247 272 342 (9.2) (20.5) Worldwide 416 476 695 (12.8) (31.5) Cardiovascular / Metabolism / Other U.S. 3,509 3,734 4,279 (6.0) (12.7) International 1,369 1,458 1,537 (6.1) (5.2) Worldwide 4,878 5,192 5,816 (6.0) (10.7) XARELTO ® U.S. 2,345 2,313 2,477 1.4 (6.6) International — — — — — Worldwide 2,345 2,313 2,477 1.4 (6.6) INVOKANA ® / INVOKAMET ® U.S. 564 536 711 5.2 (24.6) International 231 199 170 16.3 17.3 Worldwide 795 735 881 8.2 (16.5) PROCRIT ® / EPREX ® U.S. 277 505 674 (45.1) (25.1) International 274 285 314 (3.8) (9.2) Worldwide 552 790 988 (30.2) (20.0) OTHER U.S. 323 380 417 (15.1) (9.1) International 864 974 1,053 (11.3) (7.6) Worldwide 1,186 1,353 1,470 (12.4) (8.0) TOTAL PHARMACEUTICAL U.S. 25,735 23,874 23,286 7.8 2.5 International 19,837 18,324 17,448 8.3 5.0 Worldwide 45,572 42,198 40,734 8.0 3.6 MEDICAL DEVICES Diabetes Care U.S. — — 371 — International — — 638 — Worldwide — — 1,009 — Interventional Solutions U.S. 1,452 1,443 1,283 0.6 12.5 International 1,594 1,554 1,363 2.6 14.0 Worldwide 3,046 2,997 2,646 1.6 13.3 Orthopaedics U.S. 4,779 5,319 5,281 (10.2) 0.7 International 2,984 3,520 3,604 (15.2) (2.3) Worldwide 7,763 8,839 8,885 (12.2) (0.5) HIPS U.S. 793 863 841 (8.2) 2.6 International 487 575 577 (15.3) (0.3) Worldwide 1,280 1,438 1,418 (11.0) 1.4 KNEES U.S. 743 889 911 (16.4) (2.4) International 427 591 591 (27.8) 0.0 Worldwide 1,170 1,480 1,502 (21.0) (1.4) TRAUMA U.S. 1,648 1,652 1,599 (0.2) 3.3 International 966 1,068 1,100 (9.6) (2.9) Worldwide 2,614 2,720 2,699 (3.9) 0.8 SPINE, SPORTS & OTHER (3) U.S. 1,595 1,915 1,930 (16.7) (0.8) International 1,104 1,286 1,336 (14.1) (3.8) Worldwide 2,699 3,201 3,266 (15.7) (2.0) Surgery U.S. 3,249 3,828 4,125 (15.1) (7.2) International 4,983 5,673 5,776 (12.2) (1.8) Worldwide 8,232 9,501 9,901 (13.4) (4.0) ADVANCED U.S. 1,535 1,637 1,657 (6.2) (1.2) International 2,304 2,458 2,345 (6.2) 4.8 Worldwide 3,839 4,095 4,002 (6.2) 2.3 GENERAL U.S. 1,714 2,192 2,468 (21.8) (11.2) International 2,679 3,215 3,431 (16.7) (6.3) Worldwide 4,392 5,406 5,899 (18.8) (8.4) Vision U.S. 1,557 1,794 1,777 (13.2) 0.9 International 2,362 2,830 2,776 (16.5) 2.0 Worldwide 3,919 4,624 4,553 (15.2) 1.6 CONTACT LENSES / OTHER U.S. 1,213 1,304 1,237 (7.0) 5.4 International 1,781 2,088 2,065 (14.7) 1.1 Worldwide 2,994 3,392 3,302 (11.7) 2.7 SURGICAL U.S. 344 490 540 (29.7) (9.4) International 581 742 711 (21.7) 4.4 Worldwide 925 1,232 1,251 (24.9) (1.6) TOTAL MEDICAL DEVICES U.S. 11,036 12,384 12,837 (10.9) (3.5) International 11,923 13,579 14,157 (12.2) (4.1) Worldwide 22,959 25,963 26,994 (11.6) (3.8) WORLDWIDE U.S. 43,133 42,097 41,884 2.5 0.5 International 39,451 39,962 39,697 (1.3) 0.7 Worldwide $ 82,584 82,059 81,581 0.6 % 0.6 (3) Previously referred to as Spine & Other Certain prior year amounts have been reclassified to conform to current year presentation *Percentage greater than 100% or not meaningful
Schedule of Segment Reporting Information	Income (Loss) Before Tax Identifiable Assets (Dollars in Millions) 2020 (3) 2019 (4) 2018 (5) 2020 2019 Consumer Health $ (1,064) 2,061 2,320 $ 27,355 26,618 Pharmaceutical 15,462 8,816 12,568 66,158 56,292 Medical Devices 3,044 7,286 4,397 49,578 49,462 Total 17,442 18,163 19,285 143,091 132,372 Less: Expense not allocated to segments (1) 945 835 1,286 General corporate (2) 31,803 25,356 Worldwide total $ 16,497 17,328 17,999 $ 174,894 157,728 Additions to Property, Depreciation and (Dollars in Millions) 2020 2019 2018 2020 2019 2018 Consumer Health $ 248 328 438 $ 785 765 688 Pharmaceutical 863 950 1,012 4,006 3,910 3,802 Medical Devices 1,980 1,912 1,843 2,140 2,014 2,103 Segments total 3,091 3,190 3,293 6,931 6,689 6,593 General corporate 256 308 377 300 320 336 Worldwide total $ 3,347 3,498 3,670 $ 7,231 7,009 6,929
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas	Sales to Customers Long-Lived Assets (6) (Dollars in Millions) 2020 2019 2018 2020 2019 United States $ 43,133 42,097 41,884 $ 49,951 41,528 Europe 18,980 18,466 18,753 49,363 48,015 Western Hemisphere excluding U.S. 5,335 5,941 6,113 2,734 2,862 Asia-Pacific, Africa 15,136 15,555 14,831 5,484 5,486 Segments total 82,584 82,059 81,581 107,532 97,891 General corporate 1,029 1,049 Other non long-lived assets 66,333 58,788 Worldwide total $ 82,584 82,059 81,581 $ 174,894 157,728 See Note 1 for a description of the segments in which the Company operates. Export sales are not significant. In fiscal year 2020, the Company utilized three wholesalers distributing products for all three segments that represented approximately 16.0%, 12.0% and 12.0% of the total consolidated revenues. In fiscal year 2019, the Company had three wholesalers distributing products for all three segments that represented approximately 15.0%, 12.0% and 11.0% of the total consolidated revenues. In fiscal year 2018, the Company had three wholesalers distributing products for all three segments that represented approximately 14.0%, 11.0%, and 11.0% of the total consolidated revenues. (1) Amounts not allocated to segments include interest (income) expense and general corporate (income) expense. (2) General corporate includes cash, cash equivalents and marketable securities. (3) Consumer Health includes: • Litigation expense of $3.9 billion, primarily talc related reserves and certain settlements. Pharmaceutical includes: • Litigation expense of $0.8 billion, primarily related to the agreement in principle to settle opioid litigation • An unrealized gain on securities of $0.5 billion • A restructuring related charge of $0.1 billion Medical Devices includes: • A contingent consideration reversal of $1.1 billion related to the timing of certain developmental milestones associated with the Auris Health acquisition. • Litigation expense of $0.3 billion • A restructuring related charge of $0.3 billion • An in-process research and development expense of $0.2 billion • A Medical Device Regulation charge of $0.1 billion (4) Consumer Health includes: • A gain of $0.3 billion related to the Company's previously held equity investment in DR. CI:LABO • Litigation expense of $0.4 billion • A restructuring related charge of $0.1 billion Pharmaceutical includes: • Litigation expense of $4.3 billion of which $4.0 billion is related to the agreement in principle to settle opioid litigation • An in-process research and development expense of $0.9 billion related to the Alios asset • A research and development expense of $0.3 billion for an upfront payment related to argenx • An unrealized gain on securities of $0.6 billion • Actelion acquisition and integration related costs of $0.2 billion • A restructuring charge of $0.1 billion Medical Devices includes: • A gain of $2.0 billion from the divestiture of the ASP business • A restructuring related charge of $0.4 billion • Litigation expense of $0.4 billion • Auris Health acquisition and integration related costs of $0.1 billion (5) Consumer Health includes: • A gain of $0.3 billion from the divestiture of NIZORAL ® • Litigation expense of $0.3 billion Pharmaceutical includes: • An in-process research and development charge of $1.1 billion related to the Alios and XO1 assets and the corresponding XO1 contingent liability reversal of $0.2 billion • Actelion acquisition and integration related costs of $0.2 billion • An unrealized loss on securities of $0.2 billion • A gain of $0.2 billion from the divestiture of certain non-strategic Pharmaceutical products Medical Devices includes: • Litigation expense of $1.7 billion • A restructuring related charge of $0.6 billion • AMO acquisition and integration related costs of $0.1 billion • A gain of $0.5 billion from the divestiture of the LifeScan business (6) Long-lived assets include property, plant and equipment, net for fiscal years 2020, and 2019 of $18,766 and $17,658, respectively, and intangible assets and goodwill, net for fiscal years 2020 and 2019 of $89,795 and $81,282, respectively.

Restructuring (Tables)

Restructuring (Tables)	12 Months Ended
Restructuring (Tables)	Jan. 03, 2021
Restructuring and Related Activities [Abstract]
Summary of Severance Charges and Associated Spending	The following table summarizes the severance charges and the associated spending under these initiatives through the fiscal year ended 2020: (Dollars in Millions) Severance Asset Write-offs/Sales Other (2) Total Reserve balance, December 30, 2018 $ 194 — 48 242 2019 activity (30) — (32) (62) Reserve balance, December 29, 2019 164 — 16 180 Current year activity: Charges — 43 405 448 Cash settlements (29) 24 (4) (399) (404) Settled non cash — (67) (13) (3) (80) Reserve balance, January 3, 2021 (1) $ 135 — 9 144 (1) Cash outlays for severance are expected to be substantially paid out over the next 2 years in accordance with the Company's plans and local laws. (2) Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses. (3) Relates to pension related net actuarial losses associated with the transfer of employees to Jabil Inc. as part of the strategic collaboration. (4) Represents gain on sale of an asset

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Narrative (Details) $ in Millions	12 Months Ended
	Jan. 03, 2021USD ($)EmployeeSegment	Dec. 29, 2019USD ($)	Dec. 30, 2018USD ($)	Dec. 31, 2017
Concentration of Credit Risk [Line Items]
Number of employees \| Employee	134,500
Number of business segments \| Segment	3
Accrued Rebates Returns And Promotions	$ 11,513	$ 10,883
Minimum reverse repurchase agreement collateral (as a percent)	102.00%
Sales return reserve (as a percent)	1.00%	1.00%	1.00%
Percentage of profit share payments (less than)	3.00%	3.00%	3.00%
Cost of products sold	$ 28,427	$ 27,556	$ 27,091
Shipping and handling costs as a percent of sales	0.50%	0.50%	0.50%
Advertising expense	$ 2,100	$ 2,200	$ 2,600
Operating Lease, Right-of-Use Asset	1,000	1,000
Present Value of lease liabilities	1,100	1,000
Operating lease costs	300	300	$ 300
Cash paid for operating leases	$ 300	$ 300
U.S. statutory rate	21.00%	21.00%	21.00%	35.00%
TCJA, undistributed foreign earnings percent related to cash and cash equivalents				15.50%
TCJA, undistributed foreign earnings percent related to earnings other than cash and cash equivalents				8.00%
TCJA, provisional liability	$ 7,700
TJCA , provisional liability, non-current	6,900
Repatriation of foreign earnings amount	$ 700
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	us-gaap:OtherLiabilitiesNoncurrent	us-gaap:OtherLiabilitiesNoncurrent
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	us-gaap:OtherAssets	us-gaap:OtherAssets
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent	us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
Minimum \| Software Development
Concentration of Credit Risk [Line Items]
Estimated useful lives of the assets	3 years
Maximum \| Software Development
Concentration of Credit Risk [Line Items]
Estimated useful lives of the assets	8 years
R&D Expense
Concentration of Credit Risk [Line Items]
Concentration risk (as a percent)	5.00%
Shipping and Handling
Concentration of Credit Risk [Line Items]
Cost of products sold	$ 1,000	$ 1,000	$ 1,100
Pharmaceutical
Concentration of Credit Risk [Line Items]
Accrued Rebates Returns And Promotions	$ 7,200	$ 7,000

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Cumulative Effect Adjustments (Details) - USD ($) $ in Millions	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018	Jan. 01, 2018	Dec. 31, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative Effect of Adjustment	$ 63,278	$ 59,471	$ 59,752		$ 60,160
Cumulative Effect, Period of Adoption, Adjustment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative Effect of Adjustment					(486)
Retained Earnings
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative Effect of Adjustment	$ 113,890	$ 110,659	$ 106,216		101,793
Retained Earnings \| Cumulative Effect, Period of Adoption, Adjustment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative Effect of Adjustment				$ (254)	$ (254)
ASU 2014-09 - Revenue from Contracts with Customers \| Retained Earnings \| Cumulative Effect, Period of Adoption, Adjustment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative Effect of Adjustment				(47)
ASU 2016-01 - Financial Instruments \| Retained Earnings \| Cumulative Effect, Period of Adoption, Adjustment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative Effect of Adjustment				232
ASU 2016-16 - Income Taxes: Intra-Entity Transfers \| Retained Earnings \| Cumulative Effect, Period of Adoption, Adjustment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative Effect of Adjustment				$ (439)

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Estimated Useful Lives of Assets (Details)	12 Months Ended
	Jan. 03, 2021
Minimum \| Building and building equipment
Property, Plant and Equipment [Line Items]
Estimated useful lives of the assets	20 years
Minimum \| Land And Leasehold Improvements
Property, Plant and Equipment [Line Items]
Estimated useful lives of the assets	10 years
Minimum \| Machinery and Equipment
Property, Plant and Equipment [Line Items]
Estimated useful lives of the assets	2 years
Maximum \| Building and building equipment
Property, Plant and Equipment [Line Items]
Estimated useful lives of the assets	30 years
Maximum \| Land And Leasehold Improvements
Property, Plant and Equipment [Line Items]
Estimated useful lives of the assets	20 years
Maximum \| Machinery and Equipment
Property, Plant and Equipment [Line Items]
Estimated useful lives of the assets	13 years

Cash, Cash Equivalents and Cu_3

Cash, Cash Equivalents and Current Marketable Securities - Cash and Cash Equivalent Composition (Details) - USD ($) $ in Millions	Jan. 03, 2021	Dec. 29, 2019
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Cash & Cash Equivalents	$ 13,985	$ 17,305
Debt Securities, Held-to-maturity, Fair Value	2,863
Current Marketable Securities	11,200	1,982
Held-to-maturity Securities
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Carrying Amount, held-to-maturity	11,143	14,919
Cash & Cash Equivalents	9,230	14,195
Debt Securities, Held-to-maturity, Fair Value	11,143
Current Marketable Securities	1,913	724
Held-to-maturity Securities \| Cash
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Carrying Amount, held-to-maturity	2,863	2,637
Cash & Cash Equivalents	2,863	2,637
Current Marketable Securities	0	0
Held-to-maturity Securities \| Non-U.S. Sovereign Securities(1)
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Carrying Amount, held-to-maturity	690	439
Cash & Cash Equivalents	0	149
Debt Securities, Held-to-maturity, Fair Value	690
Current Marketable Securities	690	290
Held-to-maturity Securities \| U.S. Reverse repurchase agreements
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Carrying Amount, held-to-maturity	1,937	6,375
Cash & Cash Equivalents	1,937	6,375
Debt Securities, Held-to-maturity, Fair Value	1,937
Current Marketable Securities	0	0
Held-to-maturity Securities \| Other Reverse repurchase agreements
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Carrying Amount, held-to-maturity		375
Cash & Cash Equivalents		375
Current Marketable Securities		0
Held-to-maturity Securities \| Corporate debt securities(1)
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Carrying Amount, held-to-maturity	2,674	1,323
Cash & Cash Equivalents	1,451	889
Debt Securities, Held-to-maturity, Fair Value	2,674
Current Marketable Securities	1,223	434
Held-to-maturity Securities \| Money market funds
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Carrying Amount, held-to-maturity	2,102	2,864
Cash & Cash Equivalents	2,102	2,864
Debt Securities, Held-to-maturity, Fair Value	2,102
Current Marketable Securities	0	0
Held-to-maturity Securities \| Time deposits(1)
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Carrying Amount, held-to-maturity	877	906
Cash & Cash Equivalents	877	906
Debt Securities, Held-to-maturity, Fair Value	877
Current Marketable Securities	0	0
Available-for-sale Securities
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Carrying Amount, available-for-sale	14,041	4,368
Cash & Cash Equivalents	4,755	3,110
Debt Securities, Held-to-maturity, Fair Value	14,042
Current Marketable Securities	9,287	1,258
Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain	1
Available-for-sale Securities \| U.S. Gov't Securities
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Carrying Amount, available-for-sale	13,777	4,102
Cash & Cash Equivalents	4,731	3,095
Debt Securities, Held-to-maturity, Fair Value	13,778
Current Marketable Securities	9,047	1,007
Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain	1
Available-for-sale Securities \| Corporate debt securities(1)
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Carrying Amount, available-for-sale	250	266
Cash & Cash Equivalents	24	15
Debt Securities, Held-to-maturity, Fair Value	250
Current Marketable Securities	226	$ 251
Available-for-sale Securities \| Other Sovereign Securities
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Carrying Amount, available-for-sale	14
Cash & Cash Equivalents	0
Debt Securities, Held-to-maturity, Fair Value	14
Current Marketable Securities	$ 14

Cash, Cash Equivalents and Cu_4

Cash, Cash Equivalents and Current Marketable Securities - Contractual Maturities of Available for Sale Securities (Details) $ in Millions	Jan. 03, 2021USD ($)
Cost Basis
Due within one year	$ 14,026
Due after one year through five years	15
Due after five years through ten years	0
Total debt securities	14,041
Fair Value
Due within one year	14,027
Due after one year through five years	15
Due after five years through ten years	0
Total debt securities	$ 14,042

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Jan. 03, 2021	Dec. 29, 2019
Summary of Inventories
Raw materials and supplies	$ 1,410	$ 1,117
Goods in process	2,040	1,832
Finished goods	5,894	6,071
Total inventories (1)	$ 9,344	$ 9,020

Property, Plant and Equipment -

Property, Plant and Equipment - Property, Plant and Equipment at Cost and Accumulated Depreciation (Details) - USD ($) $ in Millions	Jan. 03, 2021	Dec. 29, 2019
Property, Plant and Equipment, Net [Abstract]
Land and land improvements	$ 882	$ 854
Buildings and building equipment	12,502	11,877
Machinery and equipment	29,104	26,964
Construction in progress	4,316	3,637
Total property, plant and equipment, gross	46,804	43,332
Less accumulated depreciation	28,038	25,674
Total property, plant and equipment, net(1)	$ 18,766	$ 17,658

Property, Plant and Equipment_2

Property, Plant and Equipment - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Property, Plant and Equipment [Abstract]
Interest expense capitalized	$ 63	$ 70	$ 86
Depreciation expense, including the amortization of capitalized interest	$ 2,600	$ 2,500	$ 2,600

Intangible Assets and Goodwil_2

Intangible Assets and Goodwill - Schedule of Intangible Assets and Goodwill (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]
Research and Development in Process	$ 181	$ 890	$ 1,126
Intangible assets with indefinite lives:
Indefinite lived intangible assets	19,044	11,569
Total intangible assets - net	53,402	47,643
Trademarks
Intangible assets with indefinite lives:
Indefinite lived intangible assets	7,195	6,922
Purchased in-process research and development
Intangible assets with indefinite lives:
Indefinite lived intangible assets	11,849	4,647
Patents And Trademarks
Intangible assets with definite lives:
Finite lived intangible assets gross	39,990	36,634
Less accumulated amortization	17,618	13,154
Finite lived intangible assets net	22,372	23,480
Customer relationships and other intangible assets
Intangible assets with definite lives:
Finite lived intangible assets gross	22,898	22,056
Less accumulated amortization	10,912	9,462
Finite lived intangible assets net	11,986	$ 12,594
Momenta \| In Process Research and Development
Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]
Research and Development in Process	6,000
bermekimab \| In Process Research and Development
Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]
Research and Development in Process	800
Verb Surgical Inc. \| In Process Research and Development
Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]
Research and Development in Process	$ 400

Intangible Assets and Goodwil_3

Intangible Assets and Goodwill - Goodwill (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019
Goodwill [Roll Forward]
Goodwill beginning of period	$ 33,639	$ 30,453
Goodwill, related to acquisitions	1,460	3,281
Currency translation/other	1,294	(95)
Goodwill end of period	36,393	33,639
Consumer
Goodwill [Roll Forward]
Goodwill beginning of period	9,736	8,670
Goodwill, related to acquisitions	0	1,188
Currency translation/other	600	(122)
Goodwill end of period	10,336	9,736
Pharmaceutical
Goodwill [Roll Forward]
Goodwill beginning of period	9,169	9,063
Goodwill, related to acquisitions	1,222	75
Currency translation/other	618	31
Goodwill end of period	11,009	9,169
Medical Devices
Goodwill [Roll Forward]
Goodwill beginning of period	14,734	12,720
Goodwill, related to acquisitions	238	2,018
Currency translation/other	76	(4)
Goodwill end of period	$ 15,048	$ 14,734

Intangible Assets and Goodwil_4

Intangible Assets and Goodwill - Narrative (Details) - USD ($) $ in Billions	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Finite-Lived Intangible Assets [Line Items]
Amortization expense of amortizable intangible assets	$ 4.7	$ 4.5	$ 4.4
Patents And Trademarks
Finite-Lived Intangible Assets [Line Items]
Intangible assets useful life	12 years
Customer relationships and other intangible assets
Finite-Lived Intangible Assets [Line Items]
Intangible assets useful life	21 years

Intangible Assets and Goodwil_5

Intangible Assets and Goodwill - Amortization of Intangible Assets (Details) $ in Millions	Jan. 03, 2021USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Finite lived intangibles, amortization expense next twelve months	$ 4,600
Finite lived intangibles, amortization expense, year two	4,200
Finite lived intangibles, amortization expense, year three	4,100
Finite lived intangibles, amortization expense, year four	3,900
Finite lived intangibles, amortization expense, year five	$ 3,200

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Derivative [Line Items]
Contingent consideration liability	$ 633	$ 1,715
Fair Value, measurement with unobservable inputs reconciliation, recurring basis, liability value	633	1,715	$ 397	$ 600
Other assets, noncurrent	6,562	5,695
Deferred net losses (gains) on derivatives included in accumulated other comprehensive income	$ (652)
Description of reclassification of cash flow hedge gain (loss)	next 12 months
Maximum length of time for hedging transaction exposure	18 months
Contingent consideration reversal	$ (1,148)	0	0
Additions	106	1,246	125
Payments	(99)	(79)	(172)
Foreign exchange contracts
Derivative [Line Items]
Collateral paid	1,100
Derivative, notional amount	37,800	45,300
Cross currency interest rate swaps
Derivative [Line Items]
Derivative, notional amount	30,600	20,100
Equity securities \| Equity Investments with Readily Determinable Value
Derivative [Line Items]
Marketable securities, noncurrent	1,481	1,148	511
Other assets, noncurrent	1,481	1,148
Equity, fair value adjustment	527	533
Equity investments, increase (decrease) from acquisition (sale) during period	(194)	104
Equity securities \| Equity Investments without Readily Determinable Value
Derivative [Line Items]
Equity, fair value adjustment, impairment loss	(76)	(57)
Other assets, noncurrent	738	712
Equity, fair value adjustment	(55)	(38)
Equity investments, increase (decrease) from acquisition (sale) during period	81	69
Equity, fair value adjustment, change in observable prices	21	19
Equity securities without readily determinable fair value, amount	738	712	681
Fair Value, Inputs, Level 3
Derivative [Line Items]
Contingent consideration liability	633	1,715
Other Current Liabilities
Derivative [Line Items]
Contingent consideration liability	39	84
Other Noncurrent Liabilities
Derivative [Line Items]
Contingent consideration liability	$ 594	$ 1,631	$ 397

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Derivative Activity (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019
Sales \| Cross currency interest rate swaps contracts: \| Fair Value Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	$ 0	$ 0
Amount of gain or (loss) recognized in AOCI	0	0
Sales \| Cross currency interest rate swaps contracts: \| Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into income	0	0
Amount of gain or (loss) recognized in AOCI	0	0
Sales \| Forward foreign exchange contracts: \| Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into income	12	(54)
Amount of gain or (loss) recognized in AOCI	44	(20)
Cost of Products Sold \| Cross currency interest rate swaps contracts: \| Fair Value Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	0	0
Amount of gain or (loss) recognized in AOCI	0	0
Cost of Products Sold \| Cross currency interest rate swaps contracts: \| Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into income	0	0
Amount of gain or (loss) recognized in AOCI	0	0
Cost of Products Sold \| Forward foreign exchange contracts: \| Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into income	(329)	(321)
Amount of gain or (loss) recognized in AOCI	298	(606)
R&D Expense \| Cross currency interest rate swaps contracts: \| Fair Value Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	0	0
Amount of gain or (loss) recognized in AOCI	0	0
R&D Expense \| Cross currency interest rate swaps contracts: \| Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into income	0	0
Amount of gain or (loss) recognized in AOCI	0	0
R&D Expense \| Forward foreign exchange contracts: \| Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into income	(137)	(105)
Amount of gain or (loss) recognized in AOCI	(191)	(94)
Interest (Income) Expense \| Cross currency interest rate swaps contracts: \| Fair Value Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	153	159
Amount of gain or (loss) recognized in AOCI	153	159
Interest (Income) Expense \| Cross currency interest rate swaps contracts: \| Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into income	370	292
Amount of gain or (loss) recognized in AOCI	748	417
Interest (Income) Expense \| Forward foreign exchange contracts: \| Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into income	0	0
Amount of gain or (loss) recognized in AOCI	0	0
Other (Income) Expense \| Cross currency interest rate swaps contracts: \| Fair Value Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	0	0
Amount of gain or (loss) recognized in AOCI	0	0
Other (Income) Expense \| Cross currency interest rate swaps contracts: \| Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into income	0	0
Amount of gain or (loss) recognized in AOCI	0	0
Other (Income) Expense \| Forward foreign exchange contracts: \| Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into income	(16)	22
Amount of gain or (loss) recognized in AOCI	$ (52)	$ 39

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019
Forward foreign exchange contracts: \| Not Designated as Hedging Instrument \| Other (Income) Expense
Derivative Instruments, Gain (Loss) [Line Items]
Gain/(Loss) Recognized In Income on Derivative	$ 24	$ (144)

Fair Value Measurements - Sch_2

Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019
Derivative Instruments, Gain (Loss) [Line Items]
Gain/(Loss) Recognized In Accumulated OCI	$ (473)	$ 121
Cross currency interest rate swaps contracts:
Derivative Instruments, Gain (Loss) [Line Items]
Gain/(Loss) Recognized In Accumulated OCI	65	488
Sale of Subsidiary Gain (Loss)
Derivative Instruments, Gain (Loss) [Line Items]
Gain/(Loss) Reclassified From Accumulated OCI Into Income	0	0
Other (Income) Expense
Derivative Instruments, Gain (Loss) [Line Items]
Gain/(Loss) Reclassified From Accumulated OCI Into Income	$ 0	$ 0

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of Activity Related to Equity Investments (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Equity Investment [Roll Forward]
Other assets, noncurrent	$ 6,562	$ 5,695
Equity securities \| Equity Investments with Readily Determinable Value
Equity Investment [Roll Forward]
Marketable securities, noncurrent	1,481	1,148	$ 511
Equity, fair value adjustment	527	533
Equity investments, increase (decrease) from acquisition (sale) during period	(194)	104
Other assets, noncurrent	1,481	1,148
Equity securities \| Equity Investments without Readily Determinable Value
Equity Investment [Roll Forward]
Equity, fair value adjustment	(55)	(38)
Equity investments, increase (decrease) from acquisition (sale) during period	81	69
Other assets, noncurrent	738	712
Equity securities without readily determinable fair value, amount	$ 738	$ 712	$ 681

Fair Value Measurements - Finan

Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018	Apr. 01, 2019
Financial assets and liabilities at fair value
Derivative Instruments in Hedges, Assets, at Fair Value	$ 1,089
Derivative Instruments in Hedges, Liabilities, at Fair Value	2,271
Equity Securities, FV-NI	1,481	$ 1,148
Debt securities	14,042	4,368
Contingent consideration liability	633	1,715
Derivative Asset, Fair Value, Gross Asset	1,138	925
Derivative Asset, Fair Value, Gross Liability	(1,107)	(841)
Derivative Asset	31	84
Derivative Liability, Fair Value, Gross Liability	2,309	652
Derivative Liability, Fair Value, Gross Asset	(2,172)	(586)
Derivative Liability	137	66
Beginning Balance	1,715	397	$ 600
Changes in estimated fair value (7)	(1,089)	151	(156)
Additions	106	1,246	125
Payments	(99)	(79)	(172)
Ending Balance	633	1,715	397
Contingent consideration reversal	(1,148)	0	0
Other Noncurrent Liabilities
Financial assets and liabilities at fair value
Contingent consideration liability	594	1,631	$ 397
Other Current Liabilities
Financial assets and liabilities at fair value
Contingent consideration liability	39	84
Auris Health
Financial assets and liabilities at fair value
Contingent consideration liability	1,100			$ 2,350
Contingent consideration reversal	(1,148)
Level 1
Financial assets and liabilities at fair value
Derivative Instruments in Hedges, Assets, at Fair Value	0
Derivative Instruments in Hedges, Liabilities, at Fair Value	0
Equity Securities, FV-NI	1,481	1,148
Debt securities	0
Level 2
Financial assets and liabilities at fair value
Derivative Instruments in Hedges, Assets, at Fair Value	1,089	902
Derivative Instruments in Hedges, Liabilities, at Fair Value	2,271	619
Equity Securities, FV-NI	0
Debt securities	14,042
Level 3
Financial assets and liabilities at fair value
Derivative Instruments in Hedges, Assets, at Fair Value	0
Derivative Instruments in Hedges, Liabilities, at Fair Value	0
Equity Securities, FV-NI	0
Debt securities	0
Contingent consideration liability	633	1,715
Interest rate swaps contracts:
Financial assets and liabilities at fair value
Derivative Instruments in Hedges, Assets, at Fair Value	240
Derivative Instruments in Hedges, Liabilities, at Fair Value	1,569
Derivative Asset, Noncurrent		1
Interest rate swaps contracts: \| Level 1
Financial assets and liabilities at fair value
Derivative Instruments in Hedges, Assets, at Fair Value	0
Derivative Instruments in Hedges, Liabilities, at Fair Value	0
Interest rate swaps contracts: \| Level 2
Financial assets and liabilities at fair value
Derivative Instruments in Hedges, Assets, at Fair Value	240	693
Derivative Instruments in Hedges, Liabilities, at Fair Value	1,569	193
Interest rate swaps contracts: \| Level 3
Financial assets and liabilities at fair value
Derivative Instruments in Hedges, Assets, at Fair Value	0
Derivative Instruments in Hedges, Liabilities, at Fair Value	0
Foreign exchange contracts
Financial assets and liabilities at fair value
Derivative Instruments in Hedges, Assets, at Fair Value	849
Derivative Instruments in Hedges, Liabilities, at Fair Value	702
Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Asset at Fair Value	49
Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Liability at Fair Value	38
Foreign exchange contracts \| Level 1
Financial assets and liabilities at fair value
Derivative Instruments in Hedges, Assets, at Fair Value	0
Derivative Instruments in Hedges, Liabilities, at Fair Value	0
Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Asset at Fair Value	0
Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Liability at Fair Value	0
Foreign exchange contracts \| Level 2
Financial assets and liabilities at fair value
Derivative Instruments in Hedges, Assets, at Fair Value	849	209
Derivative Instruments in Hedges, Liabilities, at Fair Value	702	426
Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Asset at Fair Value	49	23
Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Liability at Fair Value	38	$ 33
Foreign exchange contracts \| Level 3
Financial assets and liabilities at fair value
Derivative Instruments in Hedges, Assets, at Fair Value	0
Derivative Instruments in Hedges, Liabilities, at Fair Value	0
Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Asset at Fair Value	0
Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Liability at Fair Value	$ 0

Borrowings - Schedule of Long-t

Borrowings - Schedule of Long-term Debt Instruments (Details) € in Millions, £ in Millions, $ in Millions	Jan. 03, 2021USD ($)	Jan. 03, 2021EUR (€)	Jan. 03, 2021GBP (£)	Sep. 27, 2020USD ($)	Dec. 29, 2019USD ($)	Dec. 29, 2019EUR (€)	Dec. 29, 2019GBP (£)
Debt Instrument [Line Items]
Effective interest rate	2.85%	2.85%	2.85%		3.19%	3.19%	3.19%
Borrowed under the commercial paper program	$ 1,800				$ 1,100
Total long-term debt	32,635				26,494
Senior Notes
Debt Instrument [Line Items]
Total long-term debt				$ 7,500
Carrying (Reported) Amount, Fair Value Disclosure
Debt Instrument [Line Items]
Long-term debt	34,434				27,594
Less current portion	1,799				1,100
Total long-term debt	$ 32,635				$ 26,494
3% Zero Coupon Convertible Subordinated Debentures due 2020
Debt Instrument [Line Items]
Effective interest rate	0.00%	0.00%	0.00%		3.00%	3.00%	3.00%
Long-term debt	$ 0				$ 51
Stated interest rate (as a percent)	3.00%	3.00%	3.00%
2.95% Debentures due 2020
Debt Instrument [Line Items]
Effective interest rate	0.00%	0.00%	0.00%		3.15%	3.15%	3.15%
Long-term debt	$ 0				$ 549
Stated interest rate (as a percent)	2.95%	2.95%	2.95%
1.950% Notes due 2020
Debt Instrument [Line Items]
Effective interest rate	0.00%	0.00%	0.00%		1.99%	1.99%	1.99%
Long-term debt	$ 0				$ 500
Stated interest rate (as a percent)	1.95%	1.95%	1.95%
3.55% Notes due 2021
Debt Instrument [Line Items]
Effective interest rate	3.67%	3.67%	3.67%		3.67%	3.67%	3.67%
Long-term debt	$ 450				$ 449
Stated interest rate (as a percent)	3.55%	3.55%	3.55%
2.45% Notes due 2021
Debt Instrument [Line Items]
Effective interest rate	2.48%	2.48%	2.48%		2.48%	2.48%	2.48%
Long-term debt	$ 350				$ 349
Stated interest rate (as a percent)	2.45%	2.45%	2.45%
1.65% Notes due 2021
Debt Instrument [Line Items]
Effective interest rate	1.65%	1.65%	1.65%		1.65%	1.65%	1.65%
Long-term debt	$ 999				$ 999
Stated interest rate (as a percent)	1.65%	1.65%	1.65%
0.250% Notes due 2022 (1B Euro 1.2281)(2)/(1B Euro 1.1096)(3)
Debt Instrument [Line Items]
Effective interest rate	0.26%	0.26%	0.26%		0.26%	0.26%	0.26%
Long-term debt	$ 1,227				$ 1,108
Stated interest rate (as a percent)	0.25%	0.25%	0.25%
Debt Instrument, Face Amount \| €		€ 1,000				€ 1,000
Foreign currency exchange rate, translation	1.2281	1.2281	1.2281		1.1096	1.1096	1.1096
2.25% Notes due 2022
Debt Instrument [Line Items]
Effective interest rate	2.31%	2.31%	2.31%		2.31%	2.31%	2.31%
Long-term debt	$ 999				$ 998
Stated interest rate (as a percent)	2.25%	2.25%	2.25%
6.73% Debentures due 2023
Debt Instrument [Line Items]
Effective interest rate	6.73%	6.73%	6.73%		6.73%	6.73%	6.73%
Long-term debt	$ 250				$ 250
Stated interest rate (as a percent)	6.73%	6.73%	6.73%
3.375% Notes due 2023
Debt Instrument [Line Items]
Effective interest rate	3.17%	3.17%	3.17%		3.17%	3.17%	3.17%
Long-term debt	$ 803				$ 804
Stated interest rate (as a percent)	3.375%	3.375%	3.375%
2.05% Notes due 2023
Debt Instrument [Line Items]
Effective interest rate	2.09%	2.09%	2.09%		2.09%	2.09%	2.09%
Long-term debt	$ 499				$ 498
Stated interest rate (as a percent)	2.05%	2.05%	2.05%
0.650% Notes due 2024 (750MM Euro 1.2281)(2)/(750MM Euro 1.1096)(3)
Debt Instrument [Line Items]
Effective interest rate	0.68%	0.68%	0.68%		0.68%	0.68%	0.68%
Long-term debt	$ 919				$ 829
Stated interest rate (as a percent)	0.65%	0.65%	0.65%
Debt Instrument, Face Amount \| €		€ 750				€ 750
Foreign currency exchange rate, translation	1.2281	1.2281	1.2281		1.1096	1.1096	1.1096
5.50% Notes due 2024 (500MM 1.3654 GBP )(2)/(500MM GBP 1.2987)(3)
Debt Instrument [Line Items]
Effective interest rate	6.75%	6.75%	6.75%		6.75%	6.75%	6.75%
Long-term debt	$ 679				$ 645
Stated interest rate (as a percent)	5.50%	5.50%	5.50%
Debt Instrument, Face Amount \| £			£ 500				£ 500
Foreign currency exchange rate, translation	1.3654	1.3654	1.3654		1.2987	1.2987	1.2987
2.625% Notes due 2025
Debt Instrument [Line Items]
Effective interest rate	2.63%	2.63%	2.63%		2.63%	2.63%	2.63%
Long-term debt	$ 748				$ 748
Stated interest rate (as a percent)	2.625%	2.625%	2.625%
0.55% Notes due 2025(5)
Debt Instrument [Line Items]
Stated interest rate (as a percent)	0.55%	0.55%	0.55%
0.55% Notes due 2025(5) \| Carrying (Reported) Amount, Fair Value Disclosure
Debt Instrument [Line Items]
Effective interest rate	0.57%	0.57%	0.57%
Total long-term debt	$ 996
2.45% Notes due 2026
Debt Instrument [Line Items]
Effective interest rate	2.47%	2.47%	2.47%		2.47%	2.47%	2.47%
Long-term debt	$ 1,994				$ 1,993
Stated interest rate (as a percent)	2.45%	2.45%	2.45%
2.95% Notes due 2027
Debt Instrument [Line Items]
Effective interest rate	2.96%	2.96%	2.96%		2.96%	2.96%	2.96%
Long-term debt	$ 997				$ 996
Stated interest rate (as a percent)	2.95%	2.95%	2.95%
0.95% Notes due 2027
Debt Instrument [Line Items]
Stated interest rate (as a percent)	0.95%	0.95%	0.95%
0.95% Notes due 2027 \| Carrying (Reported) Amount, Fair Value Disclosure
Debt Instrument [Line Items]
Effective interest rate	0.96%	0.96%	0.96%
Total long-term debt	$ 1,494
1.150% Notes due 2028 (750MM Euro 1.2281)(2)/(750MM Euro 1.1096)(3)
Debt Instrument [Line Items]
Effective interest rate	1.21%	1.21%	1.21%		1.21%	1.21%	1.21%
Long-term debt	$ 915				$ 825
Stated interest rate (as a percent)	1.15%	1.15%	1.15%
Debt Instrument, Face Amount \| €		€ 750				€ 750
Foreign currency exchange rate, translation	1.2281	1.2281	1.2281		1.1096	1.1096	1.1096
2.90% Notes due 2028
Debt Instrument [Line Items]
Effective interest rate	2.91%	2.91%	2.91%		2.91%	2.91%	2.91%
Long-term debt	$ 1,495				$ 1,494
Stated interest rate (as a percent)	2.90%	2.90%	2.90%
6.95% Notes due 2029
Debt Instrument [Line Items]
Effective interest rate	7.14%	7.14%	7.14%		7.14%	7.14%	7.14%
Long-term debt	$ 297				$ 297
Stated interest rate (as a percent)	6.95%	6.95%	6.95%
1.30% Notes due 2030
Debt Instrument [Line Items]
Stated interest rate (as a percent)	1.30%	1.30%	1.30%
1.30% Notes due 2030 \| Carrying (Reported) Amount, Fair Value Disclosure
Debt Instrument [Line Items]
Effective interest rate	1.30%	1.30%	1.30%
Total long-term debt	$ 1,743
4.95% Debentures due 2033
Debt Instrument [Line Items]
Effective interest rate	4.95%	4.95%	4.95%		4.95%	4.95%	4.95%
Long-term debt	$ 498				$ 498
Stated interest rate (as a percent)	4.95%	4.95%	4.95%
4.375% Notes due 2033
Debt Instrument [Line Items]
Effective interest rate	4.24%	4.24%	4.24%		4.24%	4.24%	4.24%
Long-term debt	$ 855				$ 855
Stated interest rate (as a percent)	4.375%	4.375%	4.375%
1.650% Notes due 2035 (1.5B Euro 1.2281)(2)/(1.5B Euro 1.1096)(3)
Debt Instrument [Line Items]
Effective interest rate	1.68%	1.68%	1.68%		1.68%	1.68%	1.68%
Long-term debt	$ 1,827				$ 1,649
Stated interest rate (as a percent)	1.65%	1.65%	1.65%
Debt Instrument, Face Amount \| €		€ 1,500				€ 1,500
Foreign currency exchange rate, translation	1.2281	1.2281	1.2281		1.1096	1.1096	1.1096
3.55% Notes due 2036
Debt Instrument [Line Items]
Effective interest rate	3.59%	3.59%	3.59%		3.59%	3.59%	3.59%
Long-term debt	$ 989				$ 989
Stated interest rate (as a percent)	3.55%	3.55%	3.55%
5.95% Notes due 2037
Debt Instrument [Line Items]
Effective interest rate	5.99%	5.99%	5.99%		5.99%	5.99%	5.99%
Long-term debt	$ 992				$ 992
Stated interest rate (as a percent)	5.95%	5.95%	5.95%
3.625% Notes due 2037
Debt Instrument [Line Items]
Effective interest rate	3.64%	3.64%	3.64%		3.64%	3.64%	3.64%
Long-term debt	$ 1,488				$ 1,487
Stated interest rate (as a percent)	3.625%	3.625%	3.625%
5.85% Debentures due 2038
Debt Instrument [Line Items]
Effective interest rate	5.85%	5.85%	5.85%		5.85%	5.85%	5.85%
Long-term debt	$ 696				$ 696
Stated interest rate (as a percent)	5.85%	5.85%	5.85%
3.400% Notes due 2038
Debt Instrument [Line Items]
Effective interest rate	3.42%	3.42%	3.42%		3.42%	3.42%	3.42%
Long-term debt	$ 991				$ 991
Stated interest rate (as a percent)	3.40%	3.40%	3.40%
4.50% Debentures due 2040
Debt Instrument [Line Items]
Effective interest rate	4.63%	4.63%	4.63%		4.63%	4.63%	4.63%
Long-term debt	$ 539				$ 539
Stated interest rate (as a percent)	4.50%	4.50%	4.50%
2.10% Notes due 2040
Debt Instrument [Line Items]
Stated interest rate (as a percent)	2.10%	2.10%	2.10%
2.10% Notes due 2040 \| Carrying (Reported) Amount, Fair Value Disclosure
Debt Instrument [Line Items]
Effective interest rate	2.14%	2.14%	2.14%
Total long-term debt	$ 986
4.85% Notes due 2041
Debt Instrument [Line Items]
Effective interest rate	4.89%	4.89%	4.89%		4.89%	4.89%	4.89%
Long-term debt	$ 297				$ 297
Stated interest rate (as a percent)	4.85%	4.85%	4.85%
4.50% Notes due 2043
Debt Instrument [Line Items]
Effective interest rate	4.52%	4.52%	4.52%		4.52%	4.52%	4.52%
Long-term debt	$ 496				$ 495
Stated interest rate (as a percent)	4.50%	4.50%	4.50%
3.70% Notes due 2046
Debt Instrument [Line Items]
Effective interest rate	3.74%	3.74%	3.74%		3.74%	3.74%	3.74%
Long-term debt	$ 1,974				$ 1,973
Stated interest rate (as a percent)	3.70%	3.70%	3.70%
3.75% Notes due 2047
Debt Instrument [Line Items]
Effective interest rate	3.76%	3.76%	3.76%		3.76%	3.76%	3.76%
Long-term debt	$ 991				$ 991
Stated interest rate (as a percent)	3.75%	3.75%	3.75%
3.500% Notes due 2048
Debt Instrument [Line Items]
Effective interest rate	3.52%	3.52%	3.52%		3.52%	3.52%	3.52%
Long-term debt	$ 742				$ 742
Stated interest rate (as a percent)	3.50%	3.50%	3.50%
2.250% Notes due 2050
Debt Instrument [Line Items]
Stated interest rate (as a percent)	2.25%	2.25%	2.25%
2.250% Notes due 2050 \| Carrying (Reported) Amount, Fair Value Disclosure
Debt Instrument [Line Items]
Effective interest rate	2.29%	2.29%	2.29%
Total long-term debt	$ 984
2.450% Notes due 2060
Debt Instrument [Line Items]
Stated interest rate (as a percent)	2.45%	2.45%	2.45%
2.450% Notes due 2060 \| Carrying (Reported) Amount, Fair Value Disclosure
Debt Instrument [Line Items]
Effective interest rate	2.49%	2.49%	2.49%
Total long-term debt	$ 1,228
Other
Debt Instrument [Line Items]
Effective interest rate	0.00%	0.00%	0.00%		0.00%	0.00%	0.00%
Long-term debt	$ 7				$ 18

Borrowings - Narrative (Details

Borrowings - Narrative (Details) - USD ($) $ in Billions	12 Months Ended
Borrowings - Narrative (Details) - USD ($) $ in Billions	Jan. 03, 2021	Dec. 29, 2019
Debt Disclosure [Abstract]
Excess of fair value over carrying value of debt	$ 5.4	$ 3
Borrowing capacity under credit facility	10
Short-term borrowings and the current portion of long-term debt	2.6	1.2
Borrowed under the commercial paper program	$ 1.8	$ 1.1

Borrowings - Aggregate Maturiti

Borrowings - Aggregate Maturities of Long Term Obligations (Details) $ in Millions	Jan. 03, 2021USD ($)
Aggregate maturities of long-term obligations
2021	$ 1,799
2022	2,226
2023	1,552
2024	1,598
2025	1,744
After 2025	$ 25,515

Income Taxes - Provision for In

Income Taxes - Provision for Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 30, 2018	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Currently payable:
U.S. taxes		$ 1,026	$ 1,941	$ 1,284
International taxes		1,898	2,744	2,434
Total currently payable		2,924	4,685	3,718
Deferred:
U.S. taxes		(76)	(814)	1,210
International taxes		(1,065)	(1,662)	(2,226)
Total deferred		(1,141)	(2,476)	(1,016)
Provision for taxes on income		$ 1,783	$ 2,209	$ 2,702
GILTI, deferred tax cost	$ 1,400
Tax benefits on Capital Loss		(1.20%)	(0.30%)

Income Taxes - Comparison of In

Income Taxes - Comparison of Income Taxes at Statutory Rate and Company's Effective Tax Rate (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Comparison Of Income Tax Expense At Statutory Rate And Company's Tax Rate Abstract
U.S.	$ 4,312	$ 3,543	$ 5,575
International	12,185	13,785	12,424
Earnings before provision for taxes on income	$ 16,497	$ 17,328	$ 17,999
Tax rates:
U.S. statutory rate	21.00%	21.00%	21.00%	35.00%
International operations (1)	(9.90%)	(5.90%)	(3.70%)
U.S. taxes on international income (2)	2.70%	1.80%	1.40%
Tax benefits on Capital Loss	(1.20%)	(0.30%)
Tax benefits on share-based compensation	(1.50%)	(0.50%)	(1.50%)
TCJA and related impacts	0.70%	(3.90%)	(1.90%)
All other	(1.00%)	0.50%	(0.30%)
Effective tax rate	10.80%	12.70%	15.00%

Income Taxes - Temporary Differ

Income Taxes - Temporary Differences and Carryforwards (Details) - USD ($) $ in Millions	Jan. 03, 2021	Dec. 29, 2019
Components of Deferred Tax Assets and Liabilities [Abstract]
Deferred Tax Assets, Employee related obligations	$ 2,434	$ 2,473
Deferred Tax Assets, Stock based compensation	627	595
Deferred Tax Assets, Property, Plant and Equipment	721	1,122
Deferred Tax Assets, International R&D capitalized for tax	1,517	1,189
Deferred Tax Assets, Reserves & liabilities	3,466	2,337
Deferred Tax Assets, Income reported for tax purposes	1,705	1,605
Deferred Tax Assets, Net operating loss carryforward international	990	838
Deferred Tax Assets, Undistributed Foreign Earnings	812	765
Deferred Tax Assets, Miscellaneous international	854	696
Deferred Tax Assets Other Domestic	12	411
Deferred Tax Liabilities, Non-deductible intangibles	(6,567)	(5,835)
Deferred Tax Liabilities, Operating Loss Carryforwards, Foreign
Deferred Tax Liabilities, Undistributed Foreign Earnings	(1,435)	(1,289)
Deferred Tax Liability, Global Intangible Low-Taxed Income	(3,606)	(2,965)
Deferred Tax Liabilities, Miscellaneous international	(211)	(81)
Deferred Tax Assets, Total deferred income taxes	13,138	12,031
Deferred Tax Liabilities, Total deferred income taxes	$ (11,819)	$ (10,170)

Income Taxes - Summary of Activ

Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Summary of unrecognized tax benefits
Beginning of year	$ 3,853	$ 3,326	$ 3,151
Increases related to current year tax positions	265	249	242
Increases related to prior period tax positions	668	408	145
Decreases related to prior period tax positions	(551)	(105)	(137)
Settlements	(839)	(9)	(40)
Lapse of statute of limitations	(23)	(16)	(35)
End of year	$ 3,373	$ 3,853	$ 3,326

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended			12 Months Ended
Income Taxes - Narrative (Details) - USD ($) $ in Millions	Dec. 29, 2019	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017	Oct. 31, 2020	Oct. 31, 2019
Tax Credit Carryforward [Line Items]
U.S. statutory rate					21.00%	21.00%	21.00%	35.00%
Net decrease in tax rate					1.90%
Reversal of deferred tax liability		$ 600				$ 2,800
Reversal of deferred tax asset		200				900
TJCA foreign tax credits, net deferred tax expense (benefit)		$ (400)				$ 1,900
Effective income tax rate reconciliation, increase (decrease), percent						(2.30%)
TJCA, foreign tax credit percent	1.70%	(2.20%)
Increase (decrease) in earnings before taxes, percent			(23.50%)
Effective tax rate reconciliation, litigation settlement, percent			(2.10%)
TCJA, increase (decrease) in deferred tax asset	$ 300
Increase (decrease) in unrecognized tax benefits					$ 300
Effective tax rate reconciliation, unrecognized tax benefits, percent					1.50%
Effective income tax rate reconciliation, other reconciling items, percent					1.20%
Income tax expense recorded related to TRAF					$ 400	$ 100
TRAF effect on tax rate					2.60%	0.60%
Income tax expense related to change in tax rate from TRAF					$ 300	$ 600
Deferred tax asset recorded related to TRAF					450	900
Deferred tax expense related to TRAF					300	450
Tax Cuts and Jobs Act, incomplete accounting, net adjustments for provisional income tax expense (benefit)						200
Deferred tax liability foreign taxes	1,289	$ 1,435	$ 1,289		$ 1,435	1,289
GILTI, deferred tax cost				$ 1,400
Effective income tax rate reconciliation, deduction					(1.20%)
Unrecognized tax benefits	3,853	3,373	3,853	$ 3,326	$ 3,373	3,853	$ 3,326	$ 3,151
Unrecognized tax benefits, interest on income tax expense					32	50	53
Unrecognized tax benefits, interest on income taxes accrued	559	$ 468	559		$ 468	559
Talc
Tax Credit Carryforward [Line Items]
Effective tax rate reconciliation, litigation settlement, percent					23.50%
Opiods
Tax Credit Carryforward [Line Items]
Effective tax rate reconciliation, litigation settlement, percent					21.40%
Consumer
Tax Credit Carryforward [Line Items]
Litigation expense					$ 3,900	400	$ 300
Consumer \| Talc
Tax Credit Carryforward [Line Items]
Litigation expense					4,000
Pharmaceutical
Tax Credit Carryforward [Line Items]
Litigation expense					800	4,300
Pharmaceutical \| Opiods
Tax Credit Carryforward [Line Items]
Litigation expense					1,000
Internal Revenue Service (IRS)
Tax Credit Carryforward [Line Items]
Payment on unrecognized tax benefit liability					$ 700
Accrued Taxes On Income
Tax Credit Carryforward [Line Items]
Unrecognized tax benefits	$ 900		$ 900			$ 900
Pending Litigation
Tax Credit Carryforward [Line Items]
Loss contingency, estimate of possible loss									$ 5,000	$ 4,000

Employee Related Obligations -

Employee Related Obligations - Employee Related Obligations (Details) - USD ($) $ in Millions	Jan. 03, 2021	Dec. 29, 2019
Employee-related Liabilities [Abstract]
Pension benefits	$ 5,761	$ 5,538
Postretirement benefits	2,229	2,297
Postemployment benefits	3,078	3,004
Deferred compensation	250	338
Total employee obligations	11,318	11,177
Less current benefits payable	547	514
Employee related obligations — non-current	$ 10,771	$ 10,663

Employee Related Obligations _2

Employee Related Obligations - Narrative (Details) - USD ($) $ in Millions	Jan. 03, 2021	Dec. 29, 2019
Compensation Related Costs [Abstract]
Prepaid employee related obligations	$ 656	$ 551

Pensions and Other Benefit Pl_3

Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Components of net periodic benefit cost
Amendments	$ (1,800)
Retirement Plans
Components of net periodic benefit cost
Service cost	1,380	$ 1,163	$ 1,283
Interest cost	955	1,096	996
Expected return on plan assets	(2,461)	(2,322)	(2,212)
Amortization of prior service cost	2	4	3
Recognized actuarial losses (gains)	891	579	852
Curtailments and settlements	23	73	1
Net periodic benefit cost	790	593	923
Amendments	(1,780)	0
Other Benefit Plans
Components of net periodic benefit cost
Service cost	287	274	269
Interest cost	133	185	148
Expected return on plan assets	(7)	(6)	(7)
Amortization of prior service cost	(31)	(31)	(31)
Recognized actuarial losses (gains)	142	129	123
Curtailments and settlements	0	0	0
Net periodic benefit cost	524	551	$ 502
Amendments	$ 0	$ 0

Pensions and Other Benefit Pl_4

Pensions and Other Benefit Plans - Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation (Details)	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Retirement Plans
Net Periodic Benefit Cost
Service cost discount rate	2.82%	3.63%	3.20%
Interest cost discount rate	3.13%	4.13%	3.60%
Rate of increase in compensation levels	4.00%	3.99%	3.98%
Expected long-term rate of return on plan assets	8.12%	8.31%	8.46%
Benefit Obligation
Discount rate	2.14%	2.91%	3.76%
Rate of increase in compensation levels	4.00%	4.01%	3.97%
Other Benefit Plans
Net Periodic Benefit Cost
Service cost discount rate	3.04%	4.45%	3.85%
Interest cost discount rate	3.08%	4.25%	3.62%
Rate of increase in compensation levels	4.25%	4.29%	4.29%
Benefit Obligation
Discount rate	2.23%	3.39%	4.40%
Rate of increase in compensation levels	4.27%	4.29%	4.29%

Pensions and Other Benefit Pl_5

Pensions and Other Benefit Plans - Assumed Health Care Cost Trend Rates (Details)	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019
Defined Benefit Plan, Assumed Health Care Cost Trend Rates [Abstract]
Health care cost trend rate assumed for next year	5.68%	5.87%
Rate to which the cost trend rate is assumed to decline (ultimate trend)	4.49%	4.50%
Defined Benefit Plan, Year Health Care Cost Trend Rate Reaches Ultimate Trend Rate	2040	2040

Pensions and Other Benefit Pl_6

Pensions and Other Benefit Plans - Schedule of Net Funded Status (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Change in Benefit Obligation
Amendments	$ (1,800)
Amounts Recognized in the Company’s Balance Sheet consist of the following:
Non-current assets	656	$ 551
Current liabilities	(547)	(514)
Non-current liabilities	(10,771)	(10,663)
Lump-sum distribution
Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract]
Contribution to pension plans		514
Retirement Plans
Change in Benefit Obligation
Projected benefit obligation - beginning of year	37,188	31,670
Service cost	1,380	1,163	$ 1,283
Interest cost	955	1,096	996
Plan participant contributions	61	63
Amendments	(1,780)	0
Actuarial (gains) losses(2)	5,716	5,178
Divestitures & acquisitions	(88)	(278)
Curtailments, settlements & restructuring	(24)	(172)
Benefits paid from plan	(1,111)	(1,555)
Effect of exchange rates	1,003	23
Projected benefit obligation - end of year	43,300	37,188	31,670
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Plan assets at fair value — beginning of year	32,201	26,818
Actual return on plan assets	5,524	6,185
Company contributions	870	908
Plan participant contributions	61	63
Settlements	(13)	(16)
Divestitures & acquisitions	(84)	(274)
Benefits paid from plan assets	(1,111)	(1,555)
Effect of exchange rates	747	72
Plan assets at fair value - End of year	38,195	32,201	26,818
Funded status - end of year	(5,105)	(4,987)
Amounts Recognized in the Company’s Balance Sheet consist of the following:
Non-current assets	656	551
Current liabilities	(125)	(113)
Non-current liabilities	(5,636)	(5,425)
Total recognized in the consolidated balance sheet — end of year	(5,105)	(4,987)
Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract]
Net actuarial loss	10,860	8,835
Prior service cost (credit)(1)	(1,797)	(8)
Unrecognized net transition obligation	0	0
Total before tax effects	9,063	8,827
Accumulated Benefit Obligation	40,356	33,416
Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax [Abstract]
Net periodic benefit cost	790	593	923
Net actuarial (gain) loss	2,616	1,084
Amortization of net actuarial loss	(891)	(579)
Prior service cost (credit)	(1,780)	0
Amortization of prior service (cost) credit	(2)	(4)
Effect of exchange rates	293	1
Total loss/(income) recognized in other comprehensive income, before tax	236	502
Total recognized in net periodic benefit cost and other comprehensive income	1,026	1,095
Other Benefit Plans
Change in Benefit Obligation
Projected benefit obligation - beginning of year	5,076	4,480
Service cost	287	274	269
Interest cost	133	185	148
Plan participant contributions	0	0
Amendments	0	0
Actuarial (gains) losses(2)	(75)	562
Divestitures & acquisitions	0	0
Curtailments, settlements & restructuring	0	0
Benefits paid from plan	(396)	(431)
Effect of exchange rates	3	6
Projected benefit obligation - end of year	5,028	5,076	4,480
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Plan assets at fair value — beginning of year	115	180
Actual return on plan assets	14	19
Company contributions	357	347
Plan participant contributions	0	0
Settlements	0	0
Divestitures & acquisitions	0	0
Benefits paid from plan assets	(396)	(431)
Effect of exchange rates	0	0
Plan assets at fair value - End of year	90	115	180
Funded status - end of year	(4,938)	(4,961)
Amounts Recognized in the Company’s Balance Sheet consist of the following:
Non-current assets	0	0
Current liabilities	(418)	(397)
Non-current liabilities	(4,520)	(4,564)
Total recognized in the consolidated balance sheet — end of year	(4,938)	(4,961)
Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract]
Net actuarial loss	1,463	1,685
Prior service cost (credit)(1)	(44)	(75)
Unrecognized net transition obligation	0	0
Total before tax effects	1,419	1,610
Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax [Abstract]
Net periodic benefit cost	524	551	$ 502
Net actuarial (gain) loss	(81)	550
Amortization of net actuarial loss	(142)	(129)
Prior service cost (credit)	0	0
Amortization of prior service (cost) credit	31	31
Effect of exchange rates	1	1
Total loss/(income) recognized in other comprehensive income, before tax	(191)	453
Total recognized in net periodic benefit cost and other comprehensive income	$ 333	$ 1,004

Pensions and Other Benefit Pl_7

Pensions and Other Benefit Plans - Narrative (Details) - USD ($) $ in Millions	Dec. 31, 2020	Dec. 31, 2019	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Defined Benefit Plan Disclosure [Line Items]
Percentage of corridor of greater of market value of assets			10.00%
Accumulated benefit obligation unfunded plans			$ 8,800	$ 4,300
Projected benefit obligation, unfunded plans			9,800	5,200
Plan Assets			4,400	900
Fair value of company's common stock directly held in plan assets			$ 946	$ 984
Percentage of company's common stock to plan asset			2.50%	3.10%
Defined benefit plan, plan assets, accounting policy election, measurement date	Dec. 31, 2020	Dec. 31, 2019
Retirement Plans
Defined Benefit Plan Disclosure [Line Items]
Plan Assets			$ 38,195	$ 32,201	$ 26,818
Other Benefit Plans
Defined Benefit Plan Disclosure [Line Items]
Plan Assets			90	115	$ 180
U.S. Plans
Defined Benefit Plan Disclosure [Line Items]
Contribution to pension plans			441
International Plans
Defined Benefit Plan Disclosure [Line Items]
Contribution to pension plans			429
Commingled funds \| Level 2 \| Other Benefit Plans
Defined Benefit Plan Disclosure [Line Items]
Plan Assets			$ 90	84
Short-term Investments \| Level 2 \| Other Benefit Plans
Defined Benefit Plan Disclosure [Line Items]
Plan Assets				$ 31
Maximum \| Retirement Plans
Defined Benefit Plan Disclosure [Line Items]
Retirement plan benefits Employee compensation Period			5 years

Pensions and Other Benefit Pl_8

Pensions and Other Benefit Plans - Information Related to the Benefit Obligation and the Fair Value of Plan Assets (Details) - USD ($) $ in Millions	Jan. 03, 2021	Dec. 29, 2019
Qualified Plans \| U.S. Plans
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	$ 25,554	$ 21,398
Projected Benefit Obligation	25,466	22,034
Accumulated Benefit Obligation	24,158	19,831
Projected Benefit Obligation	88	(636)
Accumulated Benefit Obligation	1,396	1,567
Non-Qualified Plans \| U.S. Plans
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Projected Benefit Obligation	2,748	2,544
Accumulated Benefit Obligation	2,495	2,115
Projected Benefit Obligation	(2,748)	(2,544)
Accumulated Benefit Obligation	(2,495)	(2,115)
Funded Plans \| International Plans
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	12,641	10,803
Projected Benefit Obligation	14,541	12,132
Accumulated Benefit Obligation	13,210	11,040
Projected Benefit Obligation	(1,900)	(1,329)
Accumulated Benefit Obligation	(569)	(237)
Unfunded Plans \| International Plans
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Projected Benefit Obligation	545	478
Accumulated Benefit Obligation	493	430
Projected Benefit Obligation	(545)	(478)
Accumulated Benefit Obligation	$ (493)	$ (430)

Pensions and Other Benefit Pl_9

Pensions and Other Benefit Plans - Projected Future Benefit Payments from Company's Retirement and Other Benefit Plans (Details) $ in Millions	Jan. 03, 2021USD ($)
Retirement plans
Defined Benefit Plan Disclosure [Line Items]
2021	$ 1,257
2022	1,292
2023	1,388
2024	1,424
2025	1,494
2026-2030	8,795
Other benefit plans
Defined Benefit Plan Disclosure [Line Items]
2021	427
2022	440
2023	453
2024	465
2025	417
2026-2030	$ 2,273

Pensions and Other Benefit P_10

Pensions and Other Benefit Plans - Projected Future Minimum Contributions to the Company's U.S. and International Unfunded Retirement Plans (Details) $ in Millions	Jan. 03, 2021USD ($)
Retirement Benefits [Abstract]
2021	$ 110
2022	116
2023	121
2024	130
2025	136
2026-2030	$ 787

Pensions and Other Benefit P_11

Pensions and Other Benefit Plans - Company' Retirement Plan Asset Allocation and Target Allocations (Details)	Jan. 03, 2021	Dec. 29, 2019
Defined Benefit Plan Disclosure [Line Items]
Percent of Plan Assets	100.00%	100.00%
Target Allocation	100.00%
Equity securities
Defined Benefit Plan Disclosure [Line Items]
Percent of Plan Assets	66.00%	74.00%
Target Allocation	67.00%
Debt securities
Defined Benefit Plan Disclosure [Line Items]
Percent of Plan Assets	34.00%	26.00%
Target Allocation	33.00%

Pensions and Other Benefit P_12

Pensions and Other Benefit Plans - Schedule of Defined Benefit Plans Disclosures (Details) - Retirement plans - USD ($) $ in Millions	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	$ 38,195	$ 32,201	$ 26,818
Fair Value, Measurements, Recurring
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	38,195	32,201
Investments Measured at Net Asset Value	9,092	8,053
Fair Value, Measurements, Recurring \| Level 1
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	14,502	12,602
Fair Value, Measurements, Recurring \| Level 2
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	14,420	11,346
Fair Value, Measurements, Recurring \| Level 3
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	181	200
Fair Value, Measurements, Recurring \| Short-term investment funds
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	890	524
Fair Value, Measurements, Recurring \| Short-term investment funds \| Level 1
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	127	119
Fair Value, Measurements, Recurring \| Short-term investment funds \| Level 2
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	763	405
Fair Value, Measurements, Recurring \| Short-term investment funds \| Level 3
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Fair Value, Measurements, Recurring \| Government and agency securities
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	5,023	4,140
Fair Value, Measurements, Recurring \| Government and agency securities \| Level 1
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Fair Value, Measurements, Recurring \| Government and agency securities \| Level 2
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	5,023	4,140
Fair Value, Measurements, Recurring \| Government and agency securities \| Level 3
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Fair Value, Measurements, Recurring \| Debt instruments
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	3,931	3,452
Fair Value, Measurements, Recurring \| Debt instruments \| Level 1
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Fair Value, Measurements, Recurring \| Debt instruments \| Level 2
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	3,931	3,452
Fair Value, Measurements, Recurring \| Debt instruments \| Level 3
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Fair Value, Measurements, Recurring \| Equity securities
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	14,377	12,485
Fair Value, Measurements, Recurring \| Equity securities \| Level 1
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	14,375	12,483
Fair Value, Measurements, Recurring \| Equity securities \| Level 2
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	2	2
Fair Value, Measurements, Recurring \| Equity securities \| Level 3
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Fair Value, Measurements, Recurring \| Commingled funds
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	13,086	11,099
Investments Measured at Net Asset Value	8,236	7,580
Fair Value, Measurements, Recurring \| Commingled funds \| Level 1
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Fair Value, Measurements, Recurring \| Commingled funds \| Level 2
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	4,690	3,338
Fair Value, Measurements, Recurring \| Commingled funds \| Level 3
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	160	181
Fair Value, Measurements, Recurring \| Other assets
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	888	501
Investments Measured at Net Asset Value	856	473
Fair Value, Measurements, Recurring \| Other assets \| Level 1
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Fair Value, Measurements, Recurring \| Other assets \| Level 2
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	11	9
Fair Value, Measurements, Recurring \| Other assets \| Level 3
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	$ 21	$ 19

Savings Plan - Narrative (Detai

Savings Plan - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
Savings Plan - Narrative (Details) - USD ($) $ in Millions	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Savings Plan [Abstract]
Matching contributions	$ 243	$ 235	$ 242

Capital and Treasury Stock - Ch

Capital and Treasury Stock - Changes in Treasury Stock (Details) - USD ($) shares in Thousands, $ in Millions	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Changes in Treasury Stock Shares Outstanding [Roll Forward]
Treasury Stock, Balance, Shares	487,336	457,519	437,318
Employee compensation and stock option plans, Shares	(21,765)	(20,053)	(22,082)
Treasury Stock, Ending Balance, Shares	487,331	487,336	457,519
Changes in treasury stock
Treasury Stock, Balance	$ 38,417	$ 34,362	$ 31,554
Employee compensation and stock option plans related to treasury stock	(3,148)	(2,691)	(3,060)
Repurchase of common stock, Amounts	3,221	6,746	5,868
Treasury Stock, Ending Balance	$ 38,490	$ 38,417	$ 34,362
Treasury Stock
Changes in Treasury Stock Shares Outstanding [Roll Forward]
Repurchase of common stock, Shares	21,760	49,870	42,283
Changes in treasury stock
Repurchase of common stock, Amounts	$ 3,221	$ 6,746	$ 5,868

Capital and Treasury Stock - Na

Capital and Treasury Stock - Narrative (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Billions	Jan. 04, 2021	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018	Dec. 17, 2018
Equity, Class of Treasury Stock [Line Items]
Common stock, shares issued (in shares)		3,119,843	3,119,843	3,119,843
Cash dividends paid (in dollars per share)		$ 3.98	$ 3.75	$ 3.54
Common Stock, Dividends, Per Share, Declared	$ 1.01
December 17, 2018 Share Repurchase Program
Equity, Class of Treasury Stock [Line Items]
Stock repurchase program, authorized amount					$ 5

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance	$ 59,471	$ 59,752	$ 60,160
Net change	649	(669)	(1,791)
Ending Balance	63,278	59,471	59,752
Cumulative Effect, Period of Adoption, Adjustment
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance			(486)
Foreign Currency Translation
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance	(8,705)	(8,869)	(7,351)
Net change	(233)	164	(1,518)
Ending Balance	(8,938)	(8,705)	(8,869)
Gain/(Loss) On Securities
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance	0	0	232
Net change	1	0	0
Ending Balance	1	0	0
Gain/(Loss) On Securities \| Cumulative Effect, Period of Adoption, Adjustment
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance			(232)
Employee Benefit Plans
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance	(6,891)	(6,158)	(6,150)
Net change	(66)	(733)	(8)
Ending Balance	(6,957)	(6,891)	(6,158)
Gain/ (Loss) On Derivatives & Hedges
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance	(295)	(195)	70
Net change	947	(100)	(265)
Ending Balance	652	(295)	(195)
Accumulated Other Comprehensive Income (Loss)
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance	(15,891)	(15,222)	(13,199)
Net change	649	(669)	(1,791)
Ending Balance	$ (15,242)	$ (15,891)	(15,222)
Accumulated Other Comprehensive Income (Loss) \| Cumulative Effect, Period of Adoption, Adjustment
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance			$ (232)

International Currency Transl_2

International Currency Translation - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Foreign Currency Translation [Abstract]
Foreign currency transaction gain (loss), before tax	$ (209)	$ (267)	$ (265)

Earnings Per Share - Reconcilia

Earnings Per Share - Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share (Details) - $ / shares shares in Millions	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Reconciliation of basic net earnings per share to diluted net earnings per share
Basic net earnings per share (in dollars per share)	$ 5.59	$ 5.72	$ 5.70
Average shares outstanding — basic (in shares)	2,632.8	2,645.1	2,681.5
Potential shares exercisable under stock option plans (in shares)	118.3	136.3	139
Less: shares repurchased under treasury stock method (in shares)	(80.4)	(97.8)	(92.5)
Convertible debt shares (in shares)	0	0.7	0.7
Average shares outstanding - diluted (in shares)	2,670.7	2,684.3	2,728.7
Diluted net earnings per share (in dollars per share)	$ 5.51	$ 5.63	$ 5.61

Earnings Per Share - Narrative

Earnings Per Share - Narrative (Details) - USD ($) shares in Thousands, $ in Millions	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Earnings Per Share [Abstract]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	18,000
Interest expense convertible debt		$ 1	$ 1

Common Stock, Stock Option Pl_3

Common Stock, Stock Option Plans and Stock Compensation Agreements - Narrative (Details) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Jan. 03, 2021USD ($)StockBasedCompensationPlans$ / sharesshares	Dec. 29, 2019USD ($)$ / sharesshares	Dec. 30, 2018USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock-based compensation plans \| StockBasedCompensationPlans	2
Compensation cost charged for Long term incentive plan	$ 1,005	$ 977	$ 978
Total income tax benefit recognized	210	227	192
Exercise of options, tax benefit	248	209	264
Total compensation cost not yet recognized for option	$ 804	$ 823	$ 827
Weighted average period for total compensation cost not yet recognized	1 year 9 months 3 days	1 year 8 months 15 days	1 year 8 months 23 days
Average fair value of option granted (in dollars per share) \| $ / shares	$ 16.42	$ 17.80	$ 17.98
Total intrinsic value of options exercised	$ 1,021	$ 807	$ 1,028
Stock options outstanding (in shares) \| shares	114,250	111,637	109,652
Stock option average life	6 years	6 years	6 years 2 months 12 days
Stock options exercisable \| shares		60,761	54,862
Stock options average price \| $ / shares		$ 88.88	$ 82.03
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options expiration period	10 years
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Average fair value of RSU's and PSU's granted \| $ / shares	$ 139.58	$ 121.31	$ 119.67
Fair Value of RSU or PSU units settled	$ 650	$ 586	$ 614
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	3 years
Average fair value of RSU's and PSU's granted \| $ / shares	$ 160.54	$ 124.67	$ 120.64
Fair Value of RSU or PSU units settled	$ 91	$ 119	$ 129
Minimum \| Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	6 months
Minimum \| Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	6 months
Minimum \| Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	6 months
Vesting percentage	0.00%
Maximum \| Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	4 years
Maximum \| Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	3 years
Maximum \| Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	3 years
Vesting percentage	200.00%
2012 Long-Term Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for issuance under long-term incentive plan \| shares	650,000
Shares available for future grants under long-term incentive plan \| shares	277,000

Common Stock, Stock Option Pl_4

Common Stock, Stock Option Plans and Stock Compensation Agreements - Schedule Valuation Assumptions (Details)	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Weighted average assumptions of fair value of options
Risk-free rate	1.47%	2.56%	2.77%
Expected volatility	15.33%	16.27%	15.77%
Expected life (in years)	7 years	7 years	7 years
Expected dividend yield	2.60%	2.80%	2.70%

Common Stock, Stock Option Pl_5

Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Stock Option Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Outstanding Shares
Options outstanding beginning of period	111,637	109,652	111,306
Options granted	20,723	19,745	17,115
Options exercised	(16,275)	(14,785)	(16,228)
Options canceled/forfeited	(1,835)	(2,975)	(2,541)
Options outstanding end of period	114,250	111,637	109,652
Weighted Average Exercise Price
Options exercise price beginning of period	$ 105.63	$ 98.29	$ 90.48
Options granted, average exercise price (in dollars per share)	151.41	131.94	129.51
Options exercised, average exercise price (in dollars per share)	86.05	82.43	75.44
Options canceled/forfeited, average exercise price (in dollars per share)	137.62	125.11	112.90
Options exercise price end of period	$ 116.22	$ 105.63	$ 98.29
Aggregate intrinsic value	$ 4,703	$ 4,478	$ 3,214	$ 5,480

Common Stock, Stock Option Pl_6

Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Options Outstanding (Details) - $ / shares shares in Thousands	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Stock options outstanding and exercisable
Outstanding number of Options (in shares)	114,250	111,637	109,652
Outstanding, Average Life	6 years	6 years	6 years 2 months 12 days
Outstanding Average Exercise Price (in dollars per share)	$ 116.22
Exercisable number of Options (in shares)	61,289
Exercisable, Average Exercise Price (in dollars per share)	$ 96.97
$62.20-$72.54
Stock options outstanding and exercisable
Price Range, Minimum (in dollars per share)	62.20
Price Range, Maximum (in dollars per share)	$ 72.54
Outstanding number of Options (in shares)	11,111
Outstanding, Average Life	1 year 9 months 18 days
Outstanding Average Exercise Price (in dollars per share)	$ 70.79
Exercisable number of Options (in shares)	11,111
Exercisable, Average Exercise Price (in dollars per share)	$ 70.79
$90.44-$100.06
Stock options outstanding and exercisable
Price Range, Minimum (in dollars per share)	90.44
Price Range, Maximum (in dollars per share)	$ 100.06
Outstanding number of Options (in shares)	22,304
Outstanding, Average Life	3 years 7 months 6 days
Outstanding Average Exercise Price (in dollars per share)	$ 95.36
Exercisable number of Options (in shares)	22,304
Exercisable, Average Exercise Price (in dollars per share)	$ 95.36
$100.48-$115.67
Stock options outstanding and exercisable
Price Range, Minimum (in dollars per share)	100.48
Price Range, Maximum (in dollars per share)	$ 115.67
Outstanding number of Options (in shares)	28,180
Outstanding, Average Life	5 years 7 months 6 days
Outstanding Average Exercise Price (in dollars per share)	$ 108.64
Exercisable number of Options (in shares)	27,695
Exercisable, Average Exercise Price (in dollars per share)	$ 108.51
$129.51-$131.94
Stock options outstanding and exercisable
Price Range, Minimum (in dollars per share)	129.51
Price Range, Maximum (in dollars per share)	$ 131.94
Outstanding number of Options (in shares)	32,553
Outstanding, Average Life	7 years 7 months 6 days
Outstanding Average Exercise Price (in dollars per share)	$ 130.85
Exercisable number of Options (in shares)	145
Exercisable, Average Exercise Price (in dollars per share)	$ 130.53
$141.06-$151.41
Stock options outstanding and exercisable
Price Range, Minimum (in dollars per share)	141.06
Price Range, Maximum (in dollars per share)	$ 151.41
Outstanding number of Options (in shares)	20,102
Outstanding, Average Life	9 years 1 month 6 days
Outstanding Average Exercise Price (in dollars per share)	$ 151.41
Exercisable number of Options (in shares)	34
Exercisable, Average Exercise Price (in dollars per share)	$ 151.41

Common Stock, Stock Option Pl_7

Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Restricted Share Units (Details) shares in Thousands	12 Months Ended
	Jan. 03, 2021shares
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]
Shares, Beginning balance	2,174
Shares, granted	816
Shares, issued	(702)
Shares, canceled/forfeited/adjusted	(52)
Shares, Ending balance	2,236
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]
Shares, Beginning balance	16,769
Shares, granted	5,051
Shares, issued	(6,042)
Shares, canceled/forfieted	(780)
Shares, Ending balance	14,998

Segments of Business and Geog_3

Segments of Business and Geographic Areas - Sales by Segment of Business (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018	Oct. 31, 2020	Oct. 31, 2019
Segment Reporting Information [Line Items]
Sales to Customers	$ 82,584	$ 82,059	$ 81,581
Percentage Change In Sales By Segment Of Business	0.60%	0.60%
Consumer
Segment Reporting Information [Line Items]
Sales to Customers	$ 14,053	$ 13,898	13,853
Percentage Change In Sales By Segment Of Business	1.10%	0.30%
Pharmaceutical
Segment Reporting Information [Line Items]
Sales to Customers	$ 45,572	$ 42,198	40,734
Percentage Change In Sales By Segment Of Business	8.00%	3.60%
Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 15,055	$ 13,950	13,120
Percentage Change In Sales By Segment Of Business	7.90%	6.30%
Pharmaceutical \| Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	$ 3,574	$ 3,413	3,304
Percentage Change In Sales By Segment Of Business	4.70%	3.30%
Pharmaceutical \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 6,548	$ 6,328	6,077
Percentage Change In Sales By Segment Of Business	3.50%	4.10%
Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 12,367	$ 10,692	9,844
Percentage Change In Sales By Segment Of Business	15.70%	8.60%
Pharmaceutical \| Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers	$ 3,148	$ 2,623	2,573
Percentage Change In Sales By Segment Of Business	20.00%	1.90%
Pharmaceutical \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers	$ 4,878	$ 5,192	5,816
Percentage Change In Sales By Segment Of Business	(6.00%)	(10.70%)
Medical Devices
Segment Reporting Information [Line Items]
Sales to Customers	$ 22,959	$ 25,963	26,994
Percentage Change In Sales By Segment Of Business	(11.60%)	(3.80%)
Medical Devices \| Diabetes Care
Segment Reporting Information [Line Items]
Sales to Customers			1,009
Medical Devices \| Interventional Solutions
Segment Reporting Information [Line Items]
Sales to Customers	$ 3,046	$ 2,997	2,646
Percentage Change In Sales By Segment Of Business	1.60%	13.30%
Medical Devices \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 7,763	$ 8,839	8,885
Percentage Change In Sales By Segment Of Business	(12.20%)	(0.50%)
Medical Devices \| Surgery
Segment Reporting Information [Line Items]
Sales to Customers	$ 8,232	$ 9,501	9,901
Percentage Change In Sales By Segment Of Business	(13.40%)	(4.00%)
Medical Devices \| Vision
Segment Reporting Information [Line Items]
Sales to Customers	$ 3,919	$ 4,624	4,553
Percentage Change In Sales By Segment Of Business	(15.20%)	1.60%
Baby Care \| Consumer
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,517	$ 1,675	1,858
Percentage Change In Sales By Segment Of Business	(9.40%)	(9.90%)
Oral Care \| Consumer
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,641	$ 1,528	1,555
Percentage Change In Sales By Segment Of Business	7.40%	(1.70%)
OTC \| Consumer
Segment Reporting Information [Line Items]
Sales to Customers	$ 4,824	$ 4,444	4,334
Percentage Change In Sales By Segment Of Business	8.50%	2.50%
Women's Health \| Consumer
Segment Reporting Information [Line Items]
Sales to Customers	$ 901	$ 986	1,049
Percentage Change In Sales By Segment Of Business	(8.60%)	(6.00%)
Wound Care and Other \| Consumer
Segment Reporting Information [Line Items]
Sales to Customers	$ 720	$ 671	675
Percentage Change In Sales By Segment Of Business	7.20%	(0.60%)
Remicade \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 3,747	$ 4,380	5,326
Percentage Change In Sales By Segment Of Business	(14.40%)	(17.80%)
Simponi/Simponi Aria \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,243	$ 2,188	2,084
Percentage Change In Sales By Segment Of Business	2.60%	5.00%
Stelara \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 7,707	$ 6,361	5,156
Percentage Change In Sales By Segment Of Business	21.10%	23.40%
Tremfya \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,347	$ 1,012	544
Percentage Change In Sales By Segment Of Business	33.20%	85.90%
Other Immunology \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 11	$ 10	10
Percentage Change In Sales By Segment Of Business	6.40%	4.50%
EDURANT/rilpivirine \| Pharmaceutical \| Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	$ 964	$ 861	816
Percentage Change In Sales By Segment Of Business	11.90%	5.60%
PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA \| Pharmaceutical \| Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,184	$ 2,110	1,955
Percentage Change In Sales By Segment Of Business	3.50%	8.00%
Other Infectious Diseases \| Pharmaceutical \| Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	$ 427	$ 441	533
Percentage Change In Sales By Segment Of Business	(3.20%)	(17.30%)
CONCERTA/Methylphenidate \| Pharmaceutical \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 622	$ 696	663
Percentage Change In Sales By Segment Of Business	(10.60%)	4.90%
INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA \| Pharmaceutical \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 3,653	$ 3,330	2,928
Percentage Change In Sales By Segment Of Business	9.70%	13.70%
RISPERDAL CONSTA \| Pharmaceutical \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 642	$ 688	737
Percentage Change In Sales By Segment Of Business	(6.80%)	(6.70%)
OTHER NEUROSCIENCE \| Pharmaceutical \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,632	$ 1,614	1,749
Percentage Change In Sales By Segment Of Business	1.10%	(7.70%)
DARZALEX \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 4,190	$ 2,998	2,025
Percentage Change In Sales By Segment Of Business	39.80%	48.00%
Erleada \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 760	$ 332	124
IMBRUVICA \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 4,128	$ 3,411	2,615
Percentage Change In Sales By Segment Of Business	21.00%	30.40%
VELCADE \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 408	$ 751	1,116
Percentage Change In Sales By Segment Of Business	(45.70%)	(32.70%)
ZYTIGA \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,470	$ 2,795	3,498
Percentage Change In Sales By Segment Of Business	(11.60%)	(20.10%)
Other Oncology \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 413	$ 407	466
Percentage Change In Sales By Segment Of Business	1.70%	(12.70%)
OPSUMIT \| Pharmaceutical \| Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,639	$ 1,327	1,215
Percentage Change In Sales By Segment Of Business	23.50%	9.20%
UPTRAVI \| Pharmaceutical \| Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,093	$ 819	663
Percentage Change In Sales By Segment Of Business	33.50%	23.50%
Other \| Pharmaceutical \| Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers	$ 416	$ 476	695
Percentage Change In Sales By Segment Of Business	(12.80%)	(31.50%)
Other \| Pharmaceutical \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,186	$ 1,353	1,470
Percentage Change In Sales By Segment Of Business	(12.40%)	(8.00%)
Xarelto \| Pharmaceutical \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,345	$ 2,313	2,477
Percentage Change In Sales By Segment Of Business	1.40%	(6.60%)
INVOKANA/INVOKAMET \| Pharmaceutical \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers	$ 795	$ 735	881
Percentage Change In Sales By Segment Of Business	8.20%	(16.50%)
PROCRIT/EPREX \| Pharmaceutical \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers	$ 552	$ 790	988
Percentage Change In Sales By Segment Of Business	(30.20%)	(20.00%)
HIPS \| Medical Devices \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,280	$ 1,438	1,418
Percentage Change In Sales By Segment Of Business	(11.00%)	1.40%
KNEES \| Medical Devices \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,170	$ 1,480	1,502
Percentage Change In Sales By Segment Of Business	(21.00%)	(1.40%)
TRAUMA \| Medical Devices \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,614	$ 2,720	2,699
Percentage Change In Sales By Segment Of Business	(3.90%)	0.80%
SPINE & OTHER \| Medical Devices \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,699	$ 3,201	3,266
Percentage Change In Sales By Segment Of Business	(15.70%)	(2.00%)
ADVANCED \| Medical Devices \| Surgery
Segment Reporting Information [Line Items]
Sales to Customers	$ 3,839	$ 4,095	4,002
Percentage Change In Sales By Segment Of Business	(6.20%)	2.30%
GENERAL \| Medical Devices \| Surgery
Segment Reporting Information [Line Items]
Sales to Customers	$ 4,392	$ 5,406	5,899
Percentage Change In Sales By Segment Of Business	(18.80%)	(8.40%)
CONTACT LENSES/OTHER \| Medical Devices \| Vision
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,994	$ 3,392	3,302
Percentage Change In Sales By Segment Of Business	(11.70%)	2.70%
SURGICAL \| Medical Devices \| Vision
Segment Reporting Information [Line Items]
Sales to Customers	$ 925	$ 1,232	1,251
Percentage Change In Sales By Segment Of Business	(24.90%)	(1.60%)
Skin health/Beauty \| Consumer
Segment Reporting Information [Line Items]
Sales to Customers	$ 4,450	$ 4,593	4,382
Percentage Change In Sales By Segment Of Business	(3.10%)	4.80%
United States
Segment Reporting Information [Line Items]
Sales to Customers	$ 43,133	$ 42,097	41,884
Percentage Change In Sales By Segment Of Business	2.50%	0.50%
United States \| Consumer
Segment Reporting Information [Line Items]
Sales to Customers	$ 6,362	$ 5,839	5,761
Percentage Change In Sales By Segment Of Business	9.00%	1.40%
United States \| Pharmaceutical
Segment Reporting Information [Line Items]
Sales to Customers	$ 25,735	$ 23,874	23,286
Percentage Change In Sales By Segment Of Business	7.80%	2.50%
United States \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 10,175	$ 9,641	9,073
Percentage Change In Sales By Segment Of Business	5.50%	6.30%
United States \| Pharmaceutical \| Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,735	$ 1,597	1,378
Percentage Change In Sales By Segment Of Business	8.60%	15.90%
United States \| Pharmaceutical \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 3,091	$ 2,919	2,574
Percentage Change In Sales By Segment Of Business	5.90%	13.40%
United States \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 5,092	$ 4,299	4,331
Percentage Change In Sales By Segment Of Business	18.50%	(0.70%)
United States \| Pharmaceutical \| Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,133	$ 1,684	1,651
Percentage Change In Sales By Segment Of Business	26.60%	2.00%
United States \| Pharmaceutical \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers	$ 3,509	$ 3,734	4,279
Percentage Change In Sales By Segment Of Business	(6.00%)	(12.70%)
United States \| Pharmaceutical \| OPSUMIT
Segment Reporting Information [Line Items]
Percentage Change In Sales By Segment Of Business		9.40%
United States \| Medical Devices
Segment Reporting Information [Line Items]
Sales to Customers	$ 11,036	$ 12,384	12,837
Percentage Change In Sales By Segment Of Business	(10.90%)	(3.50%)
United States \| Medical Devices \| Diabetes Care
Segment Reporting Information [Line Items]
Sales to Customers			371
United States \| Medical Devices \| Interventional Solutions
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,452	$ 1,443	1,283
Percentage Change In Sales By Segment Of Business	0.60%	12.50%
United States \| Medical Devices \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 4,779	$ 5,319	5,281
Percentage Change In Sales By Segment Of Business	(10.20%)	0.70%
United States \| Medical Devices \| Surgery
Segment Reporting Information [Line Items]
Sales to Customers	$ 3,249	$ 3,828	4,125
Percentage Change In Sales By Segment Of Business	(15.10%)	(7.20%)
United States \| Medical Devices \| Vision
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,557	$ 1,794	1,777
Percentage Change In Sales By Segment Of Business	(13.20%)	0.90%
United States \| Baby Care \| Consumer
Segment Reporting Information [Line Items]
Sales to Customers	$ 376	$ 362	422
Percentage Change In Sales By Segment Of Business	3.70%	(14.20%)
United States \| Oral Care \| Consumer
Segment Reporting Information [Line Items]
Sales to Customers	$ 683	$ 621	637
Percentage Change In Sales By Segment Of Business	9.90%	(2.50%)
United States \| OTC \| Consumer
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,460	$ 2,010	1,850
Percentage Change In Sales By Segment Of Business	22.40%	8.60%
United States \| Women's Health \| Consumer
Segment Reporting Information [Line Items]
Sales to Customers	$ 13	$ 12	13
Percentage Change In Sales By Segment Of Business	8.20%	(5.50%)
United States \| Wound Care and Other \| Consumer
Segment Reporting Information [Line Items]
Sales to Customers	$ 480	$ 441	436
Percentage Change In Sales By Segment Of Business	8.90%	1.20%
United States \| Remicade \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,508	$ 3,079	3,664
Percentage Change In Sales By Segment Of Business	(18.50%)	(16.00%)
United States \| Simponi/Simponi Aria \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,155	$ 1,159	1,051
Percentage Change In Sales By Segment Of Business	(0.30%)	10.20%
United States \| Stelara \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 5,240	$ 4,346	3,469
Percentage Change In Sales By Segment Of Business	20.60%	25.30%
United States \| Tremfya \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 926	$ 764	453
Percentage Change In Sales By Segment Of Business	21.30%	68.50%
United States \| Other Immunology \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 0	$ 0	0
Percentage Change In Sales By Segment Of Business	0.00%	0.00%
United States \| EDURANT/rilpivirine \| Pharmaceutical \| Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	$ 44	$ 50	58
Percentage Change In Sales By Segment Of Business	(11.20%)	(13.70%)
United States \| PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA \| Pharmaceutical \| Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,587	$ 1,422	1,169
Percentage Change In Sales By Segment Of Business	11.60%	21.60%
United States \| Other Infectious Diseases \| Pharmaceutical \| Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	$ 104	$ 126	151
Percentage Change In Sales By Segment Of Business	(17.60%)	(16.50%)
United States \| CONCERTA/Methylphenidate \| Pharmaceutical \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 183	$ 233	229
Percentage Change In Sales By Segment Of Business	(21.40%)	1.70%
United States \| INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA \| Pharmaceutical \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,314	$ 2,107	1,791
Percentage Change In Sales By Segment Of Business	9.80%	17.60%
United States \| RISPERDAL CONSTA \| Pharmaceutical \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 296	$ 314	315
Percentage Change In Sales By Segment Of Business	(5.90%)	(0.30%)
United States \| OTHER NEUROSCIENCE \| Pharmaceutical \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 298	$ 266	239
Percentage Change In Sales By Segment Of Business	12.40%	11.40%
United States \| DARZALEX \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,232	$ 1,567	1,203
Percentage Change In Sales By Segment Of Business	42.40%	30.30%
United States \| Erleada \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 583	$ 297	124
Percentage Change In Sales By Segment Of Business	96.10%
United States \| IMBRUVICA \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,821	$ 1,555	1,129
Percentage Change In Sales By Segment Of Business	17.10%	37.70%
United States \| VELCADE \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 0	$ 0	0
Percentage Change In Sales By Segment Of Business	0.00%	0.00%
United States \| ZYTIGA \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 373	$ 810	1,771
Percentage Change In Sales By Segment Of Business	(54.00%)	(54.30%)
United States \| Other Oncology \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 83	$ 70	104
Percentage Change In Sales By Segment Of Business	19.20%	(32.70%)
United States \| OPSUMIT \| Pharmaceutical \| Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,008	$ 766	700
Percentage Change In Sales By Segment Of Business	31.70%
United States \| UPTRAVI \| Pharmaceutical \| Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers	$ 955	$ 714	598
Percentage Change In Sales By Segment Of Business	33.80%	19.30%
United States \| Other \| Pharmaceutical \| Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers	$ 169	$ 205	353
Percentage Change In Sales By Segment Of Business	(17.60%)	(41.90%)
United States \| Other \| Pharmaceutical \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers	$ 323	$ 380	417
Percentage Change In Sales By Segment Of Business	(15.10%)	(9.10%)
United States \| Xarelto \| Pharmaceutical \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,345	$ 2,313	2,477
Percentage Change In Sales By Segment Of Business	1.40%	(6.60%)
United States \| INVOKANA/INVOKAMET \| Pharmaceutical \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers	$ 564	$ 536	711
Percentage Change In Sales By Segment Of Business	5.20%	(24.60%)
United States \| PROCRIT/EPREX \| Pharmaceutical \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers	$ 277	$ 505	674
Percentage Change In Sales By Segment Of Business	(45.10%)	(25.10%)
United States \| HIPS \| Medical Devices \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 793	$ 863	841
Percentage Change In Sales By Segment Of Business	(8.20%)	2.60%
United States \| KNEES \| Medical Devices \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 743	$ 889	911
Percentage Change In Sales By Segment Of Business	(16.40%)	(2.40%)
United States \| TRAUMA \| Medical Devices \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,648	$ 1,652	1,599
Percentage Change In Sales By Segment Of Business	(0.20%)	3.30%
United States \| SPINE & OTHER \| Medical Devices \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,595	$ 1,915	1,930
Percentage Change In Sales By Segment Of Business	(16.70%)	(0.80%)
United States \| ADVANCED \| Medical Devices \| Surgery
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,535	$ 1,637	1,657
Percentage Change In Sales By Segment Of Business	(6.20%)	(1.20%)
United States \| GENERAL \| Medical Devices \| Surgery
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,714	$ 2,192	2,468
Percentage Change In Sales By Segment Of Business	(21.80%)	(11.20%)
United States \| CONTACT LENSES/OTHER \| Medical Devices \| Vision
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,213	$ 1,304	1,237
Percentage Change In Sales By Segment Of Business	(7.00%)	5.40%
United States \| SURGICAL \| Medical Devices \| Vision
Segment Reporting Information [Line Items]
Sales to Customers	$ 344	$ 490	540
Percentage Change In Sales By Segment Of Business	(29.70%)	(9.40%)
United States \| Skin health/Beauty \| Consumer
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,350	$ 2,392	2,403
Percentage Change In Sales By Segment Of Business	(1.70%)	(0.40%)
Non-US
Segment Reporting Information [Line Items]
Sales to Customers	$ 39,451	$ 39,962	39,697
Percentage Change In Sales By Segment Of Business	(1.30%)	0.70%
Non-US \| Consumer
Segment Reporting Information [Line Items]
Sales to Customers	$ 7,691	$ 8,059	8,092
Percentage Change In Sales By Segment Of Business	(4.60%)	(0.40%)
Non-US \| Pharmaceutical
Segment Reporting Information [Line Items]
Sales to Customers	$ 19,837	$ 18,324	17,448
Percentage Change In Sales By Segment Of Business	8.30%	5.00%
Non-US \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 4,880	$ 4,309	4,047
Percentage Change In Sales By Segment Of Business	13.20%	6.50%
Non-US \| Pharmaceutical \| Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,839	$ 1,815	1,926
Percentage Change In Sales By Segment Of Business	1.30%	(5.70%)
Non-US \| Pharmaceutical \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 3,457	$ 3,409	3,503
Percentage Change In Sales By Segment Of Business	1.40%	(2.70%)
Non-US \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 7,275	$ 6,393	5,513
Percentage Change In Sales By Segment Of Business	13.80%	16.00%
Non-US \| Pharmaceutical \| Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,015	$ 939	922
Percentage Change In Sales By Segment Of Business	8.20%	1.90%
Non-US \| Pharmaceutical \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,369	$ 1,458	1,537
Percentage Change In Sales By Segment Of Business	(6.10%)	(5.20%)
Non-US \| Pharmaceutical \| OPSUMIT
Segment Reporting Information [Line Items]
Percentage Change In Sales By Segment Of Business		9.00%
Non-US \| Medical Devices
Segment Reporting Information [Line Items]
Sales to Customers	$ 11,923	$ 13,579	14,157
Percentage Change In Sales By Segment Of Business	(12.20%)	(4.10%)
Non-US \| Medical Devices \| Diabetes Care
Segment Reporting Information [Line Items]
Sales to Customers			638
Non-US \| Medical Devices \| Interventional Solutions
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,594	$ 1,554	1,363
Percentage Change In Sales By Segment Of Business	2.60%	14.00%
Non-US \| Medical Devices \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,984	$ 3,520	3,604
Percentage Change In Sales By Segment Of Business	(15.20%)	(2.30%)
Non-US \| Medical Devices \| Surgery
Segment Reporting Information [Line Items]
Sales to Customers	$ 4,983	$ 5,673	5,776
Percentage Change In Sales By Segment Of Business	(12.20%)	(1.80%)
Non-US \| Medical Devices \| Vision
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,362	$ 2,830	2,776
Percentage Change In Sales By Segment Of Business	(16.50%)	2.00%
Non-US \| Baby Care \| Consumer
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,141	$ 1,313	1,436
Percentage Change In Sales By Segment Of Business	(13.10%)	(8.60%)
Non-US \| Oral Care \| Consumer
Segment Reporting Information [Line Items]
Sales to Customers	$ 958	$ 906	918
Percentage Change In Sales By Segment Of Business	5.70%	(1.20%)
Non-US \| OTC \| Consumer
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,364	$ 2,434	2,484
Percentage Change In Sales By Segment Of Business	(2.90%)	(2.00%)
Non-US \| Women's Health \| Consumer
Segment Reporting Information [Line Items]
Sales to Customers	$ 888	$ 974	1,036
Percentage Change In Sales By Segment Of Business	(8.80%)	(6.00%)
Non-US \| Wound Care and Other \| Consumer
Segment Reporting Information [Line Items]
Sales to Customers	$ 240	$ 230	239
Percentage Change In Sales By Segment Of Business	4.10%	(3.90%)
Non-US \| Remicade \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 893	$ 1,007	1,226
Percentage Change In Sales By Segment Of Business	(11.40%)	(17.80%)
Non-US \| Simponi/Simponi Aria \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,088	$ 1,029	1,033
Percentage Change In Sales By Segment Of Business	5.80%	(0.40%)
Non-US \| Stelara \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,467	$ 2,015	1,687
Percentage Change In Sales By Segment Of Business	22.40%	19.40%
Non-US \| Tremfya \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 421	$ 248	91
Percentage Change In Sales By Segment Of Business	69.90%
Non-US \| Other Immunology \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 11	$ 10	10
Percentage Change In Sales By Segment Of Business	6.40%	4.50%
Non-US \| EDURANT/rilpivirine \| Pharmaceutical \| Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	$ 920	$ 812	758
Percentage Change In Sales By Segment Of Business	13.30%	7.10%
Non-US \| PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA \| Pharmaceutical \| Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	$ 597	$ 689	786
Percentage Change In Sales By Segment Of Business	(13.40%)	(12.30%)
Non-US \| Other Infectious Diseases \| Pharmaceutical \| Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	$ 323	$ 315	382
Percentage Change In Sales By Segment Of Business	2.60%	(17.60%)
Non-US \| CONCERTA/Methylphenidate \| Pharmaceutical \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 439	$ 463	434
Percentage Change In Sales By Segment Of Business	(5.10%)	6.60%
Non-US \| INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA \| Pharmaceutical \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,339	$ 1,224	1,137
Percentage Change In Sales By Segment Of Business	9.40%	7.70%
Non-US \| RISPERDAL CONSTA \| Pharmaceutical \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 346	$ 374	422
Percentage Change In Sales By Segment Of Business	(7.50%)	(11.40%)
Non-US \| OTHER NEUROSCIENCE \| Pharmaceutical \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,334	$ 1,349	1,510
Percentage Change In Sales By Segment Of Business	(1.10%)	(10.70%)
Non-US \| DARZALEX \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,958	$ 1,430	822
Percentage Change In Sales By Segment Of Business	36.90%	73.90%
Non-US \| Erleada \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 176	$ 35	0
Non-US \| IMBRUVICA \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,307	$ 1,856	1,486
Percentage Change In Sales By Segment Of Business	24.30%	24.90%
Non-US \| VELCADE \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 408	$ 751	1,116
Percentage Change In Sales By Segment Of Business	(45.70%)	(32.70%)
Non-US \| ZYTIGA \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,097	$ 1,985	1,727
Percentage Change In Sales By Segment Of Business	5.60%	15.00%
Non-US \| Other Oncology \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 330	$ 336	362
Percentage Change In Sales By Segment Of Business	(1.90%)	(7.20%)
Non-US \| OPSUMIT \| Pharmaceutical \| Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers	$ 631	$ 562	515
Percentage Change In Sales By Segment Of Business	12.30%
Non-US \| UPTRAVI \| Pharmaceutical \| Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers	$ 138	$ 105	65
Percentage Change In Sales By Segment Of Business	30.90%	62.40%
Non-US \| Other \| Pharmaceutical \| Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers	$ 247	$ 272	342
Percentage Change In Sales By Segment Of Business	(9.20%)	(20.50%)
Non-US \| Other \| Pharmaceutical \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers	$ 864	$ 974	1,053
Percentage Change In Sales By Segment Of Business	(11.30%)	(7.60%)
Non-US \| Xarelto \| Pharmaceutical \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers	$ 0	$ 0	0
Percentage Change In Sales By Segment Of Business	0.00%	0.00%
Non-US \| INVOKANA/INVOKAMET \| Pharmaceutical \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers	$ 231	$ 199	170
Percentage Change In Sales By Segment Of Business	16.30%	17.30%
Non-US \| PROCRIT/EPREX \| Pharmaceutical \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers	$ 274	$ 285	314
Percentage Change In Sales By Segment Of Business	(3.80%)	(9.20%)
Non-US \| HIPS \| Medical Devices \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 487	$ 575	577
Percentage Change In Sales By Segment Of Business	(15.30%)	(0.30%)
Non-US \| KNEES \| Medical Devices \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 427	$ 591	591
Percentage Change In Sales By Segment Of Business	(27.80%)	0.00%
Non-US \| TRAUMA \| Medical Devices \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 966	$ 1,068	1,100
Percentage Change In Sales By Segment Of Business	(9.60%)	(2.90%)
Non-US \| SPINE & OTHER \| Medical Devices \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,104	$ 1,286	1,336
Percentage Change In Sales By Segment Of Business	(14.10%)	(3.80%)
Non-US \| ADVANCED \| Medical Devices \| Surgery
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,304	$ 2,458	2,345
Percentage Change In Sales By Segment Of Business	(6.20%)	4.80%
Non-US \| GENERAL \| Medical Devices \| Surgery
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,679	$ 3,215	3,431
Percentage Change In Sales By Segment Of Business	(16.70%)	(6.30%)
Non-US \| CONTACT LENSES/OTHER \| Medical Devices \| Vision
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,781	$ 2,088	2,065
Percentage Change In Sales By Segment Of Business	(14.70%)	1.10%
Non-US \| SURGICAL \| Medical Devices \| Vision
Segment Reporting Information [Line Items]
Sales to Customers	$ 581	$ 742	711
Percentage Change In Sales By Segment Of Business	(21.70%)	4.40%
Non-US \| Skin health/Beauty \| Consumer
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,100	$ 2,201	1,979
Percentage Change In Sales By Segment Of Business	(4.60%)	11.20%
UNITED STATES Exports \| Remicade \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 346	$ 294	$ 436
Percentage Change In Sales By Segment Of Business	18.00%	(32.70%)
Auris Health \| Pharmaceutical
Segment Reporting Information [Line Items]
Business Combination, Acquisition Related Costs		$ 100
Pending Litigation
Segment Reporting Information [Line Items]
Loss contingency, estimate of possible loss				$ 5,000	$ 4,000

Segments of Business and Geog_4

Segments of Business and Geographic Areas - Schedule of Segment Reporting Information (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Segment Reporting Information [Line Items]
Earnings before provision for taxes on income	$ 16,497	$ 17,328	$ 17,999
Identifiable Assets	174,894	157,728
Additions to Property, Plant & Equipment	3,347	3,498	3,670
Depreciation and Amortization	7,231	7,009	6,929
Sales to Customers	$ 82,584	$ 82,059	$ 81,581
Wholesaler 2 \| Sales Revenue, Net
Segment Reporting Information [Line Items]
Concentration risk (as a percent)	12.00%	12.00%	11.00%
United States
Segment Reporting Information [Line Items]
Sales to Customers	$ 43,133	$ 42,097	$ 41,884
Non-US
Segment Reporting Information [Line Items]
Sales to Customers	39,451	39,962	39,697
Consumer
Segment Reporting Information [Line Items]
Sales to Customers	14,053	13,898	13,853
Consumer \| United States
Segment Reporting Information [Line Items]
Sales to Customers	6,362	5,839	5,761
Consumer \| Non-US
Segment Reporting Information [Line Items]
Sales to Customers	7,691	8,059	8,092
Pharmaceutical
Segment Reporting Information [Line Items]
Sales to Customers	45,572	42,198	40,734
Pharmaceutical \| United States
Segment Reporting Information [Line Items]
Sales to Customers	25,735	23,874	23,286
Pharmaceutical \| Non-US
Segment Reporting Information [Line Items]
Sales to Customers	19,837	18,324	17,448
Medical Devices
Segment Reporting Information [Line Items]
Sales to Customers	22,959	25,963	26,994
Medical Devices \| United States
Segment Reporting Information [Line Items]
Sales to Customers	11,036	12,384	12,837
Medical Devices \| Non-US
Segment Reporting Information [Line Items]
Sales to Customers	11,923	13,579	14,157
Segments Total
Segment Reporting Information [Line Items]
Identifiable Assets	143,091	132,372
Additions to Property, Plant & Equipment	3,091	3,190	3,293
Depreciation and Amortization	6,931	6,689	6,593
Corporate, Non-Segment
Segment Reporting Information [Line Items]
Less: Expense not allocated to segments	945	835	1,286
Corporate, Non-Segment \| General Corporate
Segment Reporting Information [Line Items]
Identifiable Assets	31,803	25,356
Additions to Property, Plant & Equipment	256	308	377
Depreciation and Amortization	300	320	336
Operating Segments
Segment Reporting Information [Line Items]
Earnings before provision for taxes on income	17,442	18,163	19,285
Sales to Customers	82,584	82,059	81,581
Operating Segments \| United States
Segment Reporting Information [Line Items]
Sales to Customers	43,133	42,097	41,884
Operating Segments \| Consumer
Segment Reporting Information [Line Items]
Earnings before provision for taxes on income	(1,064)	2,061	2,320
Identifiable Assets	27,355	26,618
Additions to Property, Plant & Equipment	248	328	438
Depreciation and Amortization	785	765	688
Operating Segments \| Pharmaceutical
Segment Reporting Information [Line Items]
Earnings before provision for taxes on income	15,462	8,816	12,568
Identifiable Assets	66,158	56,292
Additions to Property, Plant & Equipment	863	950	1,012
Depreciation and Amortization	4,006	3,910	3,802
Operating Segments \| Medical Devices
Segment Reporting Information [Line Items]
Earnings before provision for taxes on income	3,044	7,286	4,397
Identifiable Assets	49,578	49,462
Additions to Property, Plant & Equipment	1,980	1,912	1,843
Depreciation and Amortization	2,140	2,014	2,103
Immunology \| Pharmaceutical
Segment Reporting Information [Line Items]
Sales to Customers	15,055	13,950	13,120
Immunology \| Pharmaceutical \| United States
Segment Reporting Information [Line Items]
Sales to Customers	10,175	9,641	9,073
Immunology \| Pharmaceutical \| Non-US
Segment Reporting Information [Line Items]
Sales to Customers	$ 4,880	$ 4,309	$ 4,047

Segments of Business and Geog_5

Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details) $ in Millions	12 Months Ended
	Jan. 03, 2021USD ($)	Dec. 29, 2019USD ($)Segment	Dec. 30, 2018USD ($)Segment	Oct. 31, 2020USD ($)	Oct. 31, 2019USD ($)
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 82,584	$ 82,059	$ 81,581
Identifiable Assets	174,894	157,728
Gain (Loss) on Disposition of Assets			1,200
Contingent consideration reversal	(1,148)	$ 0	$ 0
Number of segments \| Segment		3	3
Restructuring charges	247	$ 266	$ 251
In-process research and development (Note 5)	$ 181	$ 890	1,126
Percentage Change In Sales By Segment Of Business	0.60%	0.60%
Pending Litigation
Revenues from External Customers and Long-Lived Assets [Line Items]
Loss contingency, estimate of possible loss				$ 5,000	$ 4,000
Medical Devices
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 22,959	$ 25,963	26,994
Restructuring charges	300	400
Regulation charge	100
In-process research and development (Note 5)	200
Litigation expense	$ 300	$ 400	1,700
Restructuring Charge, Net of Accrual Adjustment			600
Percentage Change In Sales By Segment Of Business	(11.60%)	(3.80%)
Medical Devices \| Interventional Solutions
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 3,046	$ 2,997	2,646
Percentage Change In Sales By Segment Of Business	1.60%	13.30%
Medical Devices \| Diabetes Care
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers			1,009
Consumer
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 14,053	$ 13,898	13,853
Restructuring charges		100
Litigation expense	$ 3,900	$ 400	300
Percentage Change In Sales By Segment Of Business	1.10%	0.30%
Consumer \| Baby Care
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 1,517	$ 1,675	1,858
Percentage Change In Sales By Segment Of Business	(9.40%)	(9.90%)
Consumer \| OTC
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 4,824	$ 4,444	4,334
Percentage Change In Sales By Segment Of Business	8.50%	2.50%
Consumer \| Skin health/Beauty
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 4,450	$ 4,593	4,382
Percentage Change In Sales By Segment Of Business	(3.10%)	4.80%
Consumer \| Oral Care
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 1,641	$ 1,528	1,555
Percentage Change In Sales By Segment Of Business	7.40%	(1.70%)
Pharmaceutical
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 45,572	$ 42,198	40,734
Unrealized loss on securities			200
Restructuring charges	100	100
In-process research and development (Note 5)		900
Litigation expense	$ 800	4,300
Research and Development Expense		$ 300
Percentage Change In Sales By Segment Of Business	8.00%	3.60%
Pharmaceutical \| Immunology
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 15,055	$ 13,950	13,120
Percentage Change In Sales By Segment Of Business	7.90%	6.30%
Pharmaceutical \| Oncology
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 12,367	$ 10,692	9,844
Percentage Change In Sales By Segment Of Business	15.70%	8.60%
Pharmaceutical \| Pulmonary Hypertension
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 3,148	$ 2,623	2,573
Percentage Change In Sales By Segment Of Business	20.00%	1.90%
Pharmaceutical \| Stelara \| Immunology
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 7,707	$ 6,361	5,156
Percentage Change In Sales By Segment Of Business	21.10%	23.40%
Pharmaceutical \| Tremfya \| Immunology
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 1,347	$ 1,012	544
Percentage Change In Sales By Segment Of Business	33.20%	85.90%
Pharmaceutical \| Erleada \| Oncology
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 760	$ 332	124
Pharmaceutical \| IMBRUVICA \| Oncology
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 4,128	$ 3,411	2,615
Percentage Change In Sales By Segment Of Business	21.00%	30.40%
Pharmaceutical \| DARZALEX \| Oncology
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 4,190	$ 2,998	2,025
Percentage Change In Sales By Segment Of Business	39.80%	48.00%
Pharmaceutical \| OPSUMIT \| Pulmonary Hypertension
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 1,639	$ 1,327	1,215
Percentage Change In Sales By Segment Of Business	23.50%	9.20%
Property, Plant and Equipment
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-Lived Assets	$ 18,766	$ 17,658
Other Intangible Assets
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-Lived Assets	89,795	81,282
Ci:z Holdings Co. Ltd. \| Consumer
Revenues from External Customers and Long-Lived Assets [Line Items]
Gain (Loss) on Sale of Equity Investments		300
Alios Biopharma Inc and XO1 Limited \| Pharmaceutical
Revenues from External Customers and Long-Lived Assets [Line Items]
In-process research and development (Note 5)			1,100
XO1
Revenues from External Customers and Long-Lived Assets [Line Items]
Contingent consideration reversal			(200)
Actelion \| Pharmaceutical
Revenues from External Customers and Long-Lived Assets [Line Items]
Acquisition related costs		200	200
AMO \| Medical Devices
Revenues from External Customers and Long-Lived Assets [Line Items]
Acquisition related costs			100
Auris Health
Revenues from External Customers and Long-Lived Assets [Line Items]
Contingent consideration reversal	(1,148)
Auris Health \| Medical Devices \| Other Income [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Contingent consideration reversal	(1,100)
Auris Health \| Pharmaceutical
Revenues from External Customers and Long-Lived Assets [Line Items]
Acquisition related costs		100
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 43,133	$ 42,097	41,884
Percentage Change In Sales By Segment Of Business	2.50%	0.50%
United States \| Medical Devices
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 11,036	$ 12,384	12,837
Percentage Change In Sales By Segment Of Business	(10.90%)	(3.50%)
United States \| Medical Devices \| Interventional Solutions
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 1,452	$ 1,443	1,283
Percentage Change In Sales By Segment Of Business	0.60%	12.50%
United States \| Medical Devices \| Diabetes Care
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers			371
United States \| Consumer
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 6,362	$ 5,839	5,761
Percentage Change In Sales By Segment Of Business	9.00%	1.40%
United States \| Consumer \| Baby Care
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 376	$ 362	422
Percentage Change In Sales By Segment Of Business	3.70%	(14.20%)
United States \| Consumer \| OTC
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 2,460	$ 2,010	1,850
Percentage Change In Sales By Segment Of Business	22.40%	8.60%
United States \| Consumer \| Skin health/Beauty
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 2,350	$ 2,392	2,403
Percentage Change In Sales By Segment Of Business	(1.70%)	(0.40%)
United States \| Consumer \| Oral Care
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 683	$ 621	637
Percentage Change In Sales By Segment Of Business	9.90%	(2.50%)
United States \| Pharmaceutical
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 25,735	$ 23,874	23,286
Percentage Change In Sales By Segment Of Business	7.80%	2.50%
United States \| Pharmaceutical \| Immunology
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 10,175	$ 9,641	9,073
Percentage Change In Sales By Segment Of Business	5.50%	6.30%
United States \| Pharmaceutical \| Oncology
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 5,092	$ 4,299	4,331
Percentage Change In Sales By Segment Of Business	18.50%	(0.70%)
United States \| Pharmaceutical \| Pulmonary Hypertension
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 2,133	$ 1,684	1,651
Percentage Change In Sales By Segment Of Business	26.60%	2.00%
United States \| Pharmaceutical \| OPSUMIT
Revenues from External Customers and Long-Lived Assets [Line Items]
Percentage Change In Sales By Segment Of Business		9.40%
United States \| Pharmaceutical \| Stelara \| Immunology
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 5,240	$ 4,346	3,469
Percentage Change In Sales By Segment Of Business	20.60%	25.30%
United States \| Pharmaceutical \| Tremfya \| Immunology
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 926	$ 764	453
Percentage Change In Sales By Segment Of Business	21.30%	68.50%
United States \| Pharmaceutical \| Erleada \| Oncology
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 583	$ 297	124
Percentage Change In Sales By Segment Of Business	96.10%
United States \| Pharmaceutical \| IMBRUVICA \| Oncology
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 1,821	$ 1,555	1,129
Percentage Change In Sales By Segment Of Business	17.10%	37.70%
United States \| Pharmaceutical \| DARZALEX \| Oncology
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 2,232	$ 1,567	1,203
Percentage Change In Sales By Segment Of Business	42.40%	30.30%
United States \| Pharmaceutical \| OPSUMIT \| Pulmonary Hypertension
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 1,008	$ 766	700
Percentage Change In Sales By Segment Of Business	31.70%
Non-US
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 39,451	$ 39,962	39,697
Percentage Change In Sales By Segment Of Business	(1.30%)	0.70%
Non-US \| Medical Devices
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 11,923	$ 13,579	14,157
Percentage Change In Sales By Segment Of Business	(12.20%)	(4.10%)
Non-US \| Medical Devices \| Interventional Solutions
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 1,594	$ 1,554	1,363
Percentage Change In Sales By Segment Of Business	2.60%	14.00%
Non-US \| Medical Devices \| Diabetes Care
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers			638
Non-US \| Consumer
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 7,691	$ 8,059	8,092
Percentage Change In Sales By Segment Of Business	(4.60%)	(0.40%)
Non-US \| Consumer \| Baby Care
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 1,141	$ 1,313	1,436
Percentage Change In Sales By Segment Of Business	(13.10%)	(8.60%)
Non-US \| Consumer \| OTC
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 2,364	$ 2,434	2,484
Percentage Change In Sales By Segment Of Business	(2.90%)	(2.00%)
Non-US \| Consumer \| Skin health/Beauty
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 2,100	$ 2,201	1,979
Percentage Change In Sales By Segment Of Business	(4.60%)	11.20%
Non-US \| Consumer \| Oral Care
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 958	$ 906	918
Percentage Change In Sales By Segment Of Business	5.70%	(1.20%)
Non-US \| Pharmaceutical
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 19,837	$ 18,324	17,448
Percentage Change In Sales By Segment Of Business	8.30%	5.00%
Non-US \| Pharmaceutical \| Immunology
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 4,880	$ 4,309	4,047
Percentage Change In Sales By Segment Of Business	13.20%	6.50%
Non-US \| Pharmaceutical \| Oncology
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 7,275	$ 6,393	5,513
Percentage Change In Sales By Segment Of Business	13.80%	16.00%
Non-US \| Pharmaceutical \| Pulmonary Hypertension
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 1,015	$ 939	922
Percentage Change In Sales By Segment Of Business	8.20%	1.90%
Non-US \| Pharmaceutical \| OPSUMIT
Revenues from External Customers and Long-Lived Assets [Line Items]
Percentage Change In Sales By Segment Of Business		9.00%
Non-US \| Pharmaceutical \| Stelara \| Immunology
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 2,467	$ 2,015	1,687
Percentage Change In Sales By Segment Of Business	22.40%	19.40%
Non-US \| Pharmaceutical \| Tremfya \| Immunology
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 421	$ 248	91
Percentage Change In Sales By Segment Of Business	69.90%
Non-US \| Pharmaceutical \| Erleada \| Oncology
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 176	35	0
Non-US \| Pharmaceutical \| IMBRUVICA \| Oncology
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 2,307	$ 1,856	1,486
Percentage Change In Sales By Segment Of Business	24.30%	24.90%
Non-US \| Pharmaceutical \| DARZALEX \| Oncology
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 1,958	$ 1,430	822
Percentage Change In Sales By Segment Of Business	36.90%	73.90%
Non-US \| Pharmaceutical \| OPSUMIT \| Pulmonary Hypertension
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 631	$ 562	515
Percentage Change In Sales By Segment Of Business	12.30%
Corporate, Non-Segment
Revenues from External Customers and Long-Lived Assets [Line Items]
Other Non Long Lived Assets	$ 66,333	58,788
Corporate, Non-Segment \| General Corporate
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-Lived Assets	1,029	1,049
Identifiable Assets	31,803	25,356
Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	82,584	82,059	81,581
Long-Lived Assets	107,532	97,891
Operating Segments \| Medical Devices
Revenues from External Customers and Long-Lived Assets [Line Items]
Identifiable Assets	49,578	49,462
Operating Segments \| Consumer
Revenues from External Customers and Long-Lived Assets [Line Items]
Identifiable Assets	27,355	26,618
Operating Segments \| Pharmaceutical
Revenues from External Customers and Long-Lived Assets [Line Items]
Identifiable Assets	66,158	56,292
Unrealized Gain (Loss) on Securities	500	600
Operating Segments \| NIZORAL \| Consumer
Revenues from External Customers and Long-Lived Assets [Line Items]
Gain (Loss) on Disposition of Assets			300
Operating Segments \| PANCREASE \| Pharmaceutical
Revenues from External Customers and Long-Lived Assets [Line Items]
Gain (Loss) on Disposition of Assets			200
Operating Segments \| LifeScan \| Medical Devices
Revenues from External Customers and Long-Lived Assets [Line Items]
Gain (Loss) on Disposition of Business			500
Operating Segments \| United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	43,133	42,097	41,884
Long-Lived Assets	49,951	41,528
Operating Segments \| Europe
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	18,980	18,466	18,753
Long-Lived Assets	49,363	48,015
Operating Segments \| Western Hemisphere excluding U.S.
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	5,335	5,941	6,113
Long-Lived Assets	2,734	2,862
Operating Segments \| Asia-Pacific, Africa
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	15,136	15,555	$ 14,831
Long-Lived Assets	$ 5,484	$ 5,486
Wholesaler 1 \| Sales Revenue, Net
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk (as a percent)	16.00%	15.00%	14.00%
Wholesaler 2 \| Sales Revenue, Net
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk (as a percent)	12.00%	12.00%	11.00%
Wholesaler 3 \| Sales Revenue, Net
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk (as a percent)	12.00%	11.00%
AdvancedSterilizationProducts
Revenues from External Customers and Long-Lived Assets [Line Items]
Gain (Loss) on Disposition of Business		$ 2,000
AdvancedSterilizationProducts \| Operating Segments \| Medical Devices
Revenues from External Customers and Long-Lived Assets [Line Items]
Gain (Loss) on Disposition of Business		$ 2,000

Acquisitions and Divestitures -

Acquisitions and Divestitures - Narrative (Details) $ / shares in Units, shares in Millions, SFr in Millions, $ in Millions, ¥ in Billions

Jan. 31, 2021USD ($)

Oct. 01, 2020USD ($)

Apr. 01, 2019USD ($)

Jan. 17, 2019USD ($)

Jan. 17, 2019JPY (¥)

Sep. 27, 2020USD ($)

Mar. 29, 2020USD ($)

Mar. 31, 2019USD ($)

Jan. 03, 2021USD ($)$ / sharesshares

Jan. 03, 2021CHF (SFr)shares

Dec. 29, 2019USD ($)

Dec. 30, 2018USD ($)

Jan. 03, 2021CHF (SFr)

Jan. 16, 2019

Business Acquisition [Line Items]

Consideration transferred

$ 7,300

Liabilities assumed

400

$ 1,400

Goodwill

36,393

33,639

$ 30,453

Acquisition payments

7,323

5,810

899

Other (income) expense, net

(2,899)

(2,525)

(1,405)

Contingent consideration liability

633

1,715

Liabilities assumed

432

1,418

148

Gain (Loss) on Disposition of Assets

1,200

In Process Research and Development

Business Acquisition [Line Items]

Impairment of intangible assets, excluding goodwill

$ 100

2019 Acquisitions | In Process Research and Development

Business Acquisition [Line Items]

Purchase price over fair value of assets acquired

6,800

Auris Health

Business Acquisition [Line Items]

Liabilities assumed

$ 1,800

Intangible assets assumed

$ 3,000

Discount rate

10.00%

Goodwill

$ 2,000

Acquisition payments

3,400

Contingent consideration liability

2,350

1,100

Marketable securities assumed

$ 200

2018 Acquisitions | In Process Research and Development

Business Acquisition [Line Items]

Purchase price over fair value of assets acquired

1,000

Ci:z Holdings Co. Ltd.

Business Acquisition [Line Items]

Consideration transferred

$ 2,100

¥ 230

Liabilities assumed

400

Intangible assets assumed

1,500

Goodwill

$ 1,200

Foreign currency exchange rate, translation

109.06

Other (income) expense, net

$ 300

Weighted average useful life of acquired intangibles

15 years 3 months 18 days

Idorsia

Business Acquisition [Line Items]

Sale of stock (in USD per share) | $ / shares

$ 28.55

Sale of stock, number of shares issued in transaction (in shares) | shares

11.8

Sale of stock, percentage of ownership before transaction

8.30%

Proceeds from sale of available-for-sale securities, equity

$ 357

SFr 337

Convertible note, equity Interest (in shares) | shares

38.7

Convertible Note, equity interest, percentage

20.00%

Remaining borrowing capacity | SFr

SFr 243

Momenta

Business Acquisition [Line Items]

Consideration transferred

$ 6,100

Liabilities assumed

1,600

Other assets assumed

$ 500

Discount rate

13.00%

Goodwill

$ 1,200

Momenta | In Process Research and Development

Business Acquisition [Line Items]

Intangible assets assumed

$ 6,000

2020 Acquisitions | In Process Research and Development

Business Acquisition [Line Items]

Purchase price over fair value of assets acquired

$ 7,500

bermekimab

Business Acquisition [Line Items]

Consideration transferred

$ 800

Intangible assets assumed

$ 800

Discount rate

16.00%

Verb Surgical Inc.

Business Acquisition [Line Items]

Liabilities assumed

300

Intangible assets assumed

400

Other assets assumed

200

Goodwill

200

Equity method investments, fair value

$ 400

Maximum | Auris Health

Business Acquisition [Line Items]

Probability of success factor

95.00%

Maximum | Momenta

Business Acquisition [Line Items]

Probability of success factor

77.00%

Maximum | bermekimab

Business Acquisition [Line Items]

Probability of success factor

60.00%

Minimum | Auris Health

Business Acquisition [Line Items]

Probability of success factor

55.00%

Minimum | Momenta

Business Acquisition [Line Items]

Probability of success factor

20.00%

Minimum | bermekimab

Business Acquisition [Line Items]

Probability of success factor

20.00%

Convertible Debt | Idorsia

Business Acquisition [Line Items]

Long-term debt | SFr

SFr 445

AdvancedSterilizationProducts

Business Acquisition [Line Items]

Gain (Loss) on Disposition of Business

2,000

Evra and Doxil | Subsequent Event

Business Acquisition [Line Items]

Proceeds from divestiture of brands

$ 600

Discontinued Operations, Held-for-sale or Disposed of by Sale | LifeScan

Business Acquisition [Line Items]

Disposal group, including discontinued operation, consideration

$ 2,100

Discontinued Operations, Held-for-sale or Disposed of by Sale | AdvancedSterilizationProducts

Business Acquisition [Line Items]

Disposal group, including discontinued operation, consideration

2,800

Disposal group, including discontinued operation, cash

2,700

Disposal group, including discontinued operation, receivables retained

100

Discontinued Operations, Held-for-sale or Disposed of by Sale | Supply Chain

Business Acquisition [Line Items]

Disposal group, including discontinued operation, inventory, current

$ 100

Legal Proceedings (Details)

Legal Proceedings (Details) $ in Millions	Jan. 20, 2020USD ($)	Jun. 28, 2020USD ($)	Jan. 31, 2020USD ($)	Oct. 31, 2019USD ($)	Jul. 31, 2018USD ($)	Jan. 03, 2021USD ($)claimantpatient	Oct. 31, 2020USD ($)
Xarelto
Loss Contingencies [Line Items]
Number of plaintiffs						12,600
ASR
Loss Contingencies [Line Items]
Number of plaintiffs						560
Pinnacle Acetabular Cup System
Loss Contingencies [Line Items]
Number of plaintiffs						7,800
Risperdal
Loss Contingencies [Line Items]
Number of plaintiffs						9,300
Pelvic Meshes
Loss Contingencies [Line Items]
Number of plaintiffs						14,900
Invokana
Loss Contingencies [Line Items]
Number of plaintiffs						300
Physiomesh
Loss Contingencies [Line Items]
Number of plaintiffs						4,200
Talc
Loss Contingencies [Line Items]
Number of plaintiffs						25,000
Opiods
Loss Contingencies [Line Items]
Number of plaintiffs						3,100
Pending Litigation
Loss Contingencies [Line Items]
Loss Contingency, estimate of additional possible loss \| $							$ 1,000
Loss contingency, estimate of possible loss \| $				$ 4,000			$ 5,000
Judicial Ruling
Loss Contingencies [Line Items]
Loss contingency, damages awarded, value \| $	$ 344		$ 6.8	$ 8,000
Oklahoma Attorney General VS. Johnson And Johnson And JPI [Member] \| Settled Litigation
Loss Contingencies [Line Items]
Loss contingency, damages awarded, value \| $						$ 465
Oklahoma Attorney General VS. Johnson And Johnson And JPI [Member] \| Judicial Ruling
Loss Contingencies [Line Items]
Loss contingency, damages awarded, value \| $						$ 572
DePuy ASR U.S. \| Settled Litigation
Loss Contingencies [Line Items]
Number of patients in settlement \| patient						10,000
Baby Powder \| Judicial Ruling \| Damages from Product Defects
Loss Contingencies [Line Items]
Loss contingency, damages sought, value \| $		$ 2,100			$ 4,700	$ 2,500

Restructuring - Narrative (Deta

Restructuring - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
Restructuring - Narrative (Details) - USD ($) $ in Millions	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, expected period of cash outlays for severance paid	2 years
Restructuring charges	$ 247	$ 266	$ 251
Medical Devices
Restructuring Cost and Reserve [Line Items]
Restructuring charges	300	400
Supply Chain
Restructuring Cost and Reserve [Line Items]
Restructuring charges	448
Restructuring reserve		180
Restructuring costs incurred since announced	1,300
Supply Chain \| Restructuring Charges
Restructuring Cost and Reserve [Line Items]
Restructuring charges	200
Supply Chain \| Cost of products sold
Restructuring Cost and Reserve [Line Items]
Restructuring charges	100
Supply Chain \| Other Income Expense Net
Restructuring Cost and Reserve [Line Items]
Restructuring charges	100
Supply Chain \| Severance
Restructuring Cost and Reserve [Line Items]
Restructuring charges	0
Restructuring reserve		164
Supply Chain \| Asset Write-offs/Sales
Restructuring Cost and Reserve [Line Items]
Restructuring charges	43
Restructuring reserve		0
Supply Chain \| Other(2)
Restructuring Cost and Reserve [Line Items]
Restructuring charges	405
Restructuring reserve		$ 16
Supply Chain \| Minimum
Restructuring Cost and Reserve [Line Items]
Pre-tax restructuring charges	1,900
Restructuring and related cost, expected future savings	$ 600
Supply Chain \| Minimum \| Medical Devices
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, duration of restructuring plan	4 years
Supply Chain \| Maximum
Restructuring Cost and Reserve [Line Items]
Pre-tax restructuring charges	$ 2,300
Restructuring and related cost, expected future savings	$ 800
Supply Chain \| Maximum \| Medical Devices
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, duration of restructuring plan	5 years
Medical Devices
Restructuring Cost and Reserve [Line Items]
Restructuring reserve			242
Medical Devices \| Severance
Restructuring Cost and Reserve [Line Items]
Restructuring reserve			194
Medical Devices \| Asset Write-offs/Sales
Restructuring Cost and Reserve [Line Items]
Restructuring reserve			0
Medical Devices \| Other(2)
Restructuring Cost and Reserve [Line Items]
Restructuring reserve			$ 48

Restructuring - Summary of Seve

Restructuring - Summary of Severance Charges and Associated Spending (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Restructuring Reserve [Roll Forward]
Restructuring charges	$ 247	$ 266	$ 251
Supply Chain
Restructuring Reserve [Roll Forward]
Reserve balance ending	144
Supply Chain \| Severance
Restructuring Reserve [Roll Forward]
Reserve balance ending	135
Supply Chain \| Asset Write-offs/Sales
Restructuring Reserve [Roll Forward]
Reserve balance ending	0
Supply Chain \| Other(2)
Restructuring Reserve [Roll Forward]
Reserve balance ending	9
Medical Devices
Restructuring Reserve [Roll Forward]
Restructuring charges	300	400
Supply Chain
Restructuring Reserve [Roll Forward]
Reserve balance beginning	180
Activity during the period		(62)
Restructuring charges	448
Cash settlements	(404)
Settled non cash	(80)
Reserve balance ending		180
Supply Chain \| Severance
Restructuring Reserve [Roll Forward]
Reserve balance beginning	164
Activity during the period		(30)
Restructuring charges	0
Cash settlements	(29)
Settled non cash	0
Reserve balance ending		164
Supply Chain \| Asset Write-offs/Sales
Restructuring Reserve [Roll Forward]
Reserve balance beginning	0
Activity during the period		0
Restructuring charges	43
Cash settlements	24
Settled non cash	(67)
Reserve balance ending		0
Supply Chain \| Other(2)
Restructuring Reserve [Roll Forward]
Reserve balance beginning	16
Activity during the period		(32)
Restructuring charges	405
Cash settlements	(399)
Settled non cash	$ (13)
Reserve balance ending		16
Medical Devices
Restructuring Reserve [Roll Forward]
Reserve balance beginning		242
Reserve balance ending			242
Medical Devices \| Severance
Restructuring Reserve [Roll Forward]
Reserve balance beginning		194
Reserve balance ending			194
Medical Devices \| Asset Write-offs/Sales
Restructuring Reserve [Roll Forward]
Reserve balance beginning		0
Reserve balance ending			0
Medical Devices \| Other(2)
Restructuring Reserve [Roll Forward]
Reserve balance beginning		$ 48
Reserve balance ending			$ 48